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Abstract 
Crohn’s disease (CD) and colorectal cancer (CRC) are major disorders of the intestine. 
Inflammation in CD often precedes fibrosis and stricture formation, and is linked to 
increased cancer risk. Hypoxia is a common feature of inflammation and CRC that can 
severely compromise the effectiveness of current therapy regimes including chemo-
radiotherapy and maintenance of remission in CD patients. MicroRNAs (miRNAs) are 
key regulatory molecules involved in cellular proliferation, apoptosis and fibrosis, which 
are all modulated by hypoxia. This thesis aims to understand the role of miRNAs in these 
two intestinal diseases.  
 
Microarray profiling identified differentially expressed miRNA in the intestinal mucosa 
overlying strictured and non-strictured CD tissue samples and in six CRC cell lines 
cultured in hypoxic conditions compared to normoxia. Validation experiments using 
qRT-PCR confirmed the differential expression of miR-29a, -29b, -29c, -34a, -493* and -
708 in CD mucosa and miR-21, -210, -30d, -320a, -320b and -320c in CRC cell lines. 
Functionally, over-expression of miR-29b in CD intestinal fibroblasts modulated the 
down-regulation of collagen I and III transcripts and collagen III protein in a TGF-β-
dependent manner. Furthermore, miR-29b induced indirectly the expression of the anti-
apoptotic protein Mcl-1 via the cytokines IL-6 and IL-8. A positive correlation between 
miR-210 and the hypoxia marker CAIX was found in CRC tissue in vivo. Furthermore, 
HCT116 cells cultured under hypoxia were more resistant to the chemotherapy drug 5-FU 
than cells grown under normoxia. Knockdown of miR-21 or miR-30d under hypoxia may 
sensitise CRC cells to 5-FU. CRC cell lines grown under hypoxic conditions present an 
altered cellular metabolic profile compared to their normoxic counterparts. 
 
This thesis has showed that critical miRNAs have a functional role in the progression of 
two important diseases of the intestine. The work presented highlights the potential of 
miRNAs as biomarkers and therapeutic targets to improve the clinical management of 
patients with digestive diseases. 
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Chapter 1: Introduction 
My thesis is based on two diseases of the gastrointestinal tract: Crohn’s disease (CD) 
which is one of the two inflammatory bowel diseases (IBD) and Colorectal cancer (CRC). 
Inflammation is a one of the risk factors for developing IBD-associated CRC and 
microRNAs (miRNAs) are able to regulate a large number of cellular processes that are 
important in health and disease. Therefore, my project is split up in two individual, but 
overlapping, project areas based around the functionality of miRNAs and the presence of 
hypoxia as a modulator of miRNA expression in both cancer and inflammation. 
 
1.1 Colorectal Cancer 
1.1.1 Background  
CRC is the third most common cancer worldwide with approximately 1.4 million new 
cases and around 694,000 deaths in 2014 [1]. CRC is the collective term for all cancers 
that arise in the colonic segments (caecum, ascending, transverse, descending and 
sigmoid colon) and the rectum. CRC can occur anywhere along the colon but left sided 
CRC is more commonly seen [2] (Fig. 1.1). Biological ageing is a major risk factor for a 
large number of cancers including CRC. Incidence rates increase greatly from the age of 
50, with the highest incidence in individuals over 85 year old [3]. Besides ageing, 
lifestyle habits can substantially contribute to the risk of developing CRC. High meat 
consumption [4], smoking [5] and heavy alcohol intake [5, 6] have all been linked to the 
development of CRC. Furthermore, an active lifestyle can reduce the risk of developing 
various cancers, including CRC. Physical activity is inversely correlated with risk in a 
dose-dependent manner [7, 8]. By contrast, the metabolic syndrome which includes a 
group of clinical measures, such as obesity, impaired glucose regulation (diabetes) and 
elevated blood triglyceride levels, is now closely linked to the increased incidence of 
CRC [9]. Indeed, studies have demonstrated that an active lifestyle in combination with a 
healthy diet could prevent a large proportion of CRC [10].  
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Members of families with a history of CRC are at increased risk of developing CRC. For 
instance, individuals with a first-degree relative (FDR) with CRC have a relative risk of 
2.25 and this increases to 4.25 if there are multiple FDRs with CRC [11]. Also, a personal 
history of IBD, such as CD or Ulcerative Colitis (UC), increases the risk of developing 
CRC. In 1925, Crohn and Rosenberg first documented IBD-associated CRC [12] and to 
date approximately 10-15% of all deaths in IBD patients are due to CRC [13]. Therefore, 
close endoscopic surveillance to detect early neoplastic changes within the bowel is the 
recommended treatment management regime for IBD patients. 
 
Figure 1.1. Distribution of CRC along the various colon segments. Approximately 60% of CRCs were 
diagnosed on the left hand side of the large bowel between 2007 and 2009 [2]. Figure adapted from [2].  
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1.1.2 Molecular genetics of CRC 
Around 75% of all CRCs occur sporadically with no notable family history or identifiable 
inherited gene mutation. The remaining cases are either familial CRC (around 20%), 
where at least one blood relative has CRC but without a specific germline mutation, or 
hereditary CRC syndromes (5%) [14]. The next sections will introduce the various sub-
types of hereditary CRC syndromes and elaborate on the key genetic events during 
tumourigenesis. 
 
1.1.2.1 Tumourigenesis 
The epithelium of the colon consists of tens of millions of crypts. Intestinal stem cells 
located at the bottom of each crypt multiply and daughter cells migrate upwards along the 
crypt. This process takes around three to six days during which the cells at the top die and 
are replaced by the continuous supply of new cells from below. CRC results from the 
progressive accumulation of genetic and epigenetic alterations that eventually lead to the 
transformation of normal colonic epithelium to adenocarcinoma as initially proposed in 
1990 by Fearon and Vogelstein (Fig. 1.2) [15]. Despite recent advances in the field, this 
model remains one of the best paradigms of the molecular genetics of CRC. Genetic 
alterations often drive the neoplastic process by increasing cell population via activation 
of pathways involved in proliferation and growth, whilst inhibiting cell-cycle arrest and 
cell death. These genes can broadly be classed into oncogenes and tumour suppressor 
genes (TSGs). Generally, TSGs follow the “two-hit-hypothesis” proposed by Knudson 
[16], in which both alleles of the gene must be mutated for the gene to contribute to 
tumourigenesis. One frequently mutated TSG is tumour protein p53 (TP53) and 
homozygous loss of this gene is seen in around 50% of all cancers including 29% of all 
CRCs [17]. By contrast, a single mutation in one of the two alleles of certain oncogenes, 
such as kirsten rat sarcoma viral oncogene homolog (KRAS), is sufficient to promote 
cancer development. Recent efforts have focused on large scale sequencing of CRC 
tissue, which has demonstrated the presence of tens of thousands of somatic mutations, 
although only a handful of these are considered crucial to “drive” tumourigenesis [18-21]. 
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These driver genes are thought to give a selective growth advantage to the cell and to be 
fundamental in the development of CRC, unlike “passenger” mutations that seem to be 
insignificant with regard to tumour growth. CRC driver genes include adenomatous 
polyposis coli (APC), TP53 and KRAS and will be discussed in more detail below. 
 
Genetically, the majority of CRCs (~80%) can be divided into two groups: chromosomal 
instable (CIN, ~60%) and microsatellite instable (MSI, ~20%) tumours, each displaying a 
distinct pattern of genetic alterations. More recently, an additional subgroup of cancers 
with microsatellite and chromosomal stable (MACS) tumours has been identified. Each 
group will be discussed in more detail below.  
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Figure 1.2. The adenoma-carcinoma sequence. (A) This overview of the adenoma-carcinoma model 
separates the genomic instability pathways between CIN and MSI. CIN is characterised by gross 
chromosomal losses and gains through genetic alterations. Mutations, in particular in APC and KRAS, are 
observed in the early stages of CRC, whilst mutations in SMAD4, loss of 18q chromosome and mutations in 
TP53 are considered to be events contributing to transformation of late adenoma and carcinoma. The MSI 
pathway occurs through defects in the DNA mismatch repair mechanism. Mutations in APC and KRAS are 
often seen. (B) A schematic overview of the adenoma-carcinoma sequence in CRC. Early manifestations of 
colorectal neoplasia are aberrant crypt foci which could progress into adenomatous polyps. These polyps 
can acquire additional mutations and may progress into adenoma and eventually carcinoma. (Panel A and B 
are adapted from [22] and [23], respectively).  
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1.1.2.1.1 Chromosomal instability 
CIN is characterised by an accelerated rate of allelic gains or losses and gross 
chromosomal abnormalities, and is present in the large majority of CRC cases. This may 
result in an imbalance in chromosome number (aneuploidy) and a high frequency of loss 
of heterozygosity (LOH). Tumours that develop through CIN often acquire mutations in 
APC, TP53, and the KRAS oncogene [24].  
 
APC. In CRC, the APC gene was one of the first genes discovered in patients with 
familial adenomatous polyposis (FAP) [25, 26]. These individuals harbour a germline 
mutation in one copy of the APC gene and are predisposed to the development of large 
number of polyps that, if left untreated, will result in CRC. In addition, APC is frequently 
mutated in the majority of sporadic CRC [27]. APC is a key inhibitory molecule in the 
Wnt pathway promoting the degradation of β-catenin (Fig. 1.3). In the absence of APC, 
β-catenin is stabilised and is translocated to the nucleus. Here, it forms a complex with 
transcription factors resulting in transcription of Wnt target genes which are involved in 
proliferation and differentiation pathways [28]. Within the crypt of the colon, the 
constitutive activation of Wnt signalling leads to extensive proliferation of the 
stem/progenitor cells and development of cancerous tissue. Interestingly, genetic 
alterations in APC never lead to a complete loss of protein function suggesting that an 
optimal level of Wnt signalling is favourable in tumour progression, the so called the 
“just-right” theory [29]. Furthermore, in cases where APC is not directly mutated, the 
Wnt pathways is indirectly activated by mutations in other key players, such as axis 
inhibition protein 2 (AXIN2) [30] and β-catenin (CTNNB1) [31].   
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Figure 1.3. The canonical Wnt signalling. Activation of the canonical Wnt signalling pathway requires 
the binding of Wnt ligands to both Frizzled receptor and its co-receptor Lrp5/6. Activation induces 
stabilisation of β-catenin through Dishevelled (Dvl)-mediated inhibition of the destruction complex. 
Stabilised β-catenin accumulates in the nucleus where it recruits TCF and activates the transcription of Wnt 
target genes with the help of co-factors including BCL9. Secreted inhibitors such as DKK-1, DKK-2, and 
DKK-3 prevent canonical signalling through negative actions on Lrp5/6. Lrp5/6, LDL receptor-related 
proteins 5/6; DKK, Dickkopf; BCL9, B cell lymphoma 9; GSK3b, Glycogen synthetase kinase 3 beta; 
WTX, Wilm’s tumour suppressor gene; CK1, casein kinase 1. Figure adapted from [32].  
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KRAS. The KRAS oncogene is mutated in 30-50% of CRC tumours [33] and is seen as a 
secondary event following loss of APC (Fig. 1.2). The Ras protein is part of the epidermal 
growth factor (EGF) pathway where it plays a role as an on/off switch. Mutations often 
result in a permanent “on” state of the pathway, leading to proliferation and malignant 
transformation. Interestingly, the status of KRAS is known to stratify patients with respect 
to therapeutic response: tumours with activating mutations in this gene do not respond to 
anti-EGFR targeted therapy with antibodies [34, 35].  
 
TP53. P53 is known as the “The guardian of the genome” [36]. Induction of p53 through 
DNA damage and genotoxic stress results in growth arrest or apoptosis, and acts to 
reduce the risk of malignant transformation, which highlights the important function of 
this TSG [37]. Unsurprisingly, TP53 is the most frequent mutated TSG in human cancers 
and approximately 29% of all CRC cases harbour mutations in this gene [38, 39]. 
Mutations in TP53 are more often seen in more advanced stage CRC, suggesting that the 
mutation in TP53 is a late event in the adenoma-carcinoma sequence (Fig. 1.2) [17, 40]. 
 
Other. Further additional alterations, such as loss of the 18q chromosome, are frequently 
observed in up to 70% of CRC [41]. A number of key genes are located on this 
chromosome segment, including deleted in colorectal carcinoma (DCC) [42], mothers 
against DPP homolog 2 (SMAD2) [43], and SMAD4 [44]. Smad2 and 4 are both 
mediators of the transforming growth factor beta (TGF-β) pathway regulating cell growth 
and differentiation. Moreover, recent studies have identified three new CIN-suppressor 
genes: phosphatidylinositol glycan anchor biosynthesis class N (PIGN); mex-3 homolog 
C (MEX3C); and zinc finger protein 516 (ZNF516). These genes are encoded on 
chromosome 18q are lost in 79% of tumours with an abnormal number of chromosomes 
[24]. 
 
Over the past decades, extensive research has pin-pointed the mutations involved in the 
adenoma-carcinoma sequence, which is visualised as a step-wise progression. 
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Nevertheless, it is the accumulation of the majority of these mutations, rather than the 
order, that appears pivotal for the development of CRC [15]. 
 
1.1.2.1.2 Microsatellite instability 
MSI is characterised by hypermutation caused by functional loss of DNA mismatch repair 
(MMR) genes and occurs in around 15% of all sporadic CRC cases [45, 46]. 
Microsatellites are repetitive DNA sequences such as (A)n or (CA)n repeats that occur 
randomly throughout the genome. These sequences are particularly prone to changes 
through damage and replication, and mutations are mainly due to base-base mismatches 
that have escaped the cellular proofreading mechanism of DNA polymerases [47]. 
Duplication or loss of these repeats often results in frame shift mutations in the open 
reading frame that alter the amino acid sequence, thereby modifying the protein that is 
expressed. These frame shifts inevitably lead to mutations in important TSG or oncogenes 
which eventually contribute to the accumulation of mutations seen in CRC. The MMR 
system consists of six genes: MutL homolog 1 (MLH1); MutS homolog 2 (MSH2); 
MSH3; MSH6; post-meiotic segregation-1 (PMS1) and PMS2 [48, 49]. They function as a 
back-up mechanism that recognises mutations and degrades the newly-synthesised strand 
in order to give the DNA polymerase a second chance to repair the DNA. When this 
MMR system is impaired, genome-wide mutations accumulate during DNA replication, 
usually within microsatellites, giving rise to MSI and eventually cancer.  
 
The majority of sporadic microsatellite unstable cancers are CpG island methylator 
phenotype positive (CIMP+), resulting from promoter hypermethylation of the MMR 
gene MLH1 [50]. This is in contrast to the mutations in the MMR genes which gives rise 
to the hereditary Lynch syndrome (LS) (Section 1.1.2.2), suggesting the existence of 
distinct underlying molecular pathways [51, 52]. For example, CIMP+ tumours are 
associated with mutations in the BRAF gene in both sporadic microsatellite stable and 
unstable tumours [53-55], which are rare in LS. Also, CIMP+ cancers are more frequently 
observed in the proximal colon compared to distal colon and rectal cancers [55-58], 
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indicating that CIMP+ tumours form a clear subgroup within MSI cancers. Screening for 
MSI in sporadic CRC tumours is important as this may have potential prognostic and 
therapeutic value. For instance, cancers with high MSI (H-MSI) are reported to have 
better clinical outcome than low or non-MSI tumours [59-61]. Also, H-MSI tumours are 
shown to be more resistant to first line drug treatments such as 5-fluorouracil (5-FU) [62-
64]. 
 
1.1.2.1.3 Microsatellite and chromosome stable tumours 
A third subgroup of tumours that are neither CIN nor MSI was first described in 1999 
[65]. Georgiades and colleagues observed tumours that were microsatellite and 
chromosome stable or MACS. Although, subsequent studies have documented this 
subgroup of tumours in more detail, controversy about the true classification of this group 
remains. Several studies have demonstrated significant differences in clinicopathologic 
features of MACS tumours compared to the other two subtypes. For example, MACS 
tumours are more likely to develop in younger patients [66] and are localised more distal 
within the colon [67]. They have also shown to be more poorly differentiated [68] and 
more invasive at the time of diagnosis [56]. By contrast, two studies have demonstrated 
no significant differences in any clinicopathologic features [69, 70], however it should be 
acknowledged, that the sample size in the studies mentioned above are relatively small 
which may be a possible explanation for the opposing conclusions.   
 
Despite the giant leap forward in defining the genetic changes and altered pathways in 
CRC since the first proposed mechanism by Vogelstein and Fearon, the exact underlying 
mechanism by which CRC evolves has yet to be defined. Our understanding of the true 
impact of the many genes identified as involved in the development of CRC remains 
incomplete. It is likely that only some of these genes are crucial for the survival and 
migratory phenotype of metastatic cancer cells. It is also quite possible that further 
oncogenes and TSG genes, that play a key role in the progression in CRC remain to be 
discovered.  
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1.1.2.2 Hereditary CRC syndromes 
Hereditary CRC syndromes account for around 5% of all CRC cases; these cases are 
highly penetrant and passed on to the offspring in a Mendelian manner. Hereditary non-
polyposis colorectal cancer (HNPCC), or Lynch syndrome (LS) and FAP make up the 
bulk of these syndromes. More rare CRC syndromes constitute the remainder of cases. 
The two main forms, LS and FAP will be discussed in more detail below, and all 
hereditary CRC syndromes are summarised in Table 1.1. 
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Table 1.1 Hereditary CRC syndromes. LS and FAP are the two main forms of hereditary CRC 
syndromes, both with high penetrance. Other rare forms of CRC syndromes make up the remaining 
hereditary CRC cases.  
 
Syndrome Features Genetic mutation(s) 
Lynch syndrome 
Early onset, multiple colorectal 
polyps, ~80% penetrance 
DNA mismatch repair genes, 
MSH2, MSH6, MLH1, PMS2  [71-
73] 
Familial 
adenomatous 
polyposis 
100-5000 adenomatous colorectal 
polyps, 100% penetrance 
APC [25, 26] 
MUTYH-associated 
polyposis 
Multiple adenomatous colonic polyps 
(10-100) 
MUTYH [74] 
Peutz-Jeghers 
Hamartomatous GI polyps (5-100),  
~40% penetrance 
LKB1 [75, 76] 
Juvenile polyposis 
Early onset, Hamartomatous GI 
polyps (50-200), 10-40% penetrance 
SMAD4, BMPR1A [77, 78] 
POLE/POLD1 
Early onset, multiple adenomas, 
dominant inheritence 
POLε/POLD1 [79, 80] 
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LS is the most common form of hereditary CRC and is an autosomal dominant condition 
in which individuals development a small number of polyps in the colon. Affected 
individuals have a cumulative risk of developing CRC of 60-70% in men and 30-40% in 
women [46, 81]. Patients harbour mutations in DNA MMR genes, most commonly in 
MSH2, MLH1, MSH6 [72, 73] and PMS2 [71], resulting in MSI. Besides CRC, patients 
with LS have an increased risk of developing other cancers such as endometrium and 
stomach cancers [82, 83].  
 
FAP is the best characterised hereditary CRC syndrome where patients carry a mutation 
in one of the APC alleles [25, 26]. The syndrome is characterised by the development of 
many precancerous colonic polyps at a young age. Over time, the size and number of 
these polyps can increase significantly, ultimately reaching up to 5,000 in number. A 
large number of these polyps harbour a second mutation in the APC gene, of which the 
majority (>90%) are nonsense or frameshift mutations leading to a truncated APC 
protein. Due to the high number of precancerous polyps, nearly all FAP patients go on to 
develop CRC by the time they reach 40 years of age [84]. Therefore, the recommended 
management for germ-line mutation-positive members of families with FAP is early 
surveillance with endoscopy and genetic tests to identify carriers. Total resection of the 
colon is advised for patients that test positive for FAP (reviewed in [85]). 
  
1.1.3 Diagnosis and treatment of Colorectal Cancer 
 
1.1.3.1 Diagnosis 
Over the past decade, the diagnosis of CRC has massively improved mainly due to 
national bowel cancer screening programmes. Since 2003, men and women between the 
ages of 60-74 that are asymptomatic are invited to participate in these programmes every 
two years. They consist of a faecal occult blood test (FOBt), using a kit which can be 
easily performed at home. Individuals whose samples test positive for traces of blood are 
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invited for a colonoscopy procedure, which involves the visualisation of the distal part of 
the colon with a camera. Biopsies are collected for histopathological examination and/or 
suspicious lesions can be removed during the same procedure. Certain risks are associated 
with a colonoscopy procedure; major risks such as bleeding and perforation of the bowel 
wall occurs in approximately 1 in every 1000 procedures [86, 87]. Despite these risks, 
colonoscopy in combination with FOBt remains the gold standard to evaluate colonic 
mucosa and detect early adenomas [88]. From March 2013, a new screening test is being 
piloted in six bowel cancer screening centres. Men and women from the age of 55 are 
invited for a flexible sigmoidoscopy to identify pre-cancerous polyps [89]. A 
sigmoidoscopy carries reduced risks compared to a full colonoscopy and this screening 
pilot will indicate whether similar diagnostic rates may be achieved with this less risky 
approach. Other techniques including CT and high-resolution MRI are valuable for 
precise localisation of the tumour and for accurately measuring the spread of the tumour 
into the surrounding tissue.  
 
Once diagnosed, staging of the tumour is usually done according to the Tumour, Node, 
Metastasis (TNM) system. This is based on the local invasion, the degree of lymph node 
involvement, and whether there is any metastasis of the intestinal tumour to distant sites. 
The system is used to guide treatment management and prognosis and has been under 
continual refinement and its most recent revision (7
th
) was published in 2010 [90]. The 
more advanced TNM staging system has been gradually replacing the Dukes’ 
classification, which was the first clinical staging system [91-93]. In addition to TNM, a 
much broader staging system using numbers I to IV may be used, in which a higher 
number depicts a more aggressive cancer. Table 1.2 summarises the features of TNM 
staging in and shows the comparison to the other staging systems. 
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Table 1.2 Colorectal cancer staging systems. Overview of TNM staging definitions in CRC in relation to 
other staging systems. 
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1.3.1.2 Treatment of Colorectal Cancer 
Treatment of CRC is generally a combination of surgery, radiotherapy and chemotherapy; 
however, the tumour stage and the degree of tumour differentiation usually determine the 
treatment regime. Also, localisation matters as treatment management for colon and rectal 
cancers differ dramatically. 
 
1.3.1.2.1 Colon cancer 
The treatment of colon cancer is guided by tumour staging and the individual health of 
the patient. Survival rates for localised CRC (Stage 0 and I) have steadily increased 
(around 90%), and for these patients surgery alone has a high curative rate [94]. However, 
despite increasing efforts in the diagnosis of CRC, between 2004 and 2010 only 40% of 
all CRC cases were diagnosed at stage 0 to I [94]. For the majority of patients with stage 
II and III (node-positive) disease, post-operative adjuvant chemotherapy is recommended 
to decrease the risk of recurrence and increase survival rates. The chemotherapeutic agent 
5-FU has been the standard first-line treatment for the past 40 years [95]. In recent years, 
the availability of other compounds in combination with 5-FU have broadened treatment 
options. Adjuvant treatment with 5-FU/Leucovorin has been shown to increase overall 
survival in a number of studies [96-98]. This combined treatment now forms the basis of 
treatment for patients with CRC stage III; the use in stage II CRC tumours is more 
controversial [99]. In advanced CRC (stage IV) the tumour has spread to neighbouring 
tissue and distant organs and surgery alone is unlike to cure these cancers. In addition to 
5-FU/Leucovorin, compounds such as oxaliplatin (FOLFOX) and irinotecan (FOLFIRI) 
are often given. Despite the relatively high toxicity and unpleasant side effects, the use of 
FOLFOX [100-102] and FOLFIRI [103-106] has improved the survival in advanced 
CRC. 
 
In recent years, research has shed light on the importance of particular 
molecules/pathways that may serve as potential therapeutic targets. Targeted therapies, 
such those using monoclonal antibodies, often have less severe side effects and can be 
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used in combination with other chemotherapy drugs. The use of panitumumab and 
cetuximab, which target the EGFR pathway, have shown promising potential in 
improving survival of patients with metastatic CRC when used in combination with 
conventional therapy such as FOLFOX and FOLFIRI [34, 35, 107-111]. However, some 
of these studies have demonstrated the efficacy only in KRAS wild-type tumours, 
indicating that KRAS mutation status can be used as a negative predictor of response to 
anti-EGFR treatments [34, 35].  
 
1.3.1.2.2 Rectal cancer 
Rectal cancer arises in the most distal part of the large bowel which extends from the end 
of the sigmoid colon to the anus. Due to its location, the management of rectal cancer is 
different to that of cancer of the colon. For individuals diagnosed with rectal cancer, 
assessment of the precise localisation is essential for optimal treatment. Accurate 
measurement of the tumour spread is generally done with high-resolution MRI in order to 
establish the depth of invasion in the bowel wall [112]. This pre-surgery work-up of 
tumour characteristics can significantly improve surgery outcome. Surgery techniques for 
rectal cancer have dramatically improved over the past century. Abdominoperineal 
resection (APR), removal of the rectum and the insertion of a colostomy (stoma), was the 
standard of care for nearly 80 years. Improvements were necessary to address the high 
mortality rates and morbidity, such as impotence and bladder dysfunction, and to decrease 
local recurrences. In 1982, the introduction of total mesorectal excision (TME) 
dramatically changed the management of rectal cancer.  This surgery considers the plane 
of the tissues within the rectum allowing complete removal of the mesorectum, including 
its surrounding vessels and lymphatic system, which in turn reduces local tumour 
recurrence [113]. Due to these improvements, TME is now considered the gold standard 
surgical treatment for rectal cancer.  
 
Neoadjuvant treatment in the form of pre-operative chemoradiation therapy (CRT) is the 
standard care for all patients with stage II and III rectal cancers. Decreased recurrence 
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rates are seen with pre-operative CRT compared to post-operative CRT, although trials 
demonstrated no effect of pre-operative CRT on overall-survival (OS) rates [114, 115]. 
Despite the controversial debate on the use of neoadjuvant therapy, there is a clear 
advantage to treating with radiation before TME in order to improve local control [116-
118] and survival [119] in locally advanced rectal cancer. The main purpose is to down-
size/down-stage the tumour in order to increase the resectability and decrease the chances 
of recurrence. Also, tumours close to the sphincter (muscle that controls incontinence) 
require traditional surgery removing the anal opening, necessitating a stoma. Down-sizing 
of the tumour can potentially allow for a sphincter-sparing TME which can improve 
quality of life post-surgery [120]. Despite the major improvements in the management of 
CRC, tumour resistance to current treatment regimens remains a key challenge. There is 
little understanding of the mechanisms that underlie this resistance. Stratification of 
patients most likely to benefit from certain treatment will improve outcome and reduce 
healthcare burden and costs, yet to date, no such prognostic marker has been identified.  
 
1.1.4 Tumour hypoxia  
Over the past decades, it has become apparent that the metabolic control of tumour cells 
and the tumour microenvironment are very important, and need to be considered 
alongside genetic and epigenetic stress changes to the cancer genome. Low oxygen 
tension (hypoxia) within solid cancers is one of the major contributions to therapy 
resistance (reviewed in [121-123]). Also, solid tumours with hypoxic regions have a poor 
prognosis and higher recurrence rates compared to their non-hypoxic tumours [124, 125]. 
In the absence of oxygen, tumour cells adapt by activating pathways that promote tumour 
cell survival and metastatic behaviour, making therapies targeting hypoxia-induced 
pathways a promising intervention. 
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1.1.4.1 Hypoxia-induced factors  
Many of the cellular responses to hypoxia occur as a result of changes in hypoxia-
induced-genes and these genes are under the strict control of hypoxia-inducible-factors 
(HIFs) [126]. HIF is a heterodimeric transcription factor that is composed of a 
constitutively expressed HIF-β subunit and one of the three oxygen-regulated alpha 
subunits (HIF-1α, HIF-2α or HIF-3α). Under normal oxygen concentrations, usually 
between 3.1-8.7% [127], the HIF-α subunits are rapidly degraded by hydroxylation of key 
proline residues in the highly conserved oxygen-dependent degradation domain (ODD; 
Fig. 1.4). Hydroxylation is carried out by specific proline hydroxylase enzymes (PHD1-3) 
[128, 129], and is necessary for the recognition of HIF-α by the von Hippel-Lindau 
(VHL) protein. VHL is the recognition component of the E3-ubiquitin-protein ligase 
complex which directs HIF-α for degradation by the 26S proteasome [130, 131]. As the 
oxygen tension drops, HIF-α units are increasingly stabilised, however, the oxygen 
sensing mechanism of HIF hydroxylases is not completely understood. Once stabilised, 
the HIF-α units will form heterodimers with the HIF-β subunit and translocate to the 
nucleus. Here, it activates transcription through interaction with cofactors CREB-binding 
protein (CBP) and p300. Evidence has emerged that these heterodimers bind directly to 
genes that contain hypoxia-responsive-elements (HRE) through the use of prediction tools 
and expression microarray analysis [132] and chromatin immunoprecipitation (ChIP) in 
combination with DNA microarray [133, 134] or gene expression arrays [135]. 
Furthermore, ChIP in combination with sequencing techniques enabled identification of 
additional HIF targets in alternative promoters and even in putative non-coding, 
intergenic regions [136]. In contrast to the main subunit HIF-1α, which is ubiquitously 
expressed, HIF-2α expression is restricted to particular cell types, including vascular 
endothelial cells, lung type II pneumocytes, cardiomyocytes and interstitial cells in the 
kidney [137]. Finally, HIF-3α has less amino-acid sequence homology with HIF-1α and 
HIF-2α and its regulatory mechanism is not fully understood [138].  
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Interestingly, a DNA microarray study revealed that over 2% of all human genes are 
directly or indirectly targeted by HIF-1α in endothelial cells [139]. Many of these targets 
have been shown to be involved in pathways such as cell survival, angiogenesis, tumour 
metastasis, and energy metabolism and will be discussed in more detail below.  
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Figure 1.4. Stabilisation of hypoxia-inducible factor-1α by proline hydroxylation. In the presence of 
oxygen, hypoxia-inducable-factor 1 α (HIF-1α) is hydroxylated by prolyhydroxylases (PHD1-3) and 
targeted for ubiquitination, resulting in degradation by proteasomes. Under hypoxia, HIF-1α is stabilised 
and translocates to the nucleus. Here, it dimerises with HIF-1β and forms a complex with transcription 
factors p300/CBP, which allows transcription of target genes. HIF-1α regulates target genes involved in a 
wide spectrum of cellular pathways necessary for cells to adapt in hypoxic conditions. VHL, Von Hippel-
Lindau; OH, Hydroxyl radical; Ub, ubiquitin; HRE, hypoxia response element. Figure adapted from [140].  
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1.1.4.2 Angiogenesis  
Tumour expansion rapidly distances the tumour cells from local blood supply, thereby 
limiting access to oxygen and nutrients. In these situations, small molecules will fail to 
reach tumour cells and promote the production of signals that initiate the formation of 
new blood vessels from nearby pre-existing capillaries, a process called angiogenesis 
[141]. Key genes involved in angiogenesis are vascular endothelial growth factor 
(VEGF), angiopoietin 1 and 2 (ANGPT1 and ANGPT2), placental growth factor (PGF), 
and platelet-derived growth factor B (PDGFB). In particular, VEGF stimulates the 
proliferation of endothelial cells to control the formation of new blood vessels and seems 
to be the key step to initiate angiogenesis [142, 143]. Early studies demonstrated that 
VEGF is up-regulated in a range of tumours, including CRC, and increased expression of 
VEGF in CRC is correlated with poor prognosis and survival [144]. For this reason, in the 
early 1990s, researchers focussed on angiogenesis blockers as a potential treatment for 
various tumours. The anti-VEGF monoclonal antibody (bevacizumab) was reported to 
potentially inhibit growth of tumour cell lines in mice [145], and clinical trials of 
chemotherapy combined with bevacizumab in metastatic CRC showed an increase in 
survival [146-148]. Therefore, the inhibition of angiogenesis with monoclonal antibodies 
may prove to be an important addition to the spectrum of treatment for CRC. 
 
1.1.4.3 Tumour metastasis  
Hypoxia is a crucial environmental factor that promotes cancer cells to dislodge from the 
intestinal tumour and induce cell migration to distant tissue and organs, called metastasis. 
The metastatic process is complicated and multifaceted and involves the coordination of 
various steps such as angiogenesis, epithelial-mesenchymal transition (EMT), 
extracellular matrix (ECM) modulation, extravasation out of the intestinal tissue, 
circulation, and intravasation and growth in secondary organs. Besides angiogenesis, 
HIF-1α target genes have been shown to be involved in each of the steps crucial for 
tumour metastasis (reviewed in [149]). For example, important EMT regulators, such as 
twist related protein 1 (TWIST1) [150], zinc finger protein SNAI1 (SNAIL) [151], 
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transcription factor 1 (TCF1), zinc finger e-box-binding homeobox 1 (ZEB1) and ZEB2 
[152], have been shown to be regulated by HIF-1α and induce EMT and tumour cell 
dissemination. Furthermore, HIF-1α also increases the production of metalloproteinases 
(MMPs), such as MMP-1 and MMP-2, promoting intravasation [153]. Evidence of the 
involvement of hypoxia in many aspects of the metastatic process has enhanced our 
understanding of the key players in this process. This has provided novel potential 
therapeutic targets for anti-metastatic drugs in cancer therapy.  
 
1.1.4.4 Energy metabolism  
Tumour cells adapt to low oxygen conditions by down-regulating metabolic processes, 
such as mitochondrial oxidative phosphorylation, to reduce ATP utilisation. Under 
hypoxic conditions, tumour cells metabolise primarily glucose into lactate to meet most 
of their energy needs. This suppression of respiratory rate is predominantly orchestrated 
by HIF-1 (reviewed in [154]). Under normal oxygen conditions, pyruvate derived from 
the glycolytic pathway is converted into ATP through the tricarboxylic acid cycle (TCA) 
cycle. Hypoxia-induced expression of HIF-1 diminishes the rate of the TCA cycle by 
down-regulating the expression of pyruvate dehydrogenase kinase 1 (PDK1) [155, 156], a 
key enzyme for the initial step of the TCA cycle. As a consequence, pyruvate is converted 
into lactate by lactate-dehydrogenase A (LDH-A), which is induced by HIF-1 [157]. 
Furthermore, HIF-1 induces the expression of glucose transporters 1 and 3 (GLUT1, 
GLUT3) [158-161] further promoting the cellular glycolytic phenotype under hypoxic 
conditions. 
 
Altered metabolism in tumour cells was observed as early as 1920s by Otto Warburg, 
who noticed that tumour cells were able to sustain high glycolytic rates even in the 
presence of abundant oxygen, commonly called the “Warburg effect” [162]. Notably, a 
wide spectrum of human cancers have since been shown to have high glycolytic rates 
[163]. This feature is now exploited in clinical oncology to detect a variety of cancers 
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including lung, CRC and breast cancer [164]. PET scans use the glucose analogue FDG to 
detect regions of high glucose uptake. To date, it is largely unknown why cancer cells 
maintain a high glycolytic rate under aerobic conditions, as this is far less efficient in 
producing ATP from glucose than the TCA cycle (two ATPs by glycolysis vs 36 ATPs 
via the TCA cycle). One hypothesis is that these cells have been exposed to low oxygen 
conditions previously and are, therefore, selected on their ability to adapt to harsh 
environments and compete for energy [165, 166]. Evidently, high aerobic glycolytic rates 
confer a significant proliferative advantage during malignant transformation. More 
complete understanding of the molecular and physiological consequences of this 
glycolytic phenotype might reveal potential targeted therapies in cancer.  
 
1.1.4.5 Anti-HIF therapeutic strategies 
As a master regulator of downstream cellular pathways under hypoxic conditions, HIF-1 
is the most promising therapeutic target because hypoxic conditions trigger the activation 
of cellular pathways that are not generally induced in normal tissue [167]. Silencing of 
HIF-1 expression by gene interference has previously demonstrated anti-tumour activity 
in vitro and in vivo [168, 169]. However, validation of HIF-1 inhibitors in vivo is 
hampered by a lack of biomarkers consistently associated with HIF-1 in tumour tissue. 
Also, the HIF-1 inhibitors developed so far lack specificity and so HIF-1 inhibition 
cannot be separated from the off-target effects of these small molecules. Overcoming this 
challenge is essential before any potential therapeutic agents can be moved into a clinical 
setting. Nevertheless, two anti-HIF-1 small molecules, PX-478 [170, 171] and EZN-2208 
[172, 173], have entered phase I clinical trials in patients with metastatic cancer after 
promising anti-tumour activity was observed in pre-clinical models. Results from these 
trials will provide insights into the therapeutic effect of blocking HIF-1 signalling in 
cancer patients. However, better molecular understanding of hypoxic pathways, such as 
how metabolic pathways in cancer are altered, is needed to improve patient selection for 
targeted treatment regimes and treatment-response monitoring. 
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1.2 Crohn’s disease  
1.2.1 Background 
CD is one of the two types of IBD which, together with UC, forms a group of 
inflammatory conditions of the small and large intestine. Clinically, CD is a systemic 
relapsing-remitting disease with episodes of acute inflammation that predominantly 
affects the terminal ileum and colon [174]. CD causes significant morbidity with 
symptoms including abdominal pain, diarrhoea, rectal bleeding and weight loss. 
Incidence rates are higher in the western world compared to developing countries, with 
the USA and northern Europe having the highest rates. The aetiology of CD is not fully 
understood despite large cohort studies having provided strong evidence for the 
contribution of various influences including genetic susceptibility, environmental triggers 
and altered immune responses. 
 
1.2.2 Genetic factors and environmental factors 
Family history is a major risk factor for IBD with approximately 5-10% of all patients 
having a positive family history [175, 176].  For CD specifically, reports have shown a 
relative risk of 14 for relatives with patients with CD [177-179]. However, twin studies 
report a modest concordance between identical twins ranging from 20 to 50% [180-182], 
indicative of strong non-genetic components such as environmental triggers.  
 
Early linkage mapping studies in 1996 described the first locus associated with CD 
(inflammatory bowel disease 1, IBD1), which was shared amongst affected individuals 
[183]. This region was later identified as nucleotide-binding oligomerisation domain 
containing 2 (NOD2 or CARD15) [184] and is associated with susceptibility to CD [185, 
186]. The protein encoded by the NOD2 gene is an intracellular pattern recognition 
receptor that senses part of the bacterial peptidoglycan muramyl dipeptide (MDP). 
Therefore, mutations detected in this gene may be responsible for altered 
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immunorecognition of bacterial flora leading to unnecessary inflammation and 
susceptibility to CD [186]. However, NOD2 mutations are not considered to be the 
initiating factor for CD. Only 20% of CD cases carry mutations in NOD2 and these 
mutations are not linked with CD onset in Japanese individuals [187]. Also, NOD-2 
deficient mice do not develop any spontaneous inflammatory lesions [188, 189]. More 
recently, genome-wide association studies (GWAS) have advanced our understanding of 
the role of genetics in CD aetiology. In 2005, a report identified genomic regions such as 
tumour necrosis factor (TNF) superfamily member 15 (TNFSF15) which encodes for 
TNF ligand related molecule 1 (TL1A), to be associated with CD susceptibility [190]. 
Also, genes implicated in autophagy in CD, including variants in autophagy-related 16-
like 1 gene (ATG16L1) and immunity-related GTPase family M (IRGM), are 
susceptibility factors for CD [191-194]. Nevertheless, the contributions of genetic factors 
are complex and despite successful identification of susceptible loci, the precise 
functional allele or causative gene(s) in CD have not yet been defined.  
 
1.2.3 Fibrostenosing phenotype in Crohn’s Disease 
The disease progression of CD can be grouped into three categories: inflammatory; 
penetrating/fistulating and a fibrostenosing phenotype. Within 10 years of diagnosis, 
approximately 37% of CD patients move from an inflammatory phenotype onto a 
penetrating/fistulating phenotype and 30% progress to a fibrostenosing disease phenotype 
[195]. Fistulas are abnormal connections of two body cavities, such as the rectum and the 
vagina, and usually require surgical intervention. The fibrostenosing phenotype has 
significant implications for the patient’s health. For example, the estimated lifetime risk 
of surgery for patients with CD is as high as 70% [196]. Current medical therapies are 
unable to reverse fibrosis once a stricture has developed, and the removal of the narrowed 
tract represents the main indication for surgery in CD [197]. The surgical burden of 
disease has diminished since the introduction of biological therapy, but the costs related 
to surgery still accounts for a fifth of the total direct costs associated with management of 
CD [198]. The key initiatory and regulatory steps in the development of intestinal fibrosis 
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remain largely unknown. Downstream events in the process of intestinal fibrosis in CD 
include excessive synthesis and deposition of ECM components by mesenchymal cells 
such as intestinal myofibroblasts. A complex interplay between mesenchymal cells, 
inflammatory cascades, intestinal microbiota, pro-fibrotic mediators and the ECM itself 
suggests that fibrogenesis, once initiated, is a self-potentiating process (Fig. 1.5).  
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Figure 1.5. Schematic representation of the principle events responsible for the initiation and 
potentiation of fibrosis in the intestine. Epithelial injury and increased intestinal permeability result from 
gut ischaemia, oxidative stress and potentiation of injury by microbes and drugs. This leads to infiltration of 
immune cells into the intestinal wall which results in mesenchymal cell activation and proliferation via the 
secretion of pro-fibrotic cytokines and mediators. The mesenchymal autocrine mechanism allows the self-
potentiation of fibrosis independently of inflammation. Finally, a balance exists between MMPs and TIMPs 
that ensures the regulation of ECM composition. ECM, extracellular matrix; MMPs, matric 
metalloproteinases; TIMPs, tissue inhibitors of matrix metalloproteinase. Figure adapted from [199].  
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There are still significant gaps in our knowledge of the complex network of fibrotic 
mediators in the development of fibrosis. Mounting evidence implicates the pro-
fibrogenic cytokine TGF-β, in particular TGF-β1, as the main driver in fibrosis in various 
organs including the CD intestine [200-204]. TGF-β1 acts by binding to TGF-β receptor 
type II, subsequently activating and phosphorylating receptor type I [205] (Fig. 1.6). The 
resulting receptor complex phosphorylates Smad2 or Smad3, recruits Smad4, resulting in 
the translocation to the nucleus. Here, the complex binds to transcriptional co-activators, 
such as p300/CBP [206], to initiate gene transcription of various genes. In contrast to 
Smad2 and Smad3, Smad7 acts as an inhibitor of the TGF-β signalling pathway [207]. 
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Figure 1.6. The TGF-β signalling pathway. Soluble TGF-β1 binds to the TGF-β receptor II (TGF-β R II) 
to initiate the formation of receptor complexes with TGF-β receptor I (TGF-β R I). Following 
phosphorylation of both Smad2 and Smad3, co-Smad4 aids accumulation in the nucleus. Within the 
nucleus, gene transcription is initiated with the help of other co-activators and transcription factors. Smad7 
act as an antagonist, inhibiting the formation of Smad2/3 and Smad4 complexes. Figure adapted from [208].  
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TGF-β regulates the remodelling of the ECM by increasing the expression of a spectrum 
of molecules such as collagen I [209, 210], collagen II [209, 211, 212], collagen III [209, 
210, 213], collagen IV [214-216], as well as the basement protein laminin [217-219] and 
interstitial matrix molecule fibronectin [217, 218, 220, 221]. In addition, TGF-β down-
regulates collagenases (enzymes that break down collagen) MMP-1 [222-224], MMP-8 
[222] and MMP-13 [222, 224-226] directly or indirectly via the up-regulation of their 
endogenous inhibitors TIMP-1 [223, 227-229], TIMP-2 [214, 223] and TIMP-3 [227, 
230-232]. The overall net effect of these events shifts the equilibrium towards an increase 
in ECM protein deposition eventually leading to fibrosis.  
 
Despite recent advances, our knowledge of the upstream factors that initiate and regulate 
stricture formation in CD remains very limited. Further functional studies are warranted 
to uncover potential therapeutic strategies to prevent or reverse fibrosis and relieve the 
surgical burden of CD patients. There is current unmet need for biomarkers that may 
indicate the presence of on-going fibrosis or predict which CD patients are at high-risk of 
developing a fibrostenosing phenotype (reviewed in [199]). miRNAs are a novel class of 
RNA regulators that have been implicated in many biological signalling pathways 
including cancer and fibrosis. To date, very little is known about the role of miRNAs in 
the control of fibrosis, in particular intestinal fibrosis. 
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1.3 MiRNAs 
 
1.3.1 Background 
MiRNAs were first discovered by Lee and colleagues in 1993, who reported that the gene 
lin-4 does not code for a protein but instead produces a pair of small RNAs [233]. These 
RNAs were shown to have complementarities to multiple sites in the 3’ untranslated 
region (UTR) of the lin-14 gene [233] and this 3’UTR region was previously proposed to 
mediate repression of lin-14 product [234]. These initial observations demonstrated that 
components of the genome traditionally considered non-functional have regulatory 
capacity. High-throughput sequencing has led to the discovery of novel miRNAs [235-
240], many of which still need to be functionally validated. miRNAs have the potential to 
regulate over hundreds of different mRNAs and, in turn, a single mRNA can be targeted 
by numerous miRNAs, resulting in the modulation of important biological pathways 
involved in proliferation, apoptosis and differentiation [241].  
 
1.3.1.1 MiRNA biogenesis  
MiRNAs are endogenous, small non-coding RNAs consisting of 20-23 nucleotides that 
are involved in post-transcriptional regulators of gene expression. Like messenger RNAs 
(mRNA), miRNAs are transcribed by RNA polymerase II (Fig. 1.7) [242, 243]
 
and can be 
derived from independent genes or from introns of protein-coding genes. More than half 
of all miRNAs are clustered along the genome and are transcribed as a single 
polycistronic precursor RNA molecule that can mature into many individual primary 
miRNAs transcripts. Typically, there are two or three miRNA genes in a cluster, 
although, larger clusters have also been identified. For example, the miR-17/92 cluster 
consists of six miRNAs [244, 245], and the two largest clusters in the human genome are 
on chromosome 19 (Chromosome 19 miRNA cluster, C19MC [246, 247]) and  
chromosome 14 (C14MC [248]) which contain 46 and 52 miRNAs, respectively. 
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Clustered miRNAs tend to have similar sequences and are therefore thought to target 
similar genes or genes within the same cellular pathway. The double stranded primary 
miRNA (pri-miRNA) transcripts are cleaved by the Drosha/DiGeorge syndrome 
chromosomal region 8 (DGCR8) microprocessor complex following transcription to give 
rise to the precursor miRNAs (pre-miRNA). During this process, the RNase III enzyme 
Drosha cleaves at the 5’ and 3’ arms of the pri-miRNA hairpin while DGCR8 functions 
as a molecular ruler to determine the precise site of cleavage [249, 250]. The pre-miRNA 
is then exported from the nucleus into the cytoplasm by the GTP-mediated Exportin-5, 
where it is processed into a 20-23 nucleotide long miRNA/miRNA* duplex [251] by 
Dicer/Argonaute (Ago). The guide strand (miRNA) remains associated with Ago forming 
a RNA-Induced Silencing Complex (RISC) (Fig. 1.7). The passenger strand (miRNA*) is 
conventionally degraded shortly after the unwinding process although reports have 
demonstrated that these strands can also act as guide strands [252-254]. To avoid 
confusion, the nomenclature of miRNA has shifted towards the use of miR-3p (from the 
3’ arm) and -5p (from the 5’ arm) for each miRNA strand. This alternative nomenclature 
(-3p and -5p) will be used for the remainder of this thesis. 
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Figure 1.7. miRNA biogenesis and RNA interference. MiRNAs are non-coding RNAs that are 
transcribed from independent miRNA genes or intragenic regions. Pri-miRNAs are cropped by Drosha and 
DGCR8, and exported out of the nucleus by the Exportin-5/Ran-GTP transporter. In the cytoplasm, the pre-
miRNA is spliced by Dicer, and gives rise to the mature miRNA, which in turn is associated with Ago 
proteins to form the RISC complex. Gene target repression is mediated through mRNA cleavage or 
translational inhibition. DGCR8, DiGeorge syndrome chromosomal region 8; TBRP, TAR RNA-binding 
protein; PACT, proteinactivator of the interferon induced protein kinase; RISC, RNA induced silencing 
complex. Figure adapted from [255].  
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1.3.1.2 MiRNA target repression  
The binding of a miRNA to its mRNA targets occurs through complementary Watson-
Crick base pairing within the 5’-UTR, 3’-UTR or the coding sequence (CDS) of the 
mRNA, although pairing at the 3’-UTR is most often seen [256]. Conserved base pairing 
is centered on nucleotides 2-7 at the 5’ end of the miRNA, the so-called “seed region” 
[257, 258]. MiRNAs repress target gene expression in two main manners, namely mRNA 
degradation or translation inhibition. In plants, miRNAs display a high degree of 
sequence complementary to their target genes which allows mRNA degradation through 
cleavage of the mRNA transcripts [259-261]. For animal miRNAs, it remains 
controversial to what extent each mode of action contributes to the regulation of the target 
genes [262]. Initial high-throughput methods indicated that miRNAs predominantly 
function through mRNA degradation [263]. However, re-analysis of this data revealed a 
large amount of translation repression [264]. In support of this, other studies have also 
demonstrated miRNA-mediated translational repression without mRNA degradation 
[265-268]. The primary function of miRNAs is now thought to involve interference with 
the translational initiation process [265, 269-273]. In addition, miRNAs have been shown 
to mediate up-regulation of gene targets [274, 275], which are predominantly observed 
under specific conditions such as cellular quiescence [275]. The miRNA-mediated 
regulation of the transcriptome involves a complex network with many aspects, including 
biogenesis and regulatory mechanisms, still requiring full elucidation.   
 
1.3.2 MiRNAs in colorectal cancer 
MiRNAs play significant roles in regulating protein expression and thus have a role in 
regulating a variety of cellular signalling pathways. Not surprisingly, miRNAs are often 
dysregulated in various diseases, including cancers and have been extensively studied and 
reported (more than 15,000 hits on Pubmed for “microRNAs AND cancer”, as of 
07/05/2015). Calin and colleagues first demonstrated a role for miRNAs in cancer when 
they showed deletion and down-regulation of miR-15 and miR-16 in lymphocytic 
leukaemia [276]. Since then, aberrantly expressed miRNAs have been documented in 
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nearly every cancer (reviewed in [255]). Furthermore, deep sequencing and miRNA 
microarrays have consistently demonstrated altered miRNA expression patterns in CRC 
tumours compared to normal tissue (reviewed in [277]). Most human miRNAs are located 
in regions vulnerable to amplification or deletions and can, therefore, function as 
oncomiRNAs [278] or tumour suppressor miRNAs [279]. No less than 20 different 
studies have reported altered miRNA expression profiling between CRC tissue samples 
and normal tissue (reviewed in [277]). Important miRNAs that have been implicated in 
the tumourigenesis of CRC in more than one study are discussed below.  
 
1.3.2.1 OncomiRNAs  
miR-135b. Oncogenic miR-135b is up-regulated in CRC [280-284]. Functional 3’-UTR 
luciferase reporter assays demonstrated that miR-135 can directly repress the expression 
of APC [281] thereby associating miR-135 with the Wnt signalling pathway, which is 
frequently mutated or repressed in the early stages of CRC. In vivo studies show that 
silencing miR-135b significantly reduces tumour number and load in an animal CRC 
model [285], suggesting miR-135b may be a potential therapeutic target for CRC 
treatment. 
 
miR-21. miR-21 is one of the most intensively studied oncogenic miRNAs. Its up-
regulated expression has been demonstrated in CRC tumours [286], and correlated with 
lymph node positivity and the presence of distant metastases [287]. MiR-21 is involved in 
the majority of oncogenic cellular pathways including cell proliferation, invasion, 
apoptosis and metastasis; however, reports have shown that miR-21 exerts its function 
mainly through the inhibition of cellular apoptosis [288, 289]. Many targets involved in 
apoptosis have been shown to be directly targeted by miR-21 including TSG programmed 
cell death 4 (PDCD4) [290], B-cell CLL/lymphoma 2 (BCL2) [291, 292] and FAS ligand 
(FASLG) [293]. In addition, in colon cancer cells, miR-21 is induced by DNA damage 
and serum starvation, subsequently repressing the expression of cell division cycle 25A 
(CDC25A) resulting in modulation of cell cycle progression [294]. 
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1.3.2.2 Tumour suppressor miRNAs  
Let-7 family. One of the most abundantly dysregulated miRNAs in human cancers is the 
let-7 family. In humans, this family is composed of 13 members located on eight different 
chromosomes [295]. Members of the let-7 family are often down-regulated in various 
cancers including lung [296], gastric [297], ovary [298], and CRC [299]. Gene targets of 
this family include cell cycle regulators and promoters of growth, including KRAS and v-
myc avian myelocytomatosis viral oncogene homolog (MYC), and their expression 
represses cell proliferation and growth [296, 300]. Interestingly, recent studies 
demonstrate that let-7a expression is increased in metastatic CRC with activating KRAS 
mutations [301] and high levels of this miRNA might rescue anti-EGFR treatment in 
metastatic CRC [302]. 
 
miR-143/145. In 2003, Michael and colleagues were the first to demonstrate repressed 
levels of miR-143 and miR-145 in CRC compared to normal tissue [303]; this has been 
subsequently validated by others [304]. Both miRNAs are transcriptional targets of the 
p53 pathway [305, 306] and can regulate cell growth and proliferation in vivo and in vitro 
[304]. MiR-143 suppresses cell growth by directly repressing translation of KRAS [307], 
DNA methyltransferase 3A (DNMT3A) [308] and extracellular-signal-regulated kinase 5 
(ERK5) [309], whilst miR-145 targets insulin receptor substrate 1 (IRS-1) [310] and MYC 
[306] to propagate its tumour suppressor activity.  
 
miR-34a. Another direct target of the TSG p53 is miR-34a [311-316], which has been 
reported to be lost in CRC tissue compared to normal tissue [317-319]. Similar to the pro-
apoptotic function of p53, miR-34a regulates several cellular events including cell cycle, 
migration and apoptosis [311, 320]. MiR-34a targets sirtuin 1 (SIRT1), a histone 
deacetylase, and its down-regulation activates p53 activity creating a positive feedback 
loop [321]. P53-independent activation of the IL-6R/STAT3/miR-34a feedback loop 
suppresses CRC tumour progression in vivo in mice [322], demonstrating the existence of 
alternative upstream regulators of miR-34a. 
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1.3.2.3 MiRNAs in hypoxia  
As discussed previously, hypoxia is one of the environmental conditions linked to tumour 
growth as well as resistance to treatment (Section 1.1.4). Initial reports examined the 
changes in expression of miRNAs to alterations on oxygen tensions [323]. Here, a robust 
signature of 27 miRNAs was identified in a variety of cell types under 0.2% oxygen 
[323]. One of the miRNAs that has been robustly shown to be induced under hypoxic 
conditions is miR-210. This miRNA is up-regulated in various hypoxic cell lines [323-
328] and its up-regulation is mediated through HIF-1 binding at the HRE binding site in 
the promotor of miR-210 [329-331]. The function of miR-210 has now been intensively 
studied and has been implicated in a number of cellular pathways including cell cycle 
regulation [326, 332, 333], angiogenesis [334-337] and cellular metabolism [338-342]. 
However, opposing results suggest that miR-210 could act as an oncogene as well as a 
TSG (reviewed in [343]). For example, miR-210 can promote cancer cell proliferation by 
inhibiting the pro-apoptotic protein E2F transcription factor 3 (E2F3) [344]. In contrast, 
other reports have suggested a pro-apoptotic role for miR-210 via targeting the fibroblast 
growth factor receptor like-1 (FGFRL1) [345]. These contradictory observations suggest 
that the role for miR-210 under hypoxia is cell type and context dependent. However, 
these findings are still in accordance with the heterogeneity of the hypoxic response 
which can influence both cell death and cell survival [346]. Furthermore, miR-210 affects 
cellular metabolism by directly targeting iron-sulfur cluster assembly proteins (ISCU1 
and ISCU2) [339-342]. These proteins are predominantly responsible for mitochondrial 
respiration and energy production. MiR-210-mediated down-regulation of ISCU1/2 
results in a decreased metabolic activity and corresponds with the HIF-dependent 
decrease in TCA cycle [155]. This, in turn leads to increased glycolysis, eventually 
controlling cellular survival during hypoxic stress.  
 
The expression of miR-210 is up-regulated in a variety of cancers including breast [325, 
347-349], head and neck [350, 351], pancreatic [352-354], lung [355-357], renal [342, 
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358, 359] and ovarian cancer [360]. Therefore, elucidating the role of miR-210 in CRC 
would provide further insights into this hypoxamir in solid tumours. 
 
1.3.3 MiRNAs in Crohn’s disease 
Studies investigating altered miRNA expression in IBD including CD are very limited. 
To date, two studies have identified altered miRNA expression between CD and healthy 
control tissue [361, 362]. A number of miRNAs were significantly increased in CD tissue 
compared to healthy controls. Worryingly, there was only limited overlap between the 
two reports (reviewed in [199]). Also, no comprehensive analysis of the role of these 
miRNAs in intestinal fibrosis has been performed. By contrast, miRNAs expression 
profiles of fibrosis in other organs have been extensively documented (summarised in 
Table 1.3). Selected miRNAs important in the development of fibrosis are outlined 
below. 
 
miR-200 family. The miR-200 family (miR-141, -200a, -200b, -200c and -429) regulate 
EMT, a major contributor to fibrosis of the kidney [363-365], heart [366], and liver [367, 
368]; here, loss of E-cadherin is a classic hallmark. Furthermore, animal studies have 
identified a role for EMT in the development of intestinal fibrosis [369]. Down-regulation 
of the miR-200 family is considered a characteristic feature of EMT [370]. This family is 
thought to modulate EMT through targets such as ZEB1 and ZEB2, which are 
transcription repressors of E-cadherin [370], resulting in a reduction of E-cadherin. 
Recent studies have demonstrated that overexpression of miR-200 family members 
increased E-cadherin expression and hindered EMT in vitro [371].  
 
 
miR-29 family. Altered expression of the miR-29 family has been implicated in the 
pathogenesis of fibrosis in various organs. For example, the expression all three members 
is reduced in fibrosis of the kidney [372, 373]
 
and liver [374]. Additionally, miR-29b is 
down-regulated following myocardial infarction [375], in the lungs of patients with 
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idiopathic pulmonary fibrosis [376, 377] and in skin fibroblasts of patients with systemic 
sclerosis (SSc) [378]. MiR-29 regulates directly the levels of ECM molecules by targeting 
the 3’-UTR of various collagen genes including COL1, COL3 and COL4 [375, 378, 379]. 
Importantly, for its role in intestinal fibrosis, miR-29 expression is inhibited by LPS 
stimulation and TNF-α treatment in a NFκβ-dependent manner [374], suggesting a link 
between inflammation and fibrosis. In addition, the expression of miR-29 is also 
modulated by histone-deacetylases (HDACs). Low levels of miR-29b are associated with 
high HDAC-2 expression in models of Duchenne’s muscular dystrophy where fibrosis is 
a significant feature of the disease phenotype [380, 381]. Conversely, miR-29 expression 
is increased by application of class II HDAC inhibitors in hepatic stellate cell activation 
[382], suggesting that epigenetic DNA modifications may also have a role in the 
regulation of miR-29 and therefore have relevance in the treatment of fibrosis.  
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Table 1.3 miRNAs altered in fibrosis. Dysregulated miRNAs in fibrosis of various organs. MiRNAs that 
were dysregulated in two or more organs were included. 
 
 
  
MiRNA Organs 
Anti-/pro-
fibrotic 
Role 
miR-132 Heart, liver Anti Inhibits myofibroblast differentiation [383, 384] 
miR-15/miR-
16 
Liver, lung Anti Increases apoptosis signalling [385, 386] 
miR-155 Liver, lung Pro 
Inhibits mesenchymal-epithelial cross talk [387, 
388] 
miR-17/92 Liver, heart, lung Anti Down-regulates CTGF and TSP-1 [389-391] 
miR-199a/b Heart, lung Pro Increases ECM production [392, 393] 
miR-200a/b Kidney, liver Anti 
Decreases TGF-β signalling and TGF-β-
mediated EMT [387, 394, 395] 
miR-21 
Lung, heart, 
kidney 
Pro 
Activates TGF-β signalling via SMAD7 
repression [396-398] 
miR-29 
Skin, heart, lung, 
kidney, liver 
Anti 
Down-regulates various ECM molecules [372-
378] 
miR-30c Heart, lung Anti Down-regulates CTGF signalling [384, 390] 
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1.3.4 MiRNAs in the clinic 
Cancer remains a leading cause of death worldwide due to lack of early detection, the 
inability to predict recurrence after treatment and a shortage of targeted or tailored 
therapies directly appropriate to the patient and their cancer. Given that survival and 
prognosis are dependent on the tumour stage at the time of detection, diagnostics tools for 
early detection are extremely important. In particular, there is a significant need for 
biomarkers that can be used for screening in a non-invasive manner for diagnosis, disease 
progression, outcome and response to therapy. One of the key advantages of using 
miRNAs as biomarkers is their low degradation rate compared to mRNA or protein, and 
the ease with which they can be detected in frozen or fixed tissue as well as a range of 
biological fluids, such as blood [399, 400], urine [401] and faeces [402]. 
1.3.4.1 Diagnostic miRNAs in CRC  
Early profiling data demonstrated that miRNAs could classify different tumour types 
including CRC [279, 403]. Interestingly, these studies indicate that miRNAs may be more 
reliable than mRNA profiles in the same samples, indicating the potential of miRNAs for 
profiling in cancer diagnosis. Current screening methods for CRC (FOBt) lack sensitivity 
which means a large number of cancers may be missed [404] (approximately 30-50%; 
[405]), and further highlighting the need for better biomarkers. Early reports 
demonstrated that Cox-2 mRNA levels in faeces successfully detected 20 out of 29 CRC 
cases [406] and this significantly increased when used in combination with MMP7 
mRNA [407], suggesting that RNA molecules could potentially be used for early cancer 
diagnosis. More recently, a number of studies have since investigated the expression 
levels of miRNAs in stool samples for diagnostic purposes. miR-143 and miR-145 were 
decreased in the stool of CRC patients [402, 408], which is in accord with the down-
regulation of both miRNAs observed in CRC tissue [303, 309]. Further studies have 
detected altered miRNA expression in CRC stool samples with reasonably high 
sensitivity and specificity: miR-144* (sensitivity 74%, specificity 87%; [409]); miR-92a 
(sensitivity 71.6%, specificity 73.3%; [410]); miR-34b/c (sensitivity 75%, specificity 
87.2%; [411]); miR-21 (sensitivity 55.7%, specificity 73.3%; [410]); and miR-135b 
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(sensitivity 78%, specificity 68%; [412]). Strikingly, miR-92a was down-regulated after 
the tumour was removed [410] and miR-135b significantly correlated with tumour 
staging [412].  
 
Many studies have aimed to investigate the use of circulating miRNAs in the blood for 
diagnostic purposes in CRC. Initial studies by Ng and colleagues reported altered 
circulating levels of miRNAs in the plasma of CRC patients compared to controls [413]. 
In this study, miR-92 was found to be up-regulated in the plasma of patients with CRC, 
an observation which was later confirmed by others [414]. In accordance with stool 
miRNA expression, circulating miR-92 was decreased following tumour removal 
suggesting that this particular miRNA may be used as a marker for tumour recurrence 
[413].  
 
1.3.4.2 Predictive/prognostic miRNAs in CRC  
Current predictive or prognostic biomarkers for tumour progression or treatment response 
in CRC are limited. To address this, the use of miRNAs as potential biomarkers has been 
explored intensively. One particular miRNA (miR-21) has great potential for both 
prognostic and predictive purposes. Several studies have correlated high miR-21 levels 
with clinicopathological features including lymph node positivity [287], metastasis [287], 
poor therapeutic response [286, 415] and shorter disease free survival [286, 416]. In 
addition, miR-21 has now been reported to be associated with a worse prognosis in at 
least nine other cancers, which correlates with the oncogenic activity of miR-21 in a 
range of malignancies. Therefore, miR-21 may be used as a prognostic classifier in a 
variety of cancers.  
 
Tumour resistance to conventional therapy is a major concern in the treatment and 
management of CRC. Recent studies have identified altered miRNA profiles associated 
with resistance that could potentially stratify patients for certain treatment options. 
Interestingly, miR-21 is associated with tumour resistance to the chemotherapy drug 5-FU 
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[286]. In addition, the expression levels of let-7g and miR-181b were inversely correlated 
with 5-FU analogue S-1 treatment, but did not correlate to patient survival [417]. CRT 
exposure in rectal cancer was associated with increased levels of miR-125b and miR-137 
and correlated with poor treatment outcome [418]. Further studies showed that a subset of 
13 miRNAs could form a specific signature that was strongly associated with response to 
CRT [419, 420]. These reports highlight the potential use for miRNA expression profiles 
as diagnostic as well as prognostic or predictive biomarkers. However, further large scale 
clinical studies are needed to assess their true potential.  
 
Finally, the lack of consistency between miRNA expression profiling studies with regards 
to experimental design and/or data analysis is a major concern [421]. Key factors for 
these discrepancies include the variation in miRNA extraction processes, the quality and 
quantity of the extracted miRNAs and, most importantly, the normalisation processes 
during analysis. With a lack of suitable housekeeping genes, normalisation for circulating 
miRNAs is notoriously difficult. Small nuclear/nucleolar RNAs such as RNU6B, RNU44 
and RNU48 are often used [413, 422, 423]. However, their expression can vary greatly 
under different conditions [361, 423] and their use should be validated on a case-by-case 
basis. In addition, exogenous spiked-in RNAs, such as cel-miR-39, cel-miR-54 or cel-
miR-238 may also be used as normalisation controls [399, 424, 425]. Experimental 
variation and the lack of consensus on normalisation strategies for circulating miRNAs 
make comparing various studies extremely difficult.  
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1.4 Hypothesis and aims 
 
In the management of CD, fibrosis and subsequent stricture formation is a major 
complication and often requires surgical intervention. Currently, there is no gold standard 
measure for disease activity and progression. Imaging of the bowel by MRI or CT scan 
are readily used, however, they are costly and submit the patient to ionizing radiation. 
While these tools are necessary and useful for the evaluation of the disease activity, they 
offer no significant prognostic value. Therefore, there is an unmet clinical need for robust 
prognostic biomarkers.  
 
Understanding the reasons for tumour resistance and developing a way to identify and 
predict individuals who would benefit the most and least from neo-adjuvant therapy, 
remain crucial aims for the management of CRC. The tumour microenvironment, such as 
low oxygen conditions, are crucial factors that influence the tumour response to 
conventional therapies of which the underlying mechanisms remain poorly understood.  
 
MiRNAs are non-coding RNAs involved in important biological processes including 
proliferation, differentiation and apoptosis. Over the past two decades, the amount of 
studies on miRNAs has been exponentially rising and they are now considered key 
regulatory molecules in a variety of processes including inflammation and 
tumourigenesis. It is important to understand fully their involvement in intestinal cancer 
and inflammatory disease and to assess their potential as biomarkers and therapeutic 
targets. My hypotheses have been developed with these factors in mind. 
 
Firstly, I hypothesise that miRNA expression profiles are altered between mucosa-
overlying non-strictured (NSCD) and mucosa-overlying-strictured (SCD) areas of 
intestinal tissues in CD patients.  
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Aims to test this hypothesis: 
 
1. Identify and validate differentially expressed miRNAs between paired NSCD vs 
SCD tissue samples (Chapter 3); 
2. Isolate and optimise transfection protocols in intestinal fibroblasts from CD 
patients (Chapter 3); 
3. Elucidate the functional role of candidate miRNAs in intestinal fibroblasts isolated 
from CD patients and their localisation in intestinal tissues of CD patients 
(Chapter 3); 
4. Determine the expression of the miR-29 family in NSCD vs SCD tissues (Chapter 
4); and 
5. Elucidate the role of miR-29b in intestinal fibroblasts isolated from CD patients in 
respect to its regulation of ECM molecules (Chapter 4). 
 
Secondly, I hypothesise that miRNAs are differentially expressed under hypoxic 
conditions in CRC in vitro and in vivo, and influence the response to chemotherapy drugs.  
 
To address this hypothesis I aim to: 
 
1. Identify and validate differentially expressed miRNAs under hypoxic conditions 
in vitro using six CRC cell lines as a model (Chapter 5); 
2. Validate candidate miRNAs in CRC in vivo and correlating its expression to 
hypoxia marker (Chapter 5); 
3. Elucidate the role for candidate miRNAs in drug resistance under hypoxic 
conditions in vitro (Chapter 5); and 
4. Identify cellular metabolic changes under hypoxic conditions in six CRC cell lines 
(Chapter 5). 
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Chapter 2: Material and Methods 
2.1 Crohn’s disease patient recruitment 
Surgical resection specimens from patients with stricturing CD were collected (Table 
2.1). Diagnosis of CD was ascertained according to the usual clinical criteria [426]. To 
exclude inflammation as an experimental variable, mucosal specimens were taken from 
macroscopically non-inflamed SCD and NSCD ileum and colon. The site and extent of 
disease were established by endoscopy, histology and radiology and strictured areas 
identified during surgery. CD patients had not taken steroids for at least three months 
prior to resection, and none were taking methotrexate or anti-TNF-α agents at the time of 
surgery. The study received the appropriate local Ethics Committee approvals (East 
London REC2) and informed consent was obtained in all cases. 
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Table 2.1. Patients who underwent surgical resection for stricturing complications. Fresh surgical 
resection specimens and archived Formalin-fixed paraffin embedded blocks of 22 CD patients. Samples 
were used where indicated. NSCD: Non-stricture CD, SCD: stricture CD. 
 
Sample 
ID 
Location 
Tissue 
sample 
Array 
Validation 
(RNA) 
Functional 
studies 
(cell culture) 
Archive blocks  
CD1 Ileum NSDC + SCD   √  
CD2 Ileum NSCD + SCD   √  
CD3 Ileum SCD   √  
CD216 Ileum NSCD + SCD √ √   
CD328 Colon NSCD √    
CD347 Colon SCD √    
CD353 Ileum NSCD + SCD √ √  √  
CD360 Colon SCD √   √ 
CD362 Ileum SCD √   √  
CD373 Ileum NSCD + SCD √ √  √  
CD377 Colon NSCD √    
CD381 Ileum SCD √    
CD397 Ileum NSCD + SCD  √   
CD398 Ileum NSCD + SCD    √  
CD417 Ileum NSCD + SCD  √   
CD419 Ileum NSCD + SCD    √  
CD425 Ileum NSCD + SCD  √ √ √ 
CD435 Ileum NSCD + SCD  √   
CD484 Ileum NSCD + SCD  √   
CD495 Ileum SCD   √  
CD522 Colon NSCD   √  
CD637 Ileum SCD  √ √  
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2.2 MiRNA arrays 
Total RNA (2 µg) from 12 (Table 2.1) mucosa overlying strictured areas or mucosa 
overlying non-strictured CD areas were analysed by Illumina v.2.0 miRNA array 
platform which covers 95% of all miRNAs in miRBase v.12 [427]. A workflow of the 
array is depicted in Fig. 2.1. Array data processing and analysis were performed with 
Illumina GeneStudio software (www.illumina.com).  Total RNA (2 µg) of six colorectal 
cell lines grown under three different oxygen conditions (20.9%, 1% and 0.2%) for 48 hr 
were analysed using the LNA 7
th
 version miRNA array which covers 3,100 miRNAs in 
miRBase v.19 (Exiqon, Denmark). The hypoxic state was confirmed for each of the cell 
lines by western blot of HIF-1α (data not shown). Data was normalised to the plate 
intensity mean and then log transformed. 
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Figure 2.1.  Illumina miRNA array workflow. (A-B) 200ng of RNA is polyadenylated and reverse 
transcribed into cDNA using biotinylated oligo-dT primers with a universal PCR sequence at its 5’-end. (C-
D). The biotinylated cDNA is annealed to a set of miRNA-specific oligos (MSOs) that correspond to all the 
targeted miRNAs on the array. A MSO contains three parts; 1) 5’end with a universal PCR primer site 2) an 
address sequence that complements a corresponding capture sequence on the array 3) 3’ end with a 
miRNA-specific sequence. After the oligos are annealed they will undergo extension only if their 3’ bases 
are complementary to the sequence in the cDNA template. (E-F) A fluorescently labelled complementary 
strand is produced using the common PCR primers from the extended MSO. (G) The labelled strands are 
hybridised to the bead on the array containing the complementary address sequence. Fluorescent intensity is 
measured at each bead position corresponding to each individual miRNA. 
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2.3 Isolation of intestinal fibroblasts 
Human fibroblasts were obtained from mucosal layers of surgical resections in complete 
Dulbecco`s Modified Eagles Medium (DMEM, PAA, UK). Full thickness resection of 
strictured areas and non-inflamed areas were examined macro- and microscopically, and 
mucosa was separated from the muscle layers before being washed twice with Hank’s 
Balanced Salt Solution (HBSS, Invitrogen, UK) with 1 mM EDTA for 10 min at 37°C 
under gentle agitation to remove epithelial cells. Specimens were cut into smaller pieces 
and incubated in 20 ml DMEM with 1 mg/ml collagenase type 1α (R&D Systems, USA), 
and 10 U/ml DNase I (Roche, UK) for 60-90 min under gentle agitation. Cells were 
washed once with Phosphate Buffered Saline (PBS, Invitrogen, UK) and resuspended 
twice with DMEM and then cultured in T25 cm
2 
flasks.  
 
2.4 Cell culture maintenance of CRC cells and intestinal 
fibroblasts 
Cell culture was performed in flow hoods using sterile handling techniques. Three colon 
cancer cell lines (DLD-1, HCT116 and HT29), three rectal cancer cell lines (HT55, 
SW837 and VACO4s) and cervical cancer cell line HeLa were grown in T75cm
2 
vented 
flasks (VWR, UK) at 37°C in a 5% CO2 atmosphere containing 15ml DMEM 
supplemented with 10% Fetal bovine serum (FBS, PAA, UK), and 100 U/ml penicillin 
and 100 µg/ml streptomycin (PenStrep, PAA, UK). All cancer cell lines were kind gifts 
from Professor Ian Tomlinson (Wellcome Institute for human genetics, University of 
Oxford). Mutation status for six CRC cell lines are summarised in Table 2.2. For the 
maintenance of the intestinal fibroblast cultures DMEM (ATCC, UK) supplemented with 
10% heat-inactivated FBS (Gibco, UK) and PenStrep was used. For hypoxic experiments, 
cells were maintained under three different oxygen tensions (20.9 % oxygen, 1% oxygen 
and 0.2 % oxygen) and 5% CO2. The oxygen concentration was controlled by Invivo2 
1000 Hypoxia Workstation (Ruskinn Life Sciences Ltd, USA). 
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Table 2.2 Mutation status for CRC cell lines.  
Cell line Origin MSI APC KRAS P53 
DLD-1 Colon + 1417 del 1bp GGT/TGT c12 Codon 241 
HCT116 Colon + WT GGC/GAC c13 WT 
HT29 Colon - 853 CAG -> TAG WT Codon 273 
HT55 Rectum - 1131 CAA -> TAA WT WT 
SW837 Rectum + 1450 CGA -> TGA GGT/GTT c12 Codon 248 
VACO4s Rectum - 1354 del 5bp GGT/GTT c12 WT 
 
2.5 Optimisation of transfection in intestinal fibroblasts  
Three doses (0.3 µL, 0.4 µL and 0.5 µL) of four different transfection agents 
(DharmaFect (DF) 1 to 4, Dharmacon, UK) were used to optimise transfection conditions 
of intestinal fibroblasts. Cells were transfected with 60 nM negative control siRNA 
tagged with 488 fluophore (#Cat number, Qiagen, UK) for 48 hr. Cells were fixed with 
3.7% paraformaldehyde (PFA, Sigma, UK) being stained with Hoechst 33342 (1:5,000, 
Invitrogen, UK) and CellMask Deep Red (1:20,000, Invitrogen, UK) for 15 min and 
imaged on the IN Cell Analyzer 1000 microscope (GE Healthcare, UK). Cells were 
imaged with a 10X objective with a triChroic mirror. Hoechst stained nuclei were imaged 
with 350ex/455em filters, 488-tagged siRNA was imaged with 490ex/525em filters and 
CellMask Deep Red was visualised using 645ex/705em Transfection efficiency was 
assessed using the IN Cell Developer v1.8. DF3 reagent at showed the most consistent 
transfection pattern and efficiency and was selected for further optimisation. Various 
concentrations of DF3 and 60 nM siGLO Red siRNA (DY-547, #D-001630-02, 
Dharmacon, UK) were used for optimisation. This siRNA targets housekeeping gene 
cyclophilin B (PPIB). Media was changed 24 hr post transfection and cells were stained 
72 hr post transfection with Hoechst 33342 for 15 min before being fixed with 3.7% PFA. 
Cells were imaged with the IN Cell Analyzer 1000 microscope and viewed at 10X 
objective with a triChroic mirror (61003bs*): Hoechst stained nuclei were imaged with 
350ex/455em filters and siGLO staining was imaged with 555ex/605em filters. Cells were 
then subjected to immuno-fluorescence with monoclonal rabbit antibody against 
Cyclophilin B (Section 2.8), and anti-rabbit Alexa-Fluor-488 labeled secondary antibody 
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(1:500, Abcam, UK). IN Cell Developer v.1.8 (GE Healthcare, UK) was used to analyse 
the transfection efficiency and reduction of Cyclophilin B protein expression by siGLO 
siRNA to determine optimal transfection conditions. 
 
2.6 Optimisation of transfection in CRC cell lines 
The HCT116 cell line was optimised for seeding density and concentration of transfection 
agent Lipofectamine 2000 (LF2000, Invitrogen, UK) in 96 well plates by transfecting 30 
nM of Allstars non-targeting control (NTC, #SI03650318, Qiagen, UK), siGLO siRNA, 
and polo-like kinase-1 siRNA (PLK-1, #SI02223837, Qiagen, UK). PLK-1 kinase is 
required for cell division and inhibition has shown to be pro-apoptotic [428] and serves as 
a killing control. Media was changed 24 hr post transfection and siGLO siRNA 
localisation was visualised under a fluorescent microscope. 72 hr post transfection cell 
viability was measured using CellTitre Blue Reagent (Invitrogen, UK) according to 
manufacturer’s protocol. Optimum transfection conditions were determined when 
viability with PLK-1 siRNA was lowest and viability with NTC was similar to non-
treated cells. 
 
2.7 Transfection of fibroblasts and TGF-β stimulation 
Pre-miR and anti-miR transfection. Intestinal fibroblasts were seeded overnight (Nunc, 
UK) before being transiently transfected with 30 nM NTC, 30 nM pre-miRNA or 60 nM 
anti-miR (all Qiagen, UK) using DF3. Lipid containing media was replaced 24 hr post 
transfection and cells were fixed for immunofluorescence 48 hr post transfection. RNA 
was extracted for qRT-PCR and supernatants were collected for ELISA experiments.  
 
TGF-β treatments. Intestinal fibroblasts were seeded overnight. The following day, cells 
were treated with 10 ng/ml TGF-β for 48 hr. RNA was extracted for qRT-PCR and 
supernatants were collected for ELISA experiments.  
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Pre-miR and anti-miR transfection + TGF-β treatments. Intestinal fibroblasts were 
transfected as above for 24 hr before being treated with 10ng/ml TGF-β for 48 hr. Cells 
were fixed with 3.7% PFA for immunofluorescence. 
 
2.8 Immunofluorescence (IF)  
Intestinal fibroblasts cell cultures and CRC cells transfected in 96 well plates were fixed 
with 3.7% PFA for 15 min at RT before being washed with PBS and permeabilised in 
0.1% Triton-X100 (Sigma, UK) in PBS for 20 min. Cells were washed and blocked for 30 
min with 0.25% Bovine Serum Albumin (BSA, Sigma, UK) in PBS before incubated for 
2 hr with primary antibody (Table 2.4 for details). Cells were washed for 30 min with 
PBS/BSA (0.25%) and incubated for 2 hr with Alexa-Fluor-488 conjugated secondary 
antibody (1:500, Invitrogen, UK), Hoechst 33342 (1:10,000 Invitrogen, UK) and 
CellMask Deep Red (1:20,000, Invitrogen, UK) for 2 hr. Cells were washed twice with 
PBS before being imaged on the IN Cell Analyzer 1000 microscope. Pixel intensities 
were compared to NTC transfected cells. IN Cell Developer v1.8 was used to analyse the 
images.  
 
2.9 Enzyme-linked immunosorbant assay (ELISA)  
Supernatants were taken from intestinal fibroblast cultures transfected with pre-miR, anti-
miR and controls. Cytokines IL-6 and IL-8 were measured using R&D DuoSet ELISA 
kits using manufacturer’s protocol (R&D, USA). 
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2.10 MiRNA extraction & Quantitative Real-Time PCR (qRT-
PCR) 
Total RNA including small RNAs was extracted from samples using the miRNeasy kit 
(Qiagen, UK) according to manufacturer’s protocol. RNA concentration was determined 
using the NanoDrop Spectometre (Nano-Drop Technologies, USA). miRNA Reverse 
Transcriptase (RT) kit (Applied Biosystems, UK) on 10 ng RNA was used for reverse 
transcription. RT products were incubated with Taqman miRNA probe and Universal 
PCR Mastermix (Applied Biosystems, UK) on a 7500 Fast System RealTime PCR cycler 
(Applied Biosystems, UK) according to manufacturer’s protocol. Fold changes were 
calculated using the 2^
-∆∆Ct 
method normalised to endogenous control miRNAs [429]. 
Housekeeping genes that were used to normalise qRT-PCR data is summarised in Table 
2.3. 
 
Table. 2.3. Normalisers used for qRT-PCR. 
Sample Normaliser mRNA Normaliser miRNA 
CRC cell lines GAPDH   RNU19b  
CRC tissue - Geomean of miR-16 and let-7a 
Intestinal mucosa GAPDH miR-26b 
Intestinal fibroblasts GAPDH RNU6B 
 
2.11 Total RNA extraction & qRT-PCR of gene expression 
Total RNA, excluding small RNAs, was extracted using the RNeasy kit (Qiagen, UK) 
according to manufacturer’s protocol. RNA concentration was determined using the 
NanoDrop Spectrometer (Nano-Drop Technologies, USA). RT was performed using the 
High-Capacity-RNA to cDNA kit (Applied Biosystems, UK) in a 20 µL reaction. cDNA 
was incubated with Taqman assays (20x) and Universal Mastermix no UNG on a 7500 
Fast System RealTime PCR cycler according to manufacturer’s protocol. Fold changes 
were calculated using the 2^
-∆∆Ct 
method. 
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2.12 5-Fluorouracil (5-FU) drug treatments of HCT116 
HCT116 cells were seeded at 5,000 cells per well in 96 well plates overnight. The 
following day, cells were treated with various concentrations of 5-FU (1 µM, 5 µM, 10 
µM, 100 µM or 1mM) together with vehicle control, and cultured under three oxygen 
conditions (20.9%, 1% and 0.2%) for 48 hr. Cells grown in 96 well plates were fixed with 
3.7% PFA for 15 min and nuclei were stained with Hoechst 33342 (1:10,000) for 30 min. 
Cells were imaged with the IN Cell 1000 microscope using a 4X objective with a 
triChroic mirror (61003bs*). Hoechst stained nuclei were imaged with 350ex/455em filters. 
Nuclei were counted using the IN Cell Developer v1.8 and cell number was expressed 
relative to vehicle treated cells.  
 
2.13 5-FU drug treatment and transfection of HCT116 
HCT116 cells were reverse transfected with 30 nM pre-miR, NTC and 60 nM anti-miR in 
96 well plates. The following day, media was replaced with 10 µM 5-FU or vehicle 
control containing media. Cells were cultured under three oxygen conditions (20.9%, 1% 
or 0.2%) for 48 hr. Cells were fixed with 3.7% PFA for 15 min and nuclei were stained 
with Hoechst for 30 min. Cells were imaged with the IN Cell Analyzer microscope using 
a 4X objective in combination with 350ex/455em filters.  Nuclei were counted using the IN 
Cell Developer v1.8 and expressed relative to vehicle treated cells. 
 
2.14 Zeocin kill curves 
HeLa cells were plated in 6 well plates at 400,000 cells per well. The following day, cells 
were treated with a range of concentrations of Zeocin (250 µg/ml-1000 μg/ml, Invitrogen, 
UK). Cell death was monitored by eye for two weeks and media containing Zeocin was 
replaced every 2-3 days. Optimal Zeocin dose was determined at the lowest fatal 
concentration. 
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2.15 HeLa transfection optimisation 
HeLa cells were plated in 6 well plates at 400,000 cells per well. The following day cells 
were transfected using 2ug of pcDNA-EGFP plasmid (pcDNA-EGFP plasmid was a kind 
gift from Dr. P. Kemp, Imperial College, UK) and a range of LF2000 doses. Media was 
changed 24 hr post transfection and cells were fixed with 3.7% PFA for 15 min. Cells 
were incubated with Hoechst 33342 (1:10,000) for 30 min before being imaged on the IN 
Cell 1000 microscope. Images were analysed on the IN Cell Developer v1.8 and GFP 
transfection efficiency was determined. 
 
2.16 MISSION® Target ID Library transfection 
HeLa cells were plated in 6 well plates at 400,000 cells per well. The following day, cells 
were transfected with 2 µg MISSION® Target ID library plasmids using optimised 
LF2000 dose (12 replicates). The media was changed 24 hr post transfection and cells 
were treated with the optimised dose of Zeocin 72 hr post transfection. Target ID Library 
plasmids contain a Zeocin-resistance element and thus transfected cells are able to survive 
the Zeocin treatment, whilst non-transfected cells die. Cells were cultured in Zeocin-
containing media until all control cells were dead. Cells were pooled and expanded until 
cells were ready for cryo-preservation. 
 
2.17 Tissue Immunohistochemistry 
The HIF-1α responsive protein, carbonic anhydrase IX (CAIX), was used to stain rectal 
cancer tissue samples for areas of hypoxia. Six NSCD and 3 SCD blocks were stained for 
p53. 4 μm thick sections of the Formalin-fixed paraffin embedded (FFPE) samples were 
cut followed by de-waxing, hydration and blocking in goat serum. Sections were 
incubated with primary antibody mouse-anti-CAIX (1:50, SantaCruz, UK) or mouse-anti-
p53 (1:250, Abcam, UK) for 2 hr. Mouse-HRP secondary (1:500, Dako, UK) was 
incubated for 2 hr followed by washing and DAB incubation. Control samples were used 
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to ensure complete staining (stomach tissue for CAIX, breast cancer for p53). Analysis 
for CIAX staining was undertaken using a light microscope and two blinded observers 
following a staining protocol adapted from [430]. p53 staining was analysed and reported 
by a consultant pathologist (Professor Roger Feakins, Department of histopathology, The 
Royal London Hospital). 
 
2.18 Extraction of small RNAs from FFPE sections 
FFPE slides from 13 rectal cancers were used for miRNA extractions. Haematoxylin & 
Eosin staining was performed to determine the tumour tissue area by a pathologist 
(Professor Roger Feakins). Ten adjacent sections (10 µm) were then used for miRNA 
extraction using the RecoverAll Total Nucleic Acid Isolation kit (Ambion, Applied 
Biosystems, USA) according to manufacturer’s protocol. RNA concentration was 
determined using the NanoDrop Spectrometer (Nano-Drop Technologies, USA). 
 
2.19 In situ hybridisation of miRNAs on FFPE sections 
Sections (3 µm) were cut from FFPE tissue blocks in an RNAse free water to avoid RNA 
degradation. Slides were deparaffinised in xylene and ethanol solutions (100% - 95% - 
70%) at RT and incubated in PBS for 5 min. A schematic overview of the miRNA 
detection steps is shown in Fig. 2.2. Sections were then incubated with Proteinase-K (10 
µg/ml) for 15 min at 37 °C before being washed in PBS, dehydrated in ethanol solutions 
(70% - 95% - 100%) and air dried for 15 min or until the tissue was dry. Double-DIG-
labelled miRNA probes (miR-210, miR-21, miR-34a and scrambled; Exiqon, Denmark) 
were diluted in hybridising buffer (Exiqon, Denmark). The following concentrations were 
used: miR-210 (40 nM), miR-21 (40 nM), miR-34 (60 nM) and scrambled (60 nM). 
Slides were incubated with 25 µL of probe mixture at 56 °C for 1 hr on a slide hybridiser 
(Omnislide Thermal Cycler, Thermo Scientific, UK) and washed with saline-sodium 
citrate (SSC) buffer at 56 °C (5xSSC 5 min, 1xSSC, 5 min, 1xSSC 5 min, 0.2xSSC 5 min, 
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0.2xSSC 5 min) and 0.2xSSC for 5 min at RT. Slides were incubated with blocking buffer 
for 15 min before subjected to anti-DIG-AP reagent (1:600, Exiqon, Denmark) at RT. 
Slides were washed with PBS-tween and incubated with anti-AP substrate (NCT-BCIP, 
Roche, UK) for 2 hr at RT to create a blue precipitate. Slides were then washed in water 
before counterstained with Nuclear Fast Red (Vector, UK) for 1 min at RT. Slides were 
rinsed in running tap water for 10 min and dehydrated in ethanol solutions (70% - 95% - 
100%) and mounted with Eukkitt mounting medium (Sigma, UK). Slides were scanned 
using a slide scanner (Core Pathology, Pathology Department, Royal London Hospital) to 
produce high quality images. 
 
Figure 2.2. Schematic overview of the Exiqon in situ hybridisation protocol. MiRNAs were de-masked 
with Proteinase-K treatment to allow access of the double-DIG-labelled LNA probes to hybridise with the 
miRNA. The digoxigenins are recognised by a anti-DIG antibody conjugated with Alkaline Phospohatase 
(AP), which converts the substrates 4-nitro-blue tetazolium (NBT) and 5-bromo-4-chloro-3’-
indolylphosphate (BCIP) into a blue precipitate.   
 
2.20 Cell metabolite analysis  
Three colon cancer (DLD-1, HCT116 and HT29) and three rectal cancer (HT55, SW837 
and VACO4s) cell lines were cultured under three oxygen conditions (20.9%, 1% and 
0.2%) for 48 hr as described previously (Section 2.4). Cells were washed twice in 5% 
Mannitol (Wako, Japan) and incubated with 1 ml of methanol containing 3 standards 
(Methionine sulfone, MES and CSA each at 25 µM). The cells were then counted, flash 
frozen on dry ice and shipped to the Institute for Advanced Biosciences in Japan for 
capillary electrophoresis time of flight mass spectrometry (CE-TOF/MS) analysis. 
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2.21 Statistics 
General statistics. Graphpad Prism analysis software was used to perform Student’s t-
tests and one-way ANOVA tests as denoted. A p-value of less than 0.05 was considered 
statistically significant. Experiments are performed in duplicates in three independent 
experiments, unless otherwise stated.  
 
Multivariate analysis. A partial least squares discriminant analysis (PLS-DA) is a 
supervised multivariate classification technique, and so care must be taken to avoid over-
fitting. However, it is possible to fit with respect to one variable, and then examine the 
separation in another variable. Here, a supervised model to differentiate the six cell lines 
was fitted, and the miRNAs were examined for (unsupervised) separation with respect to 
oxygen tension. The loadings were then interrogated in order to identify potential 
miRNAs for further investigations. 
 
Multiple linear regression. The relationship between miRNA expression (dependent 
variable) was modelled against the independent variables oxygen tension (numerical 
variable) + cell line (categorical variable). This enabled us to identify miRNAs were 
significantly (p<0.05) associated with oxygen tensions once the effect of cell line has 
been allowed for.   
 
 
Table 2.4. Primary antibodies  
Antigen Company details Dilution 
Cyclophilin B Abcam (#ab16045) 1:200 
CAIX Santa-Cruz (#N-19) 1:50 
Collagen I Novus Biologicals (#NB600-405) 1:200 
Collagen III Abcam (#ab7778) 1:500 
Mcl-1 Abcam (#32087) 1:200 
P53 Abcam (ab26) 1:250 
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Chapter 3: Differential expression of miRNAs in 
intestinal fibrosis 
3.1 Introduction and aims 
Progression to intestinal fibrosis and subsequent stricture formation is a frequent 
complication in CD and has significant health implications of the individual patient. The 
lifetime risk of surgery for patients with CD is as high as 70% [196], with the majority 
indicated for stricturing disease. Current medical therapies are unable to reverse fibrosis, 
and the factors that initiate and drive CD fibrosis are not well understood [197]. Aberrant 
expression of miRNAs is associated with multiple disease pathologies including cancer, 
immunity and inflammation [431-434]. MiRNA dysregulation is involved in the 
development of fibrosis in various organs, including the lung, kidney, liver and heart 
(reviewed in [435]), some of which are summarised in Table 1.3 (Section 1.3.3). To date, 
the dysregulation of miRNAs in intestinal fibrosis in CD has not yet been investigated.  
 
Aims for this chapter: 
1. Identify differentially expressed miRNAs between non-inflamed mucosa 
overlying non-stricturing CD (NSCD) and -stricturing CD (SCD) tissues of CD 
patients with the use of a miRNA array; 
2. Validate selected candidate miRNAs in an independent set of paired NSCD and 
SCD tissue samples; 
3. Isolate and maintain intestinal gut mucosal fibroblasts from patients with CD and 
optimise protocols for transient transfection of miRNAs;  
4. Investigate down-stream targets of candidate miRNA(s) via transient transfection 
in intestinal fibroblasts. mRNA levels of key ECM molecules were assessed by 
qRT-PCR; and 
5. Determine the localisation and expression of candidate miRNA(s) in NSCD and 
SCD tissue samples using in situ hybridisation techniques. 
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3.2 MiRNA microarray between NSCD and SCD tissue 
To identify the differentially expression of miRNA between six NSCD and six SCD 
tissue samples, a miRNA microarray (Illumina v2.0) was performed. The mucosa was 
used in this study as it has previously been shown that events here reflect those associated 
with the fibrotic changes occurring in the deeper tissue layers during fibrogenesis [201]. 
Patient and sample details can be found in Table 2.1 (Section 2.1). The  bead-based array 
contains 1,146 miRNAs probes covering more than 97% of known miRNAs in miRBase 
v.12.0 [427]. A workflow with detailed description of the array is described in the 
methods section (Section 2.2). Fluorescent signal intensities of each miRNA for each of 
the 12 samples was analysed using GenomeStudio Software (www.illumina.com). Data 
was subjected to quantile normalisation which reduces variation by normalising the 
distribution of the probe intensities between the sample groups. This type of 
normalisation is recommended for high density oligonucleotide microarray technology 
[436]. Normalised expression values of the miRNAs were used for statistical analysis 
(corrected paired Student-Test) in GenomeStudio. 
 
To visualise the miRNA expression patterns between the NSCD vs SCD samples, 
negative log10 values of the p-value were plotted against log2 fold change values to 
create a volcano plot (Fig. 3.1A). The scatter plot quickly identifies any significant 
changes in expression in miRNA expression between NSCD and SCD tissues, and this 
analysis identified 18 significantly increased and 11 significantly decreased miRNAs in 
SCD versus NSCD tissues (p<0.05). A heatmap containing the normalised expression 
values of all of the significant differentially expressed miRNAs is shown in Fig. 3.1B. 
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Figure 3.1.  Differentially expressed miRNAs between six NSCD and six SCD tissues. (A) A volcano 
plot containing all miRNAs detected by the array. Negative log p-values are plotted against the log fold 
change values between NSCD and SCD samples. Lines represent p=0.05 and p=0.01. Any miRNAs present 
above these lines are considered significant. (B) Heatmap of normalised fluorescent intensity levels (A.U.) 
of 29 miRNAs with a p<0.05 between NSCD and SCD samples. The top panel demonstrates up-regulated 
and bottom panel down-regulated miRNAs in SCD tissue vs NSCD tissue. Increased expression is shown in 
red and decreased expression shown in green.  
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3.3 MiRNA validation by qRT-PCR 
To validate the findings of the miRNA array using a different technique, qRT-PCR was 
performed. Six up-regulated miRNAs (miR-148b, -223*, -34a, -493*, -503 and -708) and 
one down-regulated miRNA (miR-1285) were selected for further validation on an 
independent set of eight paired NSCD and SCD tissue samples (Table 2.1, Section 2.1). 
These miRNAs were selected based on p-values and/or a link to fibrosis in the literature 
(Table 3.1).  
 
Table 3.1. Candidate miRNAs selected for validation and their link to fibrosis. miRNAs are ranked in 
numerical order.  
miRNA (p-value) Role  
miR-148b (p=0.020) 
Targets LTBP1 which is involved in the pro-fibrotic TGF-β pathway 
[437] 
miR-223* (p=0.002) No link to fibrosis 
miR-34a (p=0.029) 
↑ Cardiac fibrosis [438], ↑ Liver fibrosis [387, 439, 440], ↑ Kidney 
fibrosis [441] 
miR-493* (p=0.048) ↑ in lung fibrosis [442] 
miR-503 (p=0.017) Correlated to scleroderma (fibrosis of the skin) [443] 
miR-708 (p=0.031) Targets Aquaporin-1 which is down-regulated in liver fibrosis [444] 
miR-1285 (p=0.045) No link to fibrosis 
 
A key challenge for the analysis of qRT-PCR data is the normalisation step. In contrast to 
an array, qRT-PCR relies on the stable expression of one or two references genes which 
will be different depending on tissue and cell type. Three reference miRNAs (let-7a, miR-
16 and miR-26b) that showed consistent expression between the different samples were 
picked from the array, and were assayed in the validation sample set. Cycle threshold (Ct) 
values of all three reference miRNAs for both NSCD (n=8) and SCD (n=8) samples were 
measured and mean values are shown in Fig. 3.2A. None of the three miRNAs showed a 
significant change between the two groups (let-7a, p=0.0538; miR-16, p=0.0548; miR-
26b, p=0.0591). All three miRNAs were close to significance, however, miR-26b 
exhibited the least variation within the two groups of samples (Ct StDev: let-7a, 
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NSCD=1.04, SCD=0.605; miR-16, NSCD=1.46, SCD=0.44; miR-26b, NSCD=0.73, 
SCD=0.42) and was selected as the reference gene for the validation of the target 
miRNAs. In support of this, miR-26b was recommended by Applied Biosystems as a 
suitable reference gene for human tissue samples [445]. The seven candidate miRNAs 
(miR-148b, -223*, -34a, -493*, -503, -708 and -1285) were measured in eight 
independent matched NSCD and SCD tissue samples and the data normalised to miR-26b 
(Fig. 3.2B). Statistical analysis (paired Student’s t-test) confirmed the significant up-
regulation of three miRNAs by qRT-PCR (miR-493*, p=0.0096; miR-708, p=0.0112; 
miR-34a, p=0.0165). Two miRNAs were not significant changed (miR-223*, p=0.090 
and miR-148b, p=0.2000).  
 
Two miRNAs (miR-1285 and miR-503) were only detectable in five of the eight paired 
samples tested. Relative expression of miR-1285 and miR-503 in the five pairs is shown 
in Fig 3.2C. The relative fold changes between NSCD and SCD in the five pairs were not 
significant (miR-1285, p=0.1331 and miR-503, p=0.3672), although, the mean fold 
change in the SCD versus NSCD samples correlated to the expression pattern observed in 
the array (miR-1285, down-regulated in SCD vs NSCD and miR-503, up-regulated in 
SCD vs NSCD). In conclusion, these data demonstrate that the up-regulation of miR493*, 
miR-708 and miR-34a was successfully validated between NSCD and SCD tissue 
samples.  
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Figure 3.2. Validation of seven miRNAs by qRT-PCR. qRT-PCR in eight matched paired NSCD and 
SCD tissue samples. (A) Ct values for three endogenous control miRNAs (let-7a, miR-16 and miR-26b; 
n=8) (B) qRT-PCR of five selected miRNAs normalised to miR-26b. Fold change of normalised expression 
between NSCD and SCD tissues is shown. (C) Fold change of normalised expression of miR-1285 and 
miR-503 between in NSCD and SCD samples (n=5). Bars represent mean values with SEM.  *p<0.05 and 
**p<0.01.   
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3.4 Transfection of intestinal fibroblasts from mucosa from CD 
patients 
The downstream impact of a miRNA is determined by its target mRNAs and the 
pathways they are involved in. Exogenous over-expression of miRNAs via transient 
transfection is a commonly used method to identify molecular pathways that are 
controlled by the miRNAs. To study the pathways affected by the differentially expressed 
miRNAs, intestinal fibroblasts were isolated from six SCD and four NSCD tissue samples 
(Table 2.1, Section 2.1). This particular cell type was chosen because in fibrosis, 
fibroblasts are considered responsible for the over-production of ECM molecules. 
Fibroblasts were isolated from patients undergoing surgery for stricturing CD, using 
methods described previously by others [446] (Section 2.3). To test the transfection 
efficiency of the fibroblast cultures, CD495si cells (Table 2.1, Section 2.1) were 
transfected in duplicates with three doses (0.3 µL, 0.4 µL and 0.5 µL) of four transfection 
reagents from Dharmacon (Dharmafect (DF)1-4). CD495si cells were one of the first 
fibroblast cells cultures isolated and were used to optimise transfection conditions. 
Fibroblasts were transfected with 60 nM NTC-siRNA tagged with Alexa Fluor-488 for 48 
hr. Hoechst stained nuclei and NTC-488 tagged siRNA were imaged on the IN Cell 
Analyzer microscope 1000. The percentage of transfected cells was calculated using the 
IN Cell Developer v1.8 (Section 2.5).  
 
The majority of the cells were transfected regardless of which dose or transfection reagent 
used. A transfection efficiency of >98% was observed at even the lowest dose (0.3 µL) 
for all four DF reagents (Data not shown, images Fig. 3.3A-E). A slight drop in total cell 
number was noted using the lowest dose, 0.3 µL (% reduction in cell number relative to 
untransfected cells: DF1, 14.7%; DF2, 8.5%; DF3, 11.5%; DF4, 8.3%; Fig. 3.3F). 
Comparing intracellular siRNA distribution, DF3 showed a better, more homogenous 
distribution of the 488-tagged siRNA (Fig. 3.3G), whereas the other three DF reagents 
exhibited siRNA localisation in endosomal vesicles (DF1, Fig. 3.3H; DF2 and DF4, data 
not shown). These vesicles are targeted for destruction, which consequently decreases 
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siRNA concentration and functionality (reviewed in [447]). This localisation was also 
observed using the DF3 reagent at concentrations higher than 0.3 µL (DF3 0.5 µL; Fig. 
3.3I). Therefore, DF3 was selected for further transfection optimisation experiments.  
 
As mentioned previously, fibroblasts transfected with 0.3 µL of DF3 and NTC-488 
tagged siRNA showed a reduction of 11.5% in cell number. This extent of toxicity 
following transfection is commonly seen and is generally accepted, however, follow-up 
experiments (Section 3.5) showed that fibroblasts transfected with other siRNAs did not 
display this amount of cell death (Fig. 3.4C) suggesting that it was the NTC-488 tagged 
siRNA that contributed to this toxicity in this particular experiment.  
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Figure 3.3. Transfection optimisation using fluorescent tagged siRNA. Three doses (0.3 µL, 0.4 µL and 
0.5 µL) of four DharmaFect reagents (DF, 1-4) were optimised for transfection efficiency of intestinal 
fibroblasts (n=1). (A-E) Hoechst-positive nuclei and 488-tagged siRNA staining for all DF reagents at the 
lowest dose, 0.3 µL. (F) The cell count between the different concentrations and DF reagents. (G-I) 
Homogenous cellular distribution of 488-tagged siRNA using DF3 at 0.3 µL with digitally zoomed image. 
(H) Endosomal vesicle siRNA localisation using DF3 at the highest dose, 0.5 µL, with digitally zoomed 
image. (I) Endosomal vesicle siRNA localisation using DF1 at 0.3 µL, with digitally zoomed image. Bars 
represent mean values with SEM. Size bar 100 μm (A-E, G-I) and 20 μm (G-I, digitally zoomed images).  
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3.5 Optimisation of transfection of intestinal fibroblasts with DF3 
To achieve optimal transfection conditions, fibroblasts were transfected using various 
doses (0.1 µL, 0.2 µL and 0.3 µL) of transfection reagent DF3 with or without (mock 
transfected) siGLO siRNA. SiGLO is a fluorescently tagged siRNA targeting the 
housekeeping gene cyclophilin B (PPIB), which may subsequently be assayed at either 
the mRNA or protein level to determine siRNA functionality. Cells were fixed 72 hr post-
transfection, and stained with Hoechst 33342 and an antibody against PPIB (Section 2.8), 
then imaged on the IN Cell Analyzer microscope 1000. Using the IN Cell Developer 
v1.8, an overlaying mask was created using the Hoechst-positive nuclei (Fig 3.4A-B). 
This mask was then used to define nuclear pixel intensity in the cyclophilin B fluorescent 
channel. Hoechst stained nuclei were counted and cell number for each transfection 
condition was determined. There was no difference in cell number between the 
untransfected fibroblast and the various transfection conditions within this single 
optimisation experiment (Fig. 3.4C). However, there was a slight decrease in total nuclei 
count of untransfected cells (mean cell count=1715) compared to earlier experiments 
(Section 3.4, Fig. 3.3F, mean cell count=1966). The fibroblasts (CD495si) have 
undergone several passages between the two set of experiments and are therefore closer 
to their intrinsic replicative senescence stage. Cell division rates decrease when 
fibroblasts reach this stage, and this could account for the lower total nuclei count 
between the two set of experiments. Pixel intensity of cyclophilin B expression was 
determined for each dose (0.1 µL, 0.2 µL, 0.3 µL) and plotted as a frequency distribution 
(Fig. 3.4D-F). For all three doses, cyclophilin B expression was decreased by siGLO 
siRNA compared to mock transfected cells (transfection reagent only), indicated by the 
shift of the frequency distribution line towards the left. The strongest down-regulation in 
cyclophilin B pixel intensity was observed following transfection with 0.3 µL 
(representative images, Fig. 3.4G-J). Taking into account that DF3 doses higher than 0.3 
µL resulted in endosomal vesicle localisation and elimination of the siRNA (Section 3.5), 
0.3 µL was chosen for future siRNA transfection of the isolated fibroblasts. 
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Figure 3.4. Transfection optimisation in fibroblasts using siGLO siRNA. CD495si fibroblasts were 
transfected in triplicates with three different Dharmafect (DF) 3 doses (0.1 µL, 0.2 µL or 0.3 µL) with or 
without 60 nM siGLO siRNA (n=1). (A-B) Hoechst-positive nuclei were imaged (A) and nuclei defined 
using the IN Cell Developer, and a mask generated (B) for subsequent quantification. This mask was then 
applied to the cyclophilin B staining. Nuclei were counted and cyclophilin B pixel intensity was measured. 
(C) The graph represents the nuclei count of the various doses of the three DF3 doses. (D-F) The graph 
represents frequency distributions of cyclophilin B pixel intensity of cells transfected with siGLO (blue 
line) or lipid only (mock, red line) for the three DF3 doses. Secondary antibody control pixel intensity 
represents the level of background pixel intensity (black line). (G-J) Representative images of mock and 
siGLO transfected cells in combination with 0.3 µL DF3. Bars represent mean values with SEM. Size bars 
100 µm.  
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3.6 MiR-34a does not alter the mRNA expression of fibrosis-
associated genes  
Following successful transfection of the intestinal fibroblast cell cultures, functional 
studies were conducted to determine the role of the differentially expressed miRNAs 
between NSCD and SCD tissue samples that were identified by the miRNA microarray 
and subsequent qRT-PCR validation (Section 3.2 and Section 3.3). Out of the three 
validated miRNAs (miR-34, -493* and -708; Fig 3.2B), literature reports for miR-34a 
showed it had previously been involved in fibrosis of the lung, heart and kidney (Table 
3.1), whereas the link between fibrosis and miR-493* or miR-708 was more ambiguous. 
Additionally, miR-34a has been previously shown to modulate the expression of key 
mediators in TGF-β pathway such as SMAD4 [448] and MMP genes [439]. Therefore, 
miR-34a was selected for further downstream analysis in fibroblasts isolated from CD 
patients. In mammals, the miR-34 family consists of three processed mature miRNAs 
(miR-34a, -34b and -34c) encoded by two different genes on separate chromosomes. Its 
own transcript transcribes miR-34a while miR-34b and miR-34c have a common primary 
transcript (Fig 3.5A). 
 
To investigate the downstream effects of miR-34a, intestinal fibroblasts were transfected 
with NTC and pre-miR-34a and incubated for 72 hr to enable overexpression of miR-34a 
in the cells. RNA was extracted, assayed for gene expression by qRT-PCR and 
normalised to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). A number of mRNA targets associated with fibrogenic pathways were 
investigated based on online prediction tools and/or validated by others. These were 
COL1A2, COL3A1, connective tissue growth factor (CTGF), fibronectin (FN1), MMP2 
and SMAD4. Survivin (BIRC5) was selected as a positive control gene as it is targeted by 
miR-34a [449]. To confirm that the transfection with pre-miR-34a was successful, 
expression levels of miR-34a were measured. For the normalisation of miRNAs in cells, 
Applied Biosystems recommended miR-16 [445]. Also, RNU6B has been previously 
used for normalisation in fibroblasts from other organs [450, 451], therefore, both miR-16 
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and RNU6B expression was assayed in fibroblasts transfected with NTC or pre-miR-34a. 
RNU6B expression was not significantly altered between these conditions (data not 
shown), and was used to normalise miRNA expression in future experiments on isolated 
fibroblasts. An increase of miR-34a expression in cells transfected with pre-miR-34a 
confirmed that the transfected was successful (Fig. 3.5B).  
 
mRNA expression of the seven genes is displayed as fold change in expression between 
fibroblasts transfected with NTC and pre-miR-34a (Fig. 3.5B). Statistical analysis 
revealed no significant differences between cells transfected with NTC and pre-miR-34a, 
however, the slight down-regulation in expression of SMAD4 was close to significance. 
(MMP2, p=0.088 n=4; SMAD4, p=0.0540, n=4; COL1A2, p=0.9074, n=8; COL3A1, 
p=0.3361, n=8; FN1, p=0.2155, n=4; CTGF, p=0.0541, n=4; BIRC5, p=0.1805, n=4; Fig. 
3.5D). The mean value of the positive control BIRC5 was lower than NTC treated cells 
(fold change=0.746), but this was not significant. These data suggest that miR-34a does 
not alter the expression of fibrosis-associated mediators at the mRNA level in intestinal 
fibroblasts. This observation lead to the speculation that the role of miR-34a in intestinal 
fibrosis may not be fibroblast-related but that miR-34a may be involved in regulatory 
events other cell types such as epithelial cells. To test this hypothesis, in situ hybridisation 
of miR-34a was performed (Section 3.8) to determine which cells express miR-34a.  
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Figure 3.5. Overexpression of miR-34a does not alter mRNA expression of key fibrosis-associated 
genes. (A) Schematic overview of the chromosomal location of the three family members of the miR-34a 
family. Two genes located on chromosome 1 and 11 encode the miR-34 family. Its own transcript encodes 
miR-34a whereas miR-34b and miR-34c share a common primary transcript. Each seed sequence is shown 
in red and the majority of nucleotides are shared amongst the three members (shaded box in orange). (B) 
Isolated fibroblasts (n>4) transfected with NTC and pre-miR-34a. qRT-PCR of six fibrosis-associated genes 
and the positive control BIRC5 normalised to GAPDH. The expression of miR-34a was normalised to 
RNU6B. Fold change in normalised expression is shown. Bars represent mean values with SEM.  
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3.7 Expression of p53 is not altered in intestinal fibrosis 
Previous reports have indicated that members of the miR-34 family (miR-34a, miR-
34b/c) are a direct target of TSG p53 [311, 312, 315, 316], a transcription factor activated 
in response to various stress signals leading to cell cycle arrest and apoptosis (reviewed in 
[452]). In addition, recent literature reports have suggested a link between p53 and liver 
fibrosis [389]. The next section was aimed to identify the role of p53 in intestinal fibrosis 
by determining its expression at both mRNA and protein level in NSCD and SCD tissues. 
 
In 2007, a number of groups showed that the TSG p53 is a positive upstream regulator of 
miR-34a and miR-34b/c [311, 312, 315, 316]. The promoters for both miR-34a genes 
contain conserved p53-binding sites as well as CpG islands, and methylation of both 
promoters has been reported in various human cancers [319, 453-456]. p53 is a potent 
tumour suppressor which triggers the activation of anti-proliferative cellular responses 
resulting in apoptosis, cell cycle arrest or senescence (reviewed in [452]). In addition, the 
TP53 gene is the most frequently mutated tumour suppressor gene in human cancer [457, 
458]. It is, therefore, not surprising that the over-expression of miR-34a and miR-34b/c 
can cause cell cycle arrest [311, 315, 459] and inhibit proliferation and colony formation 
[313]. Thus, as a direct target of p53, miR-34a and miR-34b/c may act as key mediators 
of p53’s tumour suppressor function.  
 
The miR-34 family has been studied predominantly in the context of cancer but the 
p53/miR-34 axis in fibrosis much less defined. For example, reports show up-regulation 
of p53 in idiopathic pulmonary fibrosis [460, 461], and in liver fibrosis where p53 was 
correlated to CTGF expression [389], a well-known marker for fibrosis. Furthermore, p53 
inhibition prevented CTGF-mediated fibrosis in the kidney of rodents [462, 463] and p53 
expression was shown to be induced by the pro-fibrotic cytokine TGF-β [462]. By 
contrast, activation of p53-mediated senescence in hepatic stellate cells was found to limit 
liver fibrosis in mice [464]. Additionally, p53 deficient cardiac fibroblasts isolated from 
mice exhibited an increase of collagen I and III production, which are key ECM 
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molecules implicated in the development of fibrosis. The role for p53 in intestinal fibrosis 
however, remains unclear. Given that miR-34a was identified and validated as up-
regulated in SCD compared to NSCD sample tissues, the aim here was to examine the 
role of p53 in intestinal fibrosis in CD by determining its expression at both mRNA and 
protein level.  
 
Initially, TP53 mRNA was measured via qRT-PCR in six matched paired NSCD and 
SCD tissues and expression was normalised to GADPH. TP53 expression levels between 
the two groups was not significantly different (p=0.252; Fig. 3.6A). Protein level of p53 
was also assessed in tissues of CD patients with (n=7) or without (n=6) fibrosis via 
immunohistochemistry. Staining was analysed and reported by a consultant pathologist 
(Professor Roger Feakins, Department of histopathology, The Royal London Hospital) 
who determined the percentage of p53-positive cells at two different staining intensity 
levels (1: weak and 2-3: moderate / strong). p53-positive staining in epithelial cells, 
immune cells (dendritic cells), and lamina proprial stromal cells was expressed as a 
percentage of total cell population analysed (Table 3.2). Immunohistochemistry showed a 
variable but generally low level of staining in epithelial, immune and lamina proprial 
stromal cells in both NSCD and SCD tissues. Often, a significant minority or in some 
cases a majority of normal crypt epithelial cells showed weak staining for p53. However, 
moderate / intense p53 staining was always focal and, even in the most strongly stained 
areas, was confined to <1% to 10% of epithelial cells (Table 3.2, arrows Fig. 3.6B). By 
contrast, the most strongly stained areas in the ulcerated fibrotic bowels showed moderate 
/ intense staining in 25% to 50% of crypt epithelial cells (arrows, Fig. 3.6C). These areas 
of intense p53 staining were typically close to the fibrotic lesions. Fibroblasts and other 
connective tissue cells showed little or no p53 expression, regardless of the presence or 
absence of ulceration and/or inflammation (arrows, Fig. 3.6D). This data indicates that the 
increase of p53 expression in fibrotic CD tissue seems to be in the epithelium as a 
response to fibrotic ulceration and/or inflammation. The lack of p53 staining in lamina 
proprial stromal cells would suggest that p53 does not play a direct role in these stromal 
cells, and might not a have a direct effect on the production of ECM in these cells.  
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The up-regulated p53 expression in epithelial cells is in contrast to the lack of differential 
expression of TP53 mRNA expression between the six matched NSCD and SCD tissues. 
This might be due to the fact that the RNA from epithelial cells represents only a fraction 
of the total RNA extracted from the mucosa. Therefore, the moderate / intense staining of 
p53 protein that was observed in epithelial cells in overlying fibrotic areas was perhaps 
not reflected at the RNA level.  
 
Previous results indicated that miR-34a did not regulate the expression of any fibrosis 
related genes (Section 3.6) and its main upstream regulator, p53, was not expressed in 
fibroblasts in SCD tissue samples (Section 3.7). These observations suggest that the role 
for miR-34a in intestinal fibrosis might not be fibroblast-related and that it may be 
functional in other cell types such as epithelial cells. The next section aims to determine 
which cells express miR-34a in NSCD and SCD tissues by performing in situ 
hybridisation.  
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Figure 3.6. Increased expression of p53 in epithelial cells in crypts overlying fibrotic lesions. (A) qRT-
PCR of TP53 mRNA in six matched NSCD and SCD tissue samples. Expression normalised to GADPH. 
(B-D) IHC of p53 in FFPE tissue from CD patients analysed by Professor Roger Feakins. (B) Weakly p53-
positive cells (black arrows) in normal crypts. (C) Moderate / strong p53-positive cells (black arrows) in 
crypts localised near fibrotic ulcers. (D) Negative lamina proprial stromal cells (black arrows) around 
fibrotic lesions. Bars represent mean values with SEM. Size bar is 100 μm. 
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Table 3.2. Immunohistochemistry staining of p53 in NSCD and SCD tissue. Classification of 
percentage of p53-positive cells in both normal (NSCD, n=6) and fibrotic (SCD, n=7) areas in CD patients. 
Percentage of staining in two staining intensities (1: weak, 2-3: moderate/strong) in three different cell types 
were noted. For the crypts, a minimum of 20 crypts in the most strongly staining area were measured per 
sample. NA, not applicable.  
 
 
 
ID Type Crypts 
Follicular dendritic 
cells 
Lamina proprial stromal 
cells 
  
% staining  
intensity 1 
% staining 
at intensity 
2-3 
% staining  
intensity 1 
% staining 
at intensity 
2-3 
% staining  
intensity 1 
% staining at 
intensity 2-3 
CD362 NSCD 10-20 <1 40 5 <1 0 
CD417 NSCD 20 5 NA NA 10 0 
CD401 NSCD 50 10 NA NA 1 0 
CD398 NSCD 40 5 30 <1 <5 0 
CD425 NSCD 50 <1 10 <1 10 <1 
CD419 NSCD 40 10 NA NA <1 0 
CD362 SCD 80 10-50 10 1 0 0 
CD417 SCD 90 40 5 1 10 1 
CD401 SCD 80 50 25 2 10 1 
CD398 SCD 80 35 NA NA 10 1 
CD425 SCD 50 30 30 2 
10 (by 
lesion) 
<1 
CD373 SCD 80 40 80 5 15-20 1 
CD419 SCD 50 30 40 2 5 0 
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3.8 Expression of miR-34a expression in gut mucosa is localised 
to the epithelial cells 
In situ hybridisation allows miRNA expression analysis to be performed directly in 
tissues. This facilitates the identification of miRNA expression in specific cell types or 
the expression pattern in tumours. Detection probes for miRNAs often contain locked 
nucleic acids (LNA) which increase hybridisation affinities over standard probes [465, 
466]. Exiqon is one of the leading companies that produce commercially available LNA 
probes for the majority of miRNAs in miRBase (www.miRbase.com). Section 2.19 and 
Fig. 2.3 show a detailed overview of the in situ hybridisation methodology performed.   
 
The aims for this part of my thesis were: 
1. To determine the localisation of miR-34a in the mucosa of patients; and 
2. Compare the expression pattern of miR-34a between NSCD and SCD. 
 
One of the most important steps in the in situ protocol is the proteinase-K treatment 
which digests the tissue allowing the probe to access the cell and bind to the miRNA. Too 
little digestion and the probe will not be able to hybridise, whereas too much digestion 
can lead to over-digestion of the tissue and cause increased signal to noise ratios. The 
incubation time with proteinase-K was therefore optimised. Three time points (15 min, 30 
min or 45 min) were performed in combination with 60 nM of miR-34a LNA probe on 
slides from FFPE blocks colon cancer tissue. Figure 3.7 shows images from the 
optimisation of miR-34a with three different proteinase K digestion times (A. 15 min, B. 
30 min and C. 45 min; Fig 3.7). Expression of miR-34a illustrated a staining intensity 
which correlated positively to an increase in digestion time; ranging from minimal 
staining after 15 min to strong staining after 45 min of proteinase-K digestion. 
Background staining increased after proteinase-K treatment for 45 min (black arrows; Fig 
3.7C) and therefore, a 30 min digestion time was selected for further in situ hybridisation 
experiments with miR-34a.  
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Figure 3.7. Optimisation of in situ hybridisation of miR-34a in colon cancer tissue. (A-C) Tissue was 
incubated with 10 µg/ml proteinase-K for three time points (15 min, 30 min and 45 min) followed by 
hybridisation with 60 nM miR-34a double-DIG-labelled LNA probe. miR-34a staining in blue and nuclear 
counterstain in red. Black rectangles outline the position of the zoomed images shown below.  
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To determine the expression of miR-34a in the gut mucosa, ten FFPE blocks (five SCD, 
five NSCD, matched tissues from the same patient) were subjected to in situ hybridisation 
with double-DIG-labelled LNA probes for miR-34a (60 nM) and a negative control 
(scrambled sequence, 60 nM). Sections were treated with 10 ug/ml proteinase-K for 30 
mins as previously optimised. Images of one pair of matched tissue (SCD and NSCD) are 
shown in Fig. 3.8. In general, miR-34a staining was predominantly observed in the 
epithelial cells in the mucosal crypts as well as some of the immune cells (black arrows; 
Fig. 3.8A, C). Minimal to no expression of miR-34a was seen in the stromal-like cells 
(red arrows; Fig. 3.8A, C), although without a marker for mesenchymal cells, stromal 
cells were hard to distinguish from other cell types with the use of a nuclear counterstain 
alone. Serial sections were hybridised with a double-DIG-labelled LNA probe for a 
scrambled sequence (negative control) which demonstrated no positive staining (Fig. 
3.8B, D), indicating that the miR-34a staining observed in adjacent sections is specific. 
 
In only two of the five paired tissue blocks, miR-34a expression was even and 
homogenous across the slide. The other three showed patchy staining, which may be due 
to uneven tissue digestion and/or uneven incubation of the hybridising probe. Because of 
this it was difficult to draw any conclusions as to whether the expression of miR-34a was 
altered in mucosa-overlying strictured areas compared to mucosa-overlying non-strictured 
areas. Although, staining in the two paired tissue blocks did not show obvious differences 
in expression levels in the epithelial cells or immune cells (Fig. 3.8A, C).  
 
In conclusion, miR-34a expression in the gut mucosa is predominantly localised to 
epithelial cells and not in stromal-like cell types. This observation is in accordance with 
the fact that p53, a major upstream regulator of miR-34, was also mainly found to be 
expressed predominantly in epithelial cells (Section 3.7). These results indicate that the 
functional role for miR-34a in gut fibrosis may not be directly in fibroblasts, but 
indirectly through the interaction between fibroblasts and other cell types with elevated 
miR-34a expression, such as epithelial cells. 
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Figure 3.8. The expression of miR-34a is localised to epithelial cells in the gut mucosa. (A-D) Images 
of two blocks of gut tissue from the same patient (1 SCD, 1 NSCD) hybridised with 60 nM double-DIG-
labelled LNA probe against miR-34a or a scrambled sequence (negative control). Black rectangles outline 
the position of the zoomed images shown on the right. Black arrows indicate positively stained epithelial 
cells and immune cells, red arrows indicate negative staining in the stromal-like cells. Size bars shown. 
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3.9 Discussion and future work 
3.9.1. Differentially expressed miRNAs between NSCD and SCD mucosal tissue  
Previous reports have indicated that molecular changes in the overlying mucosa layer can 
mimic events in underlying tissues [201]. MiRNAs regulate many cellular processes 
including proliferation, differentiation and apoptosis. I, hypothesised therefore, that the 
miRNA expression profile between NSCD and SCD areas is different. To test this, 
changes in miRNA expression were determined in mucosa samples from NSCD and SCD 
tissues and subsequent analysis identified 29 differentially expressed and significant 
differentiated miRNAs (Section 3.2). Although others have investigated the differential 
expression between CD and healthy controls [361, 362], my study was the first to profile 
altered miRNA expression in the mucosa of intestinal fibrosis in CD. Comparison 
between my data with data from the arrays mentioned above highlighted only a single 
commonly altered miRNA (miR-34c-5p,[362]), however, given the differences in sample 
groups, a true comparison is difficult.  
 
The up-regulation of three miRNAs (miR-34a, -493* and -708) in SCD tissues compared 
to NSCD was validated by qRT-PCR. Two miRNAs (miR-223* and -148b) were not 
significantly changed and two (miR-1285, -503) could only be detected in five of the 
eight paired samples that were tested (Section 3.3). One of the advantages of the Illumina 
array is its high sensitivity to detect low abundance miRNAs. This could explain why 
miR-1285 and miR-503 were not detected in all of the samples by qRT-PCR. However, 
for the samples in which miR-1285 and miR-503 could be detected, the type of 
dysregulation was in accordance with that identified by the array (miR-1285 down-
regulated in SCD vs NSCD, miR-503 up-regulated in SCD vs NSCD). In our laboratory, 
we continue to collect additional paired NSCD and SCD tissue samples. Future work 
could include further examination of both miR-503 and miR-1285 expression levels in 
these samples.  
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The expression of miR-708 was up-regulated in SCD vs NSCD and validated by qRT-
PCR (Section 3.3). This contradicts the findings of Huebert and colleagues, who 
identified miR-708 as one of the down-regulated miRNAs in cirrhotic (end-stage resulted 
from fibrosis of the liver) endothelial cells [444]. The expression of miRNAs is context 
dependent and may vary greatly between various tissue and cell types providing an 
explanation for these contradicting observations. As the array presented here was 
performed on the mucosa, which comprises of a number of cell types, it will therefore be 
important to determine the localisation of miR-708 within CD tissue samples (as was 
done for miR-34a in this thesis). For example, miR-708 has been found to induce 
apoptosis in renal cancer cells [467] and it would be very interesting to investigate the 
localisation of miR-708 in the gut mucosa in CD. As I have observed the localisation of 
pro-apoptotic miR-34/p53 axis in epithelial cells, the expression of miR-708 could 
therefore lend support to this pro-apoptotic signalling within the epithelial cells during 
fibrogenesis. On the other hand, if miR-708 is expressed in mesenchymal-like cells, 
functional studies could be performed on intestinal fibroblasts to elucidate the 
downstream mechanisms of miR-708 in intestinal fibrosis in CD.  
 
Validation by qRT-PCR showed that miR-493* displayed the largest fold increase in 
SCD vs NSCD tissues. Only one other report has suggested a potential role for miR-493* 
in fibrosis. Milosevic and colleagues demonstrated an increase of miR-493* expression in 
idiopathic pulmonary fibrosis [442]. Interestingly, miR-493* is a member of the second 
largest miRNA cluster (C14MC) in the human genome and is located at the imprinted 
DLK-1/DIO3 domain on the human chromosome 14q32 [248]. This domain is maternally 
imprinted and consists of numerous repeated, intron-embedded miRNAs that are 
processed from a single long non-coding RNA. A large number (n=24) of miRNAs from 
this cluster has been previously shown to be up-regulated in tissue samples from patients 
with pulmonary fibrosis [442]. Also, the expression of 13 C14MC miRNAs was induced 
by TGF-β, implicating these miRNAs in the pathogenesis of fibrosis [442]. On the array 
presented in this thesis (Section 3.2), three other members of this cluster were shown to 
be up-regulated in SCD vs NSCD (miR-323-3p, -369-3p, and -487b). Future work could 
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attempt to validate these miRNAs on our paired NSCD and SCD tissue samples. A 
synergistic up-regulation of more members of this cluster would strengthen the 
hypothesis that this cluster is involved in intestinal fibrosis in CD. 
 
TGF-β has been shown to be involved in the activation of Wnt signalling by decreasing 
Wnt pathway antagonist DKK-1 resulting in increased fibrosis [468]. The online target 
prediction program miRBase (www.microrna.org) predicts that DKK1 might be targeted 
by a number of members of the C14MC cluster (miR-136, -376a, -376b, -433, -493*, -
496, -543, and -656). Strikingly, an additional four miRNAs that were up-regulated in the 
array (miR-148b, -223*, -34a, and -493*) are also predicted to target this Wnt-antagonist. 
The link between these miRNAs and DKK1/Wnt signalling has not yet been investigated.  
 
Therefore, a novel line of investigation would aim to: 
1. Validate additional members of the C14MC in paired NSCD vs SCD tissue 
samples via qRT-PCR; 
2. Investigate the effect of the validated miRNAs on Wnt signalling activation. This 
could be done via transient transfection of candidate miRNAs in combination 
with a Wnt activity reporter construct (TCF-LEF-reporter) in intestinal 
fibroblasts. These experiments should be performed in the presence of TGF-β 
stimulation to elucidate the role of both TGF-β and the miRNAs on Wnt 
signalling activity; and 
3. mRNA and protein expression of key Wnt signalling mediators, including DKK1, 
could be assayed following transfection of the validated miRNAs in intestinal 
fibroblasts. 
 
3.9.2. miR-34a does not alter the mRNA expression of fibrosis-associated genes 
Intestinal fibroblasts were isolated from mucosa from six CD patients undergoing surgery 
for stricture formation (Table 2.1) using methods described by others [446] (Section 2.3). 
The benefit of using intestinal fibroblasts isolated cells from the gut of patients with CD 
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is the ability to demonstrate the role of candidate miRNAs in a physiologically relevant 
context i.e. gut fibrosis. However, transfection of isolated cells from primary tissue is 
notoriously difficult and transfection of intestinal fibroblasts has only been reported by 
one other group [469]. However, I have now shown that intestinal fibroblasts can be 
transfected successfully with siRNA/miRNAs using a lipid based system (Section 3.4 and 
Section 3.5).  
 
Overexpression of miR-34a via transient transfection of pre-miR-34a demonstrated no 
significant change in mRNA expression of fibrosis-associated genes between NTC and 
pre-miR-34a transfected fibroblasts (Section 3.6). Both MMP2 and SMAD4 were selected 
based on their 3’UTR containing predicted sites for miR-34a. However, my data showed 
that miR-34a does not influence these genes at the transcriptional level. mRNA 
expression levels of survivin (BIRC5), which previously validated to be target by miR-
34a [449] and used a positive control, was not significantly altered following 
overexpression of miR-34a. A literature search later revealed that miR-34a down-
regulates the expression of survivin solely at the protein level whilst its mRNA level 
remains unchanged [470], thereby providing an explanation for why miR-34a failed to 
reduce the mRNA levels of BIRC5. Although miR-34a expression levels were induced 
nearly 1000-fold following transfection with pre-miR-34a (Section 3.6), additional 
evidence is needed to confirm successful transfection. Future experiments to further 
investigate potential targets for miR-34a will have to include other positive controls such 
as SIRT1 [471] or BCL2 [472], which have been previously validated at the mRNA level. 
Ideally, phenotypic controls such as cell viability and/or cell number should be used. A 
decrease in these parameters could provide evidence that miR-34a is functional within the 
cell as miR-34a is known to be a potent inducer of apoptosis [471, 473].  
 
Many studies focus on the effect of miRNAs on mRNA degradation whilst reports show 
that translational repression by miRNAs can account for the majority of their regulatory 
function [266, 474]. In fact, genome-wide studies suggest that some targets are solely 
repressed at the translational level [475, 476]. These studies highlight the need for protein 
105 
 
 
expression analysis and future work may aim to further investigate miR-34a targets at the 
protein level by techniques such as western blotting or immunohistochemistry. Given the 
fact that miR-34a was predominantly expressed in epithelial cells, functional studies, such 
as over-expression of miR-34a in this cell type may be a more appropriate way to 
determine the role for miR-34a during fibrogenesis. 
 
3.9.3. p53 is expressed in epithelial cells overlying fibrotic areas in the mucosa of CD 
patients 
The TSG p53 is an upstream activator of miR-34a and miR-34b/c [311, 312, 315, 316], 
suggesting a role for p53 in intestinal fibrosis. Therefore, in Section 3.7, the expression of 
p53 was investigated in intestinal fibrosis at mRNA and protein level via qRT-PCR and 
IHC, respectively. TP53 transcript levels in six matched NSCD and SCD tissues showed 
no significant change between the two groups. Quantification of p53 protein expression 
of normal and fibrotic lesions of CD patients indicated an increase in p53 protein within 
the epithelial cells of the crypts surrounding fibrotic lesions. No p53-positive stromal 
cells were observed in either normal tissue or fibrotic lesions. The presence of p53-
positive epithelial cells in fibrotic lesions confirmed the findings of others that report an 
up-regulation of p53 in the epithelial cells of patients with pulmonary fibrosis [460, 461]. 
This observation was linked to the induction of the p53-mediated apoptosis signalling 
pathway [460, 461]. Thus, p53 may not be involved directly in the fibroblasts-associated 
events during intestinal fibrosis in CD. It has been proposed that idiopathic pulmonary 
fibrosis results from epithelial cell injury and the subsequent activation of underlying 
mesenchymal cells (reviewed in [477]). More recently, this cross talk between epithelial 
and mesenchymal cells was shown in oesophageal fibrosis [478]. Together, these findings 
support a role for the pro-apoptotic signalling through p53 in epithelial cells in intestinal 
fibrosis.  
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3.9.4. miR-34a is present in the epithelial cells in the mucosa of CD patients 
To investigate the location of miR-34a in the gut of CD patients, in situ hybridisation of 
miR-34a was performed on five matched pairs of NSCD and SCD tissues. Unfortunately, 
the staining of miR-34a was uneven in the majority of sections investigated. The majority 
of publications that include in situ hybridisation of miRNAs use a probe against small 
RNA U6 as a positive control for the staining technique. U6 is expressed ubiquitously and 
should, therefore, be present in all cell types. However, one of the down-sides of using 
U6 as a control is the fact that this small RNA is present only in the nucleus. For the 
hybridisation probe to reach the nucleus, longer digestion times are required compared to 
miRNAs in the cytoplasm. For example, when gut sections were stained with U6, both 
positive and negative stained patches within the same slide were observed (Appendix Fig. 
1). The positively stained patches appeared more digested than the negative patches, 
suggesting that more tissue digestion is required for the U6 probe to be able to access the 
nucleus and hybridise with U6 small RNA. This makes the use for U6 as a positive 
control questionable in this context. 
 
As the expression of miR-34a was uneven across the slide, and the lack of an appropriate 
positive control, I was unable to make any conclusion as to whether the expression of 
miR-34a was altered between mucosa-overlying strictured areas and non-strictured areas. 
However, I can report that the expression of miR-34a was predominantly found in 
epithelial cells with weak staining in stromal like cells. This observation is in accordance 
with previous in situ reports which demonstrate the expression of miR-34a in epithelial 
cells of bladder carcinoma [479] and breast cancer [480, 481]. Furthermore, I showed that 
one of its main upstream regulators, p53, is also expressed in the epithelial cells (Section 
3.7), which may indicate the activation of the p53/miR-34 axis in these cells. 
Functionally, any role for miR-34a in intestinal fibrosis is likely to be localised to 
epithelial cells and not in fibroblasts. As mentioned in Section 3.9.3, the activation of sub-
epithelial stromal cells has been proposed to be a secondary event following epithelial 
cell injury in pulmonary fibrosis, which might also potentially be the case for intestinal 
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fibrosis in CD. To further investigate this line of research, the following experiments 
could be performed: 
 
1) A repeat of the in situ hybridisation of miR-34a in paired NSCD and SCD tissues 
alongside multiple miRNAs as controls (e.g. miR-210 and miR-21). We know 
from experiments performed later on in this thesis (Section 5.4) that miR-210 is 
expressed in epithelial cells and that miR-21 is predominantly observed in stromal 
cells in CRC tissue. The use of these miRNAs as controls would allow me to draw 
conclusions about the localisation and relative expression of miR-34a in NSCD 
and SCD tissues;  
2) To investigate whether the expression of miR-34a is altered between NSCD and 
SCD tissues with the use of in situ LNA probes conjugated with fluorescent dyes. 
This would facilitate accurate quantification of the miRNA expression levels in 
tissue. The IN Cell Developer v1.8, which has been used in this thesis to quantify 
fluorescent images, could be used for this purpose; 
3) To investigate co-localisation of miRNAs and potential gene targets, co-staining 
could be performed. In our laboratory, miRNA in situ has been successfully 
combined with regular immunohistochemistry. This technique would allow 
identification of co-localisation of miR-34a and other proteins such as p53; and 
4) Finally, to investigate the cross-talk between epithelial cells and fibroblasts, 
organotypic cultures could be used. For example, epithelial cells (preferably 
primary/non cancer cells) should be stably transfected with miR-34a expression 
vectors and cultured on top of intestinal fibroblasts for various amounts of time 
(3-14 days). Cultures would be fixed and then stained for ECM markers such as 
collagens and α-SMA. This would test whether the up-regulation of miR-34a 
within the epithelial cells can potentially induce the activation of fibroblasts and 
promote production of ECM by these cells.  
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Chapter 4: Reduced expression of miR-29b in CD 
up-regulates collagen expression in intestinal 
fibroblasts 
4.1 Introduction and aims 
 
The preceding chapter identified differentially expressed miRNAs between NSCD and 
SCD tissues (Section 3.2 and Section 3.3). The microarray used to determine the 
expression is capable of detecting low abundance miRNAs due to the technology’s high 
sensitivity. Hence, 40 miRNAs that were highly expressed in CD tissues were not 
detected as differentially expressed because of their fluorescence being outside the 
detectable range (Appendix Table 1). This was the case for miR-29b, one of the three 
members of the miR-29 family (miR-29a, -b and –c). The miR-29 family has been 
predominantly studied in cancer and is known for its tumour-suppressor function 
(reviewed in [482]). In addition, the miR-29 family is down-regulated in fibrosis of 
various organs [372-378], although not in the intestine where changes in miR-29 
expression are yet to be investigated [372-378]. Aims for this chapter: 
 
1. Determine the expression of the miR-29 family in intestinal fibrosis in CD;  
2. Investigate down-stream targets of miR-29b in intestinal fibroblasts via transient 
transfection and assess the expression of ECM molecules, such as collagen I and 
III, at the mRNA and protein level in the presence and absence of TGF-β; and 
3. Identify the effect of miR-29b on a down-stream target, myeloid cell leukemia-1 
(Mcl-1), and the mRNA and protein level. 
 
Part of this chapter formed the basis of a manuscript published in Clinical Science in 
2014 [483].  
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4.2 MiR-29 family is down-regulated in CD fibrosis, regulates 
COL1A2 and COL3A1, and collagen III protein expression 
 
The human miR-29 family consists of miR-29a, miR-29b-1, miR-29b-2, and miR-29c. 
The gene encoding the precursors of miR-29a and miR-29b-1 is located on chromosome 
7, whilst miR-29b-2 and miR-29c are on chromosome 1 (Fig. 4.1A). Sequences of the 
mature miR-29 strands largely overlap, and are highly conserved in human, mouse and 
rat. In fact, the sequence of miR-29b-1 and -2 are identical and are collectively referred to 
as miR-29b. Additionally, the three mature miR-29 strands share corresponding 
sequences at nucleotide positions 2-7, which is known as the seed region (orange shaded 
areas; Fig 4.1A). This region is involved in facilitating the binding between the miRNA 
and its target mRNA and, as a result, the predicted target genes for the miR-29 family 
widely overlap. The miR-29 family has been previously implicated in the pathogenesis of 
fibrosis in various organs. For example, the expression of all three members is reduced in 
fibrosis of the kidney [372, 373]
 
and liver [374]. Additionally, miR-29b is down-regulated 
following myocardial infarction [375] in the lungs of patients with idiopathic pulmonary 
fibrosis [376, 377] and in skin fibroblasts of patients with systemic sclerosis [378]. To 
date, the role for the miR-29 family in intestinal fibrosis in CD remains unexplored.  
 
Because the signal for miR-29b was saturated on the array, the expression of the miR-29 
family was validated in nine paired NSCD and SCD tissues by qRT-PCR. Expression 
values were normalised to miR-16 and fold change in SCD relative to NSCD is 
calculated. All three members of the miR-29 family were significantly down-regulated in 
SCD samples compared to NSCD (n=9, miR-29a, p=0.0002; miR-29b, p=0.0010; miR-
29c, p=0.0114; Fig. 4.1B). The expression of miR-29b demonstrated the largest decrease 
in fold change in SCD relative to NSCD and miR-29b was, therefore, selected for further 
functional studies. In addition, reports have indicated that the dysregulation of key 
mediators in fibrosis of various organs is predominantly controlled by miR-29b [372, 
484]. 
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Online predication tools indicate that miR-29b targets both COL1A2 and COL3A1 
(www.microRNA.org), both of which have been validated by other groups using 3’-UTR 
luciferase assays [375, 379]. In addition, both COL1A1 and COL3A1 are important in 
intestinal fibrosis [485, 486] and were up-regulated in SCD relative NSCD tissue samples 
(Appendix Fig. 2). To validate these findings in intestinal fibrosis, fibroblasts isolated 
from CD patients were transiently transfected with NTC, pre-miR-29b or anti-miR-29b. 
Expression of COL1A2 and COL3A1 mRNA were assessed by qRT-PCR and normalised 
to GAPDH.  Fold change in expression compared to NTC demonstrated a significant 
down-regulation of both COL1A2 and COL3A1 by pre-miR-29b (COL1A2 and COL3A1, 
p<0.0001; Fig.4.1C). Additionally, both genes were significantly up-regulated following 
transfection with anti-miR-29b relative to NTC (COL1A2, p=0.037; COL3A1, p=0.0015; 
Fig. 4.1C). This data shows that miR-29b modulates the expression of both collagens at 
the mRNA level.  
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Figure 4.1. miR-29b is down-regulated in intestinal fibrosis and modulates COL1A2 and COL3A1 
mRNA (A) Schematic overview of chromosomal location of the human family members of the miR-29 
family. The miR-29 family is encoded by two genes located on chromosome 7 and 1. The mature sequence 
of miR-29b-1 and -2 are identical and referred to as miR-29b. All members share the same seed sequence 
highlighted in orange. (B) qRT-PCR of the three members in nine matched NSCD and SCD tissue samples. 
Expression normalised to miR-16. The graph represents the fold change in expression relative to NSCD. 
(C) Intestinal fibroblasts (n>3) transfected with NTC, pre-miR-29b or anti-miR-29b for 72 hr. qRT-PCR of 
COL1A2 and COL3A1 mRNA expression is normalised to GAPDH. The graph represents the fold change 
relative to NTC. Bars represent mean values with SEM. *p<0.05, **p<0.01 and ***p<0.001.  
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To investigate the effect of miR-29b on collagen I and III protein levels, 
immunofluorescence was performed. Intestinal fibroblasts were transfected with NTC, 
pre-miR-29b or anti-miR-29b for 72 hr. Cells were fixed and stained with Hoechst 33342, 
CellMask Deep Red, and antibodies against collagen I or III. The IN Cell Analyzer 1000 
microscope was used to image the cells under identical exposure conditions. A mask 
overlying the CellMask Deep Red stained cells was created using the IN Cell Developer 
v1.8. Hoechst-positive nuclei were used to clump-break the overlaying mask (Fig 4.2A-
C), which was subsequently used to define cellular pixel intensity of both collagen I and 
III in individual cells. Fold change in median pixel intensities between NTC and pre-miR-
29b or anti-miR-29b transfected fibroblasts was calculated. Fibroblasts transfected with 
pre-miR-29b demonstrated a significant decrease in pixel intensity for collagen III 
compared to cells transfected with NTC (p=0.0069; Fig. 4.2D), whereas collagen I protein 
was not altered by pre-miR-29b (p=0.163; Fig. 4.2D). Finally, fibroblasts transfected with 
anti-miR-29b did not alter endogenous collagen I or III protein levels. This observation 
was in contrast to the up-regulation of COL1A2 and COL3A1 mRNA expression 
following transfection with anti-miR-29b (Fig. 4.1C). Representative images of fold 
change in Fig. 4.2D are shown in Fig.4.2E. 
 
Together, this data demonstrates that the miR-29 family is down-regulated in intestinal 
fibrosis in CD. Furthermore, miR-29b is able to regulate both collagen I and III at the 
mRNA level, and collagen III at the protein level. Collagen I protein level was not altered 
by miR-29b in this particular experimental set-up, and this will be reviewed in the 
discussion chapter (Section 4.6.2).   
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Figure 4.2. miR-29b down-regulates collagen III protein. Intestinal fibroblasts (n=3) were transfected 
with NTC, pre- or anti-miR-29b for 72 hr and stained with Hoechst 33342 and antibodies against collagen I 
and III. (A-C) Hoechst 33342 and CellMask Deep Red staining created an overlaying mask in the CellMask 
channel, which was then used to define pixel intensity of collagen I and III in individual cells. (D) The 
graphs represent the fold change in median pixel intensity following transfection. (E) Representative images 
of collagen I and III following transfection with NTC, pre-miR-29b or anti-miR-29b. Bars represent mean 
values with SEM. **p<0.01. Size bar is 100 μm.  
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4.3 TGF-β up-regulates collagen by down-regulating miR-29b 
expression 
 
One of the key pro-fibrotic cytokines involved in the development of fibrosis in various 
organs is TGF-β (reviewed in [487]). TGF-β increases pro-fibrotic mediators through 
SMAD-mediated transcription (Section 1.2.4). MiRNAs have been shown to be regulated 
by TGF-β signalling and have the potential to work synergistically (reviewed in [488]). 
Indeed, reports have indicated that TGF- β increases the production of ECM proteins via 
the down-regulation of miR-29b in cardiac [375], kidney [372] and liver fibrosis [374]. In 
order to validate this role for TGF-β in intestinal fibrosis, fibroblasts were treated with 
TGF-β (10 ng/ml) for 48 hr and assayed for the expression of miR-29b and both COL1A2 
and COL3A1 genes by qRT-PCR. Expression of GAPDH and miR-16 were used to 
normalise for the collagen mRNA and miRNA expression, respectively. Fold change 
relative to untreated fibroblasts (NT) showed a significant down-regulation of miR-29b 
(p=0.0199; Fig. 4.3A) and an up-regulation of COL1A2 and COL3A1 expression 
(COL1A2, p=0.002; COL3A1, p=0.006; Fig. 4.3A). In accordance with previous reports, 
this data suggests a link between the down-regulation of miR-29b and the up-regulation 
of COL1A2 and COL3A1 expression.  
 
Next, the association between TGF-β, miR-29b and the downstream targets collagen I and 
III was explored further. As TGF-β down-regulates the expression of miR-29b and 
subsequently up-regulating COL1A2 and COL3A1, I hypothesised that by restoring 
endogenous levels of miR-29b levels via transfection with pre-miR-29b, this up-
regulation of COL1A2 and COL3A1 could be reversed. Likewise, reducing the 
endogenous levels of miR-29 by transfection with anti-miR-29b would further enhance 
the effect of the TGF-β treatments.  
 
To test this, intestinal fibroblasts were transfected with NTC, pre-miR-29b and anti-miR-
29b for 24 hr before treatment with TGF-β (10 ng/ml) for 48 hr. The expression of 
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COL1A2 and COL3A1 was assayed via qRT-PCR, and the fold change between cells 
transfected with pre-miR-29b or anti-miR-29 relative to cells transfected with NTC was 
calculated. As predicted, cells transfected with pre-miR-29b prior to TGF-β treatment 
demonstrated a significant inhibition of both COL1A2 and COL3A1 mRNA transcripts 
(COL1A2, p=0.0012; COL3A1, p=0.0034; Fig. 4.3B). In addition, decreasing the levels of 
endogenous miR-29b by transfection with anti-miR-29b prior to TGF-β treatments 
resulted in a significant increase in expression of both collagen transcripts (COL1A2, 
p=0.0115; COL3A1, p=0.0282; Fig. 4.3B). Together, this data suggests that the up-
regulation of both collagen gene transcripts is potentially mediated through the down-
regulation of miR-29b by TGF-β.  
 
In order to validate this observation at the protein level, immunofluorescence was 
performed using antibodies against collagen I and III. Intestinal fibroblasts were 
transfected with NTC, pre-miR-29b and anti-miR-29b for 24 hr before treatment with 
TGF-β (10 ng/ml) for 48 hr. Cells were fixed 72 hr following transfection and stained 
with Hoechst 33342, CellMask Deep Red and antibodies against collagen I and III. 
Median pixel intensities of both collagen I and III in individual cells was determined as 
described previously (Section 4.2; Fig. 4.2 A-C). Fold change in median pixel intensities 
for pre-miR-29b or anti-miR-29b relative to NTC transfected cells (all TGF-β treated) 
was calculated. Once more, it was hypothesised that by modulating endogenous levels of 
miR-29b via transfection with pre-miR-29b or anti-miR-29 prior to the TGF-β treatment 
could modulate the expression of collagen I and III proteins. 
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Figure 4.3. TGF-β up-regulates COL1A2 and COL3A1 mRNA through the down-regulation of miR-
29b. (A) Intestinal fibroblasts (n>4) were treated with TGF-β (10 ng/ml) for 48 hr and expression levels of 
miR-29b, COL1A2 and COL3A1 were assayed by qRT-PCR. The graph represents the fold change in gene 
expression relative to untreated cells (NT). (B) Intestinal fibroblasts (n=4) were transfected with NTC, pre-
miR-29b or anti-miR-29b for 24 hr prior to TGF-β (10 ng/ml) treatment. The graph represents the fold 
change of COL1A2 and COL3A1 expression following transfection with pre-miR-29b or anti-miR-29b 
relative to NTC (all TGF-β treated). Bars represent mean values with SEM. *p<0.05 and **p<0.01.  
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The transfection of pre-miR-29b prior to TGF-β treatment significantly down-regulated 
the expression of collagen III (p=0.0069; Fig. 4.4A), which supports previous data 
showing down-regulation of COL3A1 mRNA expression (Fig 4.3B). By contrast, 
collagen I protein expression was not altered following transfection with pre-miR-29b 
and TGF-β treatments (collagen I, p=0.7816; Fig. 4.4A), despite the down-regulation of 
COL1A2 mRNA (Fig. 4.3B). This lack of modulation of collagen I protein by pre-miR-
29b prior to TGF-β treatment was consistent with data shown in Section 4.2, which 
showed that intestinal fibroblasts transfected with pre-miR-29b alone also failed to alter 
collagen I expression (Fig. 4.2D). Similarly, transfection of anti-miR-29b prior to TGF-β 
treatment also failed to up-regulate either one of the collagen protein levels (Fig 4.4A), 
indicating that that there are other, more dominant, factors that drive the expression of 
collagen I and III when miR-29b is absent. In summary, this data suggests that TGF-β can 
modulate collagen III protein via the down-regulation of miR-29b. 
 
In humans, it has been suggested that miRNAs may potentially target up to 30% of all 
genes [489] and online prediction tools such as miRWalk propose a large number of 
predicted targets for miR-29b, many of which have been subsequently validated 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/). Therefore, the next section aims 
to explore additional targets for miR-29b that may be involved in the pathogenesis of 
intestinal fibrosis independently from its regulatory effect on ECM molecules such as 
collagen.  
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Figure 4.4. TGF-β up-regulates collagen III protein expression through the down-regulation of miR-
29b. Intestinal fibroblasts (n=5) were transfected with NTC, pre-miR-29b or anti-miR-29b prior to TGF-β 
(10 ng/ml) treatment. Cells were stained with Hoechst 33342, CellMask Deep Red and antibodies against 
collagen I and III. (A) The graphs represent the fold change in median pixel intensity following transfection 
with pre-miR-29b or anti-miR-29b relative to NTC (all TGF-β treated). (B) Representative images of 
collagen I and III following transfection with NTC, pre-miR-29b or anti-miR-29b. Bars represent mean 
values with SEM. **p<0.01. Size bar is 100 μm. 
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4.4 MiR-29b up-regulates Mcl-1 mRNA and protein levels 
Intestinal wound healing following the damage by inflammation is a complex sequence of 
events where inflammatory cells induce the activation of sub-epithelial fibroblasts. The 
production of ECM molecules by these fibroblasts and their ability to contract the wound 
area, play important roles in intestinal wound healing. Chronic inflammation disturbs this 
physiological response which can eventually leads to an increase in the production of 
ECM molecules by fibroblasts. The over-production of ECM molecules is normally 
avoided by the activation of apoptosis pathways from cues in the intercellular space, 
resulting in the removal of ECM-producing cells. One hypothesis for the over-production 
of ECM molecules by activated fibroblasts is decrease of apoptosis signalling in these 
cells. Indeed, reports have recently indicated that fibroblasts that are resistant to apoptosis 
might play a role in pulmonary fibrosis [490]. However, this phenomenon remains 
unexplored in intestinal fibrosis in CD.  
 
The aim of this section was to explore additional targets for miR-29b that may influence 
the susceptibility to apoptosis in isolated intestinal fibroblasts. Online prediction tools 
identified Mcl-1, a member of the Bcl-2 family, as a miR-29b target in four of the five 
target prediction sites (TargetScan, MiRWalk, miRanda and DIANA Tools). The 
predicted binding site of miR-29b is within the 3’UTR of MCL1 and is shown in Fig. 
4.5A. More importantly, several groups have now validated this prediction demonstrating 
that miR-29b binds to the 3’-UTR of MCL1 [491-496]. The human MCL1 gene consists 
of three exons which undergo alternative splicing to form three mRNA transcripts: the 
long MCL-1L, the short MCL-1S and the extra short MCL-1ES (Fig. 4.5B) [497-501]. The 
Mcl-1L protein is anti-apoptotic and shows 35% homology with the C-terminus of the 
anti-apoptotic Bcl-2 proteins, containing Bcl-2 homology domains (BH)-1, BH2 and BH3 
[497]. Due to a frameshift, Mcl-S and Mcl-1ES only contain a single BH3 domain and are 
similar to BH3-only pro-apoptotic proteins [498]. Three studies, limited to the liver, have 
shown that Mcl-1 attenuates liver fibrosis in mice [502-504] and that the deletion of Mcl-
1 in hepatocytes results in liver cell damage caused by spontaneous induction of apoptosis 
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[502, 504]. To date, the potential role of Mcl-1 in intestinal fibrosis remains unexplored, 
thus, the effect of miR-29b on Mcl-1 in isolated intestinal fibroblasts was investigated.  
Intestinal fibroblasts were transfected with NTC or pre-miR-29b and expression of Mcl-1 
mRNA was assessed via qRT-PCR. Fold change in expression compared to NTC-
transfected fibroblasts demonstrated a significant increase in the expression of Mcl-1 
isoforms (MCL-1L/MCL-1ES, p=0.004; MCL-1S, p=0.0008; Fig. 4.5C). The TaqMan 
assay used for MCL-1L also detects MCL-1ES and, therefore, the two could not be 
distinguished using this probe. However, this data suggests that miR-29b up-regulates the 
mRNA expression of MCL-1L/ES and MCL-1S in intestinal fibroblasts. This finding was 
unexpected considering that previous reports have confirmed the direct binding between 
miR-29b and the 3’-UTR of MCL1 with luciferase reporter assays [491-493]. However, 
these reports demonstrate that miR-29b down-regulates Mcl-1 at the protein level and 
does not change the mRNA expression [492]. Therefore, the protein levels of Mcl-1 were 
assessed following transfection with pre- and anti-miR-29b. 
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Figure 4.5. miR-29b upregulates Mcl-1. (A) Predicted binding site between miR-29b and MCL1. 
Nucleotides in red indicate complementary binding between the seed sequence of miR-29b and the 3’UTR 
of MCL1. (B) Schematic overview of Mcl-1 gene consisting of three exons. Alternative splicing potentially 
produces three isoforms: MCL-1L, containing the full length of all three exons; MCL-1S, exon 2 is lost due 
to alternative splicing; and MCL-1ES, in which the first exon undergoes alternative splicing. (C) Intestinal 
fibroblasts (n>5) transfected with NTC and pre-miR-29b. The graph represents the fold change in 
expression of MCL-1L/ES and MCL-1S m0easured by qRT-PCR. Bars represent mean values with SEM. 
**p<0.01 and ***p<0.001. 
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To explore further the effects of miR-29b on Mcl-1, protein expression of Mcl-1 was 
determined by immunofluorescence on intestinal fibroblasts. Fibroblasts were transfected 
with NTC, pre-miR-29b or anti-miR-29b and cells were fixed 72 hr following 
transfection and stained with Hoechst 33342 and an antibody against Mcl-1. Cells were 
imaged using the IN Cell Analyzer 1000 microscope under identical exposure conditions. 
Mcl-1 protein localised in discrete nuclear foci (Fig. 4.6A). The IN Cell Developer v1.8 
was used to create a mask overlying the foci (Fig. 4.6B). This mask, in combination with 
Hoechst-positive nuclei, was used to determine the median Mcl-1 foci mass within each 
nuclei (foci mass/nuclei = (total foci pixel intensity x total foci area)/total nuclei count). 
Fibroblasts transfected with pre-miR-29b demonstrated a significant increase in foci mass 
compared to NTC, and transfection with anti-miR-29b resulted in a significant decrease 
in Mcl-1-positive foci mass (pre-miR-29b, p=0.0029; anti-miR-29b, p=0.0003; Fig. 
4.6C). Representative images with digital zoom are shown in Fig. 4.6D-F. In conclusion, 
this data combined demonstrated that miR-29b induces an increase of Mcl-1 at both 
mRNA and protein levels in intestinal fibroblasts.  
 
In contrast to plant miRNAs, human miRNAs display only limited complementarity to 
their target mRNA and can mediate inhibition through translational repression, rather than 
mRNA degradation [233, 505-507]. Although some miRNAs have been shown to up-
regulate their mRNA targets (reviewed in [508]), this appears to be an exception to the 
rule. As miR-29b has been previously validated to target the 3’-UTR of Mcl-1 by others, 
the up-regulation of Mcl-1 by miR-29b observed here may be indirect through the 
modulation of up-stream regulators of Mcl-1. The following section aims to investigate 
the potential regulation of miR-29b on two established up-stream regulators of Mcl-1, 
interleukin (IL)-6 and 8. 
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Figure 4.6. miR-29b up-regulates Mcl-1 mRNA and protein. Intestinal fibroblasts (n=3) were 
transfected with NTC, pre-miR-29b and anti-miR-29b for 72 hr. Cells were fixed and stained with Hoechst 
33342 and an antibody against Mcl-1. (A-C) Mcl-1 positive foci were used to create an overlaying mask. 
This mask was then used to define foci mass in individual cells. The graph represents the fold change in 
median foci mass/nuclei following transfection with pre-miR-29b or anti-miR-29b relative to NTC. (D-F) 
Representative images Mcl-1 following transfection with NTC, pre-miR-29 or anti-miR-29b. Bar represents 
mean values with SEM. **p<0.01 and ***p<0.001. Size bar 20 µm ((A-B), digitally zoomed images of (D-
F)) and 100 µm (original images D-F).  
  
124 
 
 
4.5 MiR-29b up-regulates Mcl-1 potentially IL-6 and IL-8 
One of the most potent inducer of Mcl-1 is through IL-6 [509, 510]. IL-6 is a classic pro-
inflammatory cytokine crucial in mounting an effective immune response. Recent studies 
have shown that IL-6 can induce collagen I expression [511] and its expression was found 
to be up-regulated in renal fibrosis in mice [512]. Furthermore, IL-6 has been implicated 
in a variety of fibrotic conditions via alternative trans-signalling pathways (cells that do 
not normally express the IL-6 receptor, but become responsive to IL-6 due to high levels 
of soluble IL-6 receptor present in extracellular matrix) [513]. A second cytokine, IL-8, 
has also been shown to increase the expression of Mcl-1 [514], and elevated serum levels 
of IL-8 are reported to be associated with fibrosis in chronic liver disease [515].   
 
To investigate the regulatory effect of IL-6 and IL-8 on Mcl-1, intestinal fibroblasts were 
treated with IL-6 or IL-8 (both 10 ng/ml) for 4, 8 or 24 hr. Cells were fixed and stained 
with Hoechst 33342 and an antibody against Mcl-1. Cells were imaged on the IN Cell 
Analyzer 1000 microscope under identical exposure conditions and the IN Cell Developer 
v1.8 was used to calculate the median foci mass of Mcl-1 in the nuclei as described 
previously (Section 4.4, Fig. 4.6A-B). Fibroblasts treated with either IL-6 or IL-8 for 4 hr 
up-regulated the mass of Mcl-1-positive foci, of which IL-6 approached significance. (IL-
6, p=0.064; IL-8, p=0.033; Fig. 4.7A). Stimulation for longer than 4hr (8 hr or 24 hr) 
diminished this up-regulation (8 hr, IL-6, p-0.589; IL-8, p=0.378; 24 hr, IL-6, p=0.960; 
IL-8, p=0.152; Fig. 4.7A). Additionally, mRNA expression of MCL-1L/MCL-1ES and 
MCL-1S was measured by qRT-PCR following stimulation of IL-6 or IL-8 (10 ng/ml) for 
4 hr. Fold change in expression relative to NT fibroblasts demonstrated no change in 
MCL-1L/MCL-1ES (IL-6, p=0.2143; IL-8, p=0.3201; Fig. 4.7B) nor MCL-1S mRNA (IL-
6, p=0.1306; IL-8, p=0.9216; Fig. 4.7C). These results confirmed that both IL-6 and IL-8 
can induce the up-regulation of Mcl-1 protein following 4hr of treatment. However, they 
failed to alter the expression of MCL-1 at the mRNA level. In conclusion, this data shows 
that both IL-6 and IL-8 have the ability to increase the protein level of Mcl-1 (IL-6 
approached significance).  
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Figure 4.7. Mcl-1 protein expression is induced by IL-6 and IL-8 (A) Intestinal fibroblasts (n=5) were 
treated with 10 ng/ml of IL-6 or IL-8 for 4, 8 or 24 hr. Cells were fixed and stained with Hoechst 33342 and 
an antibody against Mcl-1. The graphs represent the median Mcl-1 foci mass/nuclei following treatment 
with 10 ng/ml IL-6 or IL-8 relative to NT. (B-C) Intestinal fibroblasts (n=3) were treated with 10 ng/ml of 
IL-6 or IL-8 for 4 hr. qRT-PCR was performed on extracted RNA and expression of MCL-1L/ES and MCL-
1S mRNA was determined. The graphs represent the fold change relative to NT. Bars represent mean with 
SEM. *p<0.05. 
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To test the hypothesis that miR-29b might up-regulate Mcl-1 indirectly via IL-6 or IL-8, 
intestinal fibroblasts were transfected with NTC and pre-miR-29b. Messenger RNA 
expression for IL6 and IL8 was assessed via qRT-PCR and normalised to the 
housekeeping gene GAPDH. Fibroblasts transfected with pre-miR-29b showed a 
significant increased fold change of IL6 compared to NTC transfected cells (p=0.0077; 
Fig. 4.8A). IL8 mRNA levels were also up-regulated by pre-miR-29b and approached 
significance (p=0.06, Fig. 4.8A). Furthermore, ELISA measured the production of IL-6 
and IL-8 by fibroblasts in the supernatant following transfection with NTC or pre-miR-
29b. The production of IL-6 and IL-8 were both significantly increased by fibroblasts 
transfected with pre-miR-29b compared to NTC (IL-6, p=0.0027; IL-8, p=0.0268; Fig. 
4.8B). These results suggest that miR-29b up-regulates the mRNA expression of IL6 and 
IL8 and their production into the extracellular space. 
 
I have demonstrated previously that miR-29b has the ability to down-regulate COL1A2 
and COL3A1 in intestinal fibroblasts (Section 4.2). This has been demonstrated by others 
to be directly through the 3’-UTR of both genes [375, 379]. To identify whether the miR-
29b/IL-6/IL-8 axis may also affect collagen genes, mRNA expression of both COL1A2 
and COL3A1 was measured following stimulation with IL-6 or IL-8 (10 ng/ml). Fold 
change in expression relative to NT fibroblasts demonstrated no change in the expression 
of either COL1A2 or COL3A1 following stimulation with 10 ng/ml IL-6 (COL1A2, 
p=0.1988, COL3A1, p=0.1997; Fig. 4.8C) or 10 ng/ml IL-8 (COL1A2, p=0.2274; 
COL3A1, p=0.1222; Fig. 4.8C).  
 
In conclusion, this data suggests that miR-29b indirectly up-regulates Mcl-1 protein 
expression via IL-6 and IL-8.  
  
A 
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Figure 4.8. miR-29b up-regulates IL-6 and IL-8. (A) Intestinal fibroblast (n=6) were transfected with 
NTC and pre-miR-29b for 48 hr. The graph represents the fold change in expression of IL6 and IL8 mRNA 
measured by qRT-PCR. (B) Supernatant was collected from fibroblasts transfected with NTC and pre-miR-
29b after 48 hr. The graphs represent the production of IL-6 and IL-8 measured by ELISA. (C) Intestinal 
fibroblasts (n=3) were treated with 10 ng/ml of IL-6 or IL-8 for 4 hr. qRT-PCR was performed on extracted 
RNA and expression of COL1A2 and COL3A1 mRNA were measured. The graph represents the fold 
change relative to NT. Bars represent mean values with SEM. *p<0.05 and ** p<0.01. 
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4.6 Discussion and future work 
4.6.1 The expression of miR-29 family is reduced in SCD vs NSCD tissues  
One of the major advantages of the Illumina v.2.0 array is its sensitivity and the ability to 
detect low abundance miRNAs with limited amounts of starting RNA. However, this 
sensitivity becomes a crucial limitation when evaluating highly expressed miRNAs are 
present in the sample, as this leads to saturation of the fluorescent signal for the relevant 
probes. This meant that differences in abundantly expressed miRNAs could not be 
revealed using this platform leading potentially to omission from subsequent downstream 
data analysis. One of the miR-29 family (miR-29b) was saturated on the array, and was 
therefore investigated further, along with the other members, miR-29a and miR-29c. 
Validation by qRT-PCR demonstrated that all three family members were down-regulated 
in SCD vs NSCD tissues (Section 4.2). This observation is in accordance with previous 
reports of fibrosis in other organs [372-378], indicating that the miR-29 family plays a 
key role in the pathogenesis of fibrosis in various organs.  
 
4.6.2 miR-29b down-regulates COL1A2 and COL3A1 mRNA and collagen III protein  
MiR-29b was selected for further functional studies, as reports have confirmed that this 
family member is most frequently implicated in the down-stream events leading to 
fibrosis. mRNA levels of COL1A2 and COL3A1 were down-regulated and up-regulated 
following transfection with pre-miR-29b or anti-miR-29b in isolated fibroblasts, 
respectively. This echoes previous reports in cardiac fibroblasts [375], skin fibroblasts 
[378], and human trabecular meshwork cells [379]. This also demonstrates that the effect 
of miR-29b on ECM molecules, such as collagens, is consistent in fibroblasts originating 
from various organs. Protein expression analysis of collagen I and III by 
immunofluorescence demonstrated a reduction of collagen III following transfection with 
pre-miR-29b. However, collagen I protein levels remained unchanged despite the down-
regulation of COL1A2 mRNA by pre-miR-29b. Protein expression is dependent on many 
factors, including protein turn over, and a literature report demonstrated that the turn-over 
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rate of collagen I protein is much slower than that of collagen III [516]. The effects of 
transient transfection are temporary and last around 72-96 hr, depending on cell doubling 
time and cell type. This may explain why transfection with pre-miR-29b resulted in 
down-regulated expression of COL1A2 but did not modulate collagen I protein level 
within this time-frame. Future experiments to tackle this problem could include the use of 
expression vectors to create a cell line that stably expresses miR-29b over a period of 
time. Analysis of collagen I protein in these cells could determine if sustained expression 
of miR-29b suppresses the expression of collagen I protein over a longer time course.  
 
4.6.3 TGF-β up-regulates collagen via the down-regulation of miR-29b 
TGF-β is a potent mediator in major fibrotic events, including CD fibrosis [201]. 
Intestinal fibroblasts stimulated with TGF-β displayed elevated expression of COL1A2 
and COL3A1 and suppressed miR-29b expression (Section 4.3). This is in accordance 
with previous studies in fibroblasts from the heart [375], lung [377] and liver [374], 
which demonstrated repression of miR-29b by TGF-β. Additionally, in intestinal 
fibroblasts, TGF-β stimulation following the over-expression of miR-29b demonstrated a 
repression of the TGF-β-mediated-up-regulation of COL1A2 and COL3A1 (Section 4.3). 
This suggests that TGF-β potentially exerts its pro-fibrotic effects by suppressing miR-
29b expression in CD, and that this might be universal in fibrogenesis of various tissues.  
 
Further experiments should aim to investigate the role of miR-29 in the pathogenesis of 
fibrosis in vivo mouse models of intestinal fibrosis. Unfortunately, models for IBD are 
generally focused on the inflammation side and these animals do not live long enough to 
develop fibrosis in the way that humans do. Hence, most of the current research is 
directed towards mechanistic in vitro functional experiments. However, a recent IL-10 
KO mouse has demonstrated features of intestinal fibrosis [517]. The authors showed an 
increase in ECM molecules in the mucosa, submucosa and muscularis of these mice at 
week 16, together with an increase in gene expression of TGF-β, collagen I and α-SMA 
[517]. 
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To further this line of research I would aim to: 
1. Establish a working collaboration with Yuan and colleagues in order to investigate 
the mRNA/miRNA expression in IL-10 KO mice. For instance, intestinal tissue 
could be sampled at various time points of IL-10 KO mice. These could then be 
profiled for miRNA and/or mRNA analysis, preferably using a high-throughput 
platform such as microarray or RNA sequencing. This would provide useful 
insights into the altered mRNA/miRNA expression during the course of fibrosis in 
these mice, and could potentially highlight targets that may be involved in the 
early steps of intestinal fibrosis; 
2. Identify genome-wide targets for miR-29b using the Target ID Library system. 
Given the fact that the expression of miR-29 family is dysregulated during fibrosis 
in various organs, large scale identification of their targets would provide 
important insight into the functional role of this family. Genome-wide 
transcriptome analysis following over-expression of miR-29b in mouse models 
has been previously conducted [518, 519]. However, both analyses were 
performed in the context of a diseased mouse model (liver fibrosis [518]; muscle 
dystrophy [519]). I would therefore, propose to use the Target ID Library system 
to identify genome-wide targets that are directly targeted by miR-29b; and  
3. To date, only one miR-29 KO mouse has been generated. Kogure and colleagues 
produced a tissue-specific knockout of the miR-29ab locus, ablating miR-29a and 
miR-29b expression in the hepatic stellate cells in the liver [518]. This resulted in 
an increased susceptibility to fibrosis and impaired cell survival following 
fibrogenic stimuli in the liver of these mice, compared to WT mice. Future 
experiments to investigating the role of miR-29b in intestinal fibrosis could 
include the production of a conditional miR-29 KO mouse specific to gut 
fibroblasts. Intestinal tissue would be sampled at various time points and 
investigated for fibrosis markers to elucidate whether the loss of miR-29b in 
intestinal fibroblasts is sufficient to initiate intestinal fibrosis.  
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4.6.4 Mcl-1 expression is induced by miR-29b 
Transfection with pre-miR-29b in intestinal fibroblasts showed an increase of Mcl-1 at 
both the mRNA and protein level. Furthermore, Mcl-1 protein was up-regulated 
following transfection with pre-miR-29b (Section 4.4). This result was unexpected as 
many groups have previously identified a direct down-regulation of Mcl-1 by miR-29b 
using 3’UTR-luciferase reporter assays, as well the down-regulation at RNA and protein 
level [491-494].  
 
The Mcl-1 gene undergoes alternative splicing to produce three potential isoforms: MCL-
1L, MCL-1S and MCL-1ES. The Taqman assays used to determine the mRNA levels of 
the Mcl-1 isoforms were not able to distinguish between MCL-1L and MCL-1ES. 
Nevertheless, qRT-PCR demonstrated that up-regulation of both MCL-1L/MCL-1ES and 
MCL-1S (Section 4.4), suggesting that Mcl-1 is induced by miR-29b. Future experiments 
could aim to pinpoint exactly which isoform is modulated by pre-miR-29b. For instance, 
Kim and colleagues, identified the three isoforms using distinct primer sequences [500]. 
Experiments with these primers on RNA from cells transfected with miR-29b would 
allow discrimination between the three different isoforms and demonstrate whether all of 
them are regulated by miR-29b. 
 
Due to the lack of protein isolated from intestinal fibroblasts, Mcl-1 antibody validation 
was performed on six CRC cell lines (HCT116, DLD-1, HT55, HT29, VACO4S and 
SW837). Western blot for Mcl-1 shows the dominant band at approximately 40kDa 
(Appendix Fig. 3), which correlates to the molecular weight of anti-apoptotic Mcl-1L. A 
fainter band at around 31kDa for Mcl-1S could also be seen. Mcl-1ES has a molecular 
weight of 24kDa [500] and was not detected. These results suggest that the increased 
protein expression quantified using this antibody following transfection with miR-29b 
presents both the Mcl-1L and Mcl-1S isoforms. However, the fact that this antibody does 
not detect the shortest Mcl-1ES isoform in CRC cell lines does not necessarily mean that 
this would be the case in intestinal fibroblasts. Therefore, additional western blots should 
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be performed on protein extracted from intestinal fibroblasts transfected with NTC and 
pre-miR-29b to identify which isoform is modulated by miR-29b.   
 
Nonetheless, studies that show Mcl-1 attenuates liver fibrosis in mice are a consequence 
of the knockdown of entire Mcl-1 gene which potentially involves all three isoforms. 
Therefore, future work to elucidate the role of Mcl-1 in intestinal fibrosis could include: 
 
1. The investigation of the expression of Mcl-1 at both protein and mRNA following 
TGF-β treatments in intestinal fibroblasts. If the hypothesis were that Mcl-1 is 
anti-fibrotic, I would predict TGF-β to down-regulate its expression; and  
2. If Mcl-1 is modulated by TGF-β, ectopic over-expression of Mcl-1 with the use of 
an expression vector in combination with TGF-β treatments may determine if the 
pro-fibrotic abilities of TGF-β could be abrogated by the presence of Mcl-1.  
 
4.6.5 miR-29b up-regulates Mcl-1 potentially through IL-6 and IL-8 
MiRNAs down-regulate their targets through binding predominantly within the 3’-UTR 
region of the mRNA resulting in mRNA degradation or inhibited protein translation. 
Although the direct up-regulation of genes by miRNAs has been reported, mechanistic 
evidence is currently lacking (reviewed in [508]). I, therefore, hypothesised that the up-
regulation of Mcl-1 by miR-29b is indirect in nature in this context. Literature reports 
suggests that Mcl-1 expression is induced by IL-6 [509] and IL-8 [514]. In Section 4.5, I 
demonstrated that intestinal fibroblasts treated with 10 ng/ml of IL-8 for 4 hr significantly 
up-regulated the protein expression of Mcl-1 (4 hr treatment with 10 ng/ml IL-6 
approached significance, p=0.06). Interestingly, transfection with pre-miR-29b increased 
the levels of both cytokines at the mRNA and protein level, indicating a potential link 
between miR-29b, IL-6/IL-8 and Mcl-1. Evidence from the literature on the effect of 
miR-29b on the expression of IL-6 or IL-8 in other cell types seems conflicting and 
contradictory to my findings. For example, Amodio and colleagues demonstrate a 
reduction of IL8 mRNA but no change in IL6 mRNA in endothelial cells following pre-
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miR-29b transfection [520], and Xing and colleagues showed that transfection with anti-
miR-29b resulted in an increase in IL8 mRNA in HEK293T cells [521]. On the contrary, 
Salama and colleagues demonstrated an induction of IL-6 cytokine production by 
macrophages following pre-miR-29b transfection [522], which  supports my 
observations. The different contexts and cell types used in these studies may account for 
these apparently conflicting results. Nonetheless, the up-regulation of IL-6 and IL-8 by 
miR-29b and the subsequent up-regulation of Mcl-1 by both cytokines still support the 
anti-fibrotic miR-29b/IL-6/IL-8/Mcl-1 axis in intestinal fibrosis. A hypothetical model of 
how TGF-β may exert its pro-fibrotic action through miR-29b is shown in Fig. 4.9. 
 
Further experiments are warranted to confirm this anti-fibrotic pathway. For example, to 
test whether the increase in Mcl-1 by miR-29b is a result of the increased expression of 
IL-6 and/or IL-8, knockdown of IL-6 and IL-8 via siRNA in combination with miR-29b 
transfection could be performed. 
 
134 
 
 
 
Figure 4.9 Hypothetical model of the role of miR-29b in CD fibrosis. TGF-β is a potent pro-
inflammatory cytokine. TGF-β modulates fibrosis through down-regulation of miR-29b, resulting in 
increased deposition of collagen and therefore fibrosis. In CD fibrosis, additional down-stream pathways of 
miR-29b are unknown. Up-regulation of anti-fibrotic mediator Mcl-1 by miR-29b may potentially be 
mediated through IL-6 and IL-8. Up-regulated genes in green, down-regulated genes in red.  
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Chapter 5: Hypoxia-responsive miRNAs in 
colorectal cancer 
5.1 Introduction and aims 
One of the biggest challenges in the management of CRC patients remains the wide 
spectrum of response to preoperative or neo-adjuvant treatments. This can range from 
tumours that do not respond to those that shrink completely following treatment 
(pathological complete response, pCR). Knowledge as to why there is such a great range 
of response to therapy is limited. However, it has been generally accepted that the 
effectiveness of therapy is dependent on a number of factors, including the tumour 
microenvironment. For example, the lack of oxygen (hypoxia) within the tumour is 
known to be detrimental for tumour response to CRT. Hypoxia within the tumour is a 
consequence of the rapid acceleration in growth of the tumour cells combined with a lack 
of adequately formed blood vessels. Radiotherapy relies on the transformation of oxygen 
molecules into radical oxygen which in turn aids killing of cancer cells; efficacy is, 
therefore, hindered under low oxygen tensions. In addition, some chemotherapy drugs 
require oxygen molecules to generate free radicals that contribute to cytotoxicity. 
Moreover, hypoxia induces cellular adaptation that may result in chemoresistance.  
 
Over recent decades, miRNAs have been identified as key post-transcriptional regulators 
and are dysregulated in many cancers, including CRC (Section 1.3.2). Literature reports 
have previously demonstrated altered miRNA profiles under hypoxic conditions in vitro. 
However, these are often dependent on cellular context and oxygen concentration and 
generally limited to just one or two cell lines. Therefore, I aimed to analyse the change in 
miRNA expression in six colorectal cancer cell lines (DLD-1, HCT116, HT29, HT55, 
SW837 and VACO4s) under three oxygen conditions (20.9%, 1% or 0.2%), thereby 
allowing a more comprehensive insight in miRNA changes under hypoxia in CRC in 
vitro.   
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Aims for this chapter: 
1. Identify differentially expressed miRNAs in six CRC cell lines under hypoxic 
conditions; 
2. Validate selected candidate miRNAs identified by the array using qRT-PCR; 
3. Further validate candidate miRNAs in CRC tissue and search for correlation to 
hypoxia marker CAIX; 
4. Determine the role of candidate miRNAs in the resistance to the chemotherapy 
drug 5-FU in CRC cell line under hypoxic conditions;  
5. Identify altered cellular metabolism under hypoxia in six CRC cell lines using CE-
TOFMS; and 
6. Establish a cell line stably expressing the Target ID Library system to identify 
genome-wide mRNA targets for selected candidate miRNAs. 
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5.2 Differential expression of miRNAs under hypoxia 
To identify differentially expressed miRNAs under hypoxic conditions in vitro, three 
colon cancer cell lines (DLD-1, HCT116 and HT29) and three rectal cancer cell lines 
(HT55, SW837 and VACO4s) were cultured under three different oxygen tensions 
(20.9%, 1% or 0.2%) for 48 hr. Global miRNA expression profiling was performed using 
the Exiqon 7
th
 generation miRCURY LNA miRNA Array (Capture probes for 3,100 
miRNAs, miRBase v 19.0). Raw data was initially analysed by Exiqon and data 
normalisation was performed using the mean plate intensity.  
 
Often, it is difficult to interpret large miRNA data sets easily, preventing the scientist 
from getting the most out of the data obtained. Multivariate analysis allows the 
investigation of many variables at once and helps to understand the relationship that may 
exist between each variable. For the analysis of the miRNA data, a PLS-DA was used. A 
PLS-DA is a supervised extension of the principle component analysis (PCA) and aims to 
project data into a 2D plot with axes that explain the majority of the variance in the data. 
In addition, this regression model intends to maximise the separation between groups of 
observations and identify the variables (in this case, miRNAs) that contribute to this 
separation. 
 
Log-transformed miRNA expression data of all six cancer cell lines under the three 
oxygen conditions was subject to PLS-DA modelling. Generally, axis 1 and 2 explain the 
majority of the variance in the data (Fig. 5.1A), which show that the biggest variance in 
the miRNA expression data is between the six different cell lines and not between the 
three oxygen conditions within each cell line. This is illustrated by the clustering of the 
three data points for each oxygen tensions for each cell line (Fig. 5.1A). Interestingly, 
PLS-DA axis 1 can slightly differentiate between the origin of the cell line, as rectal 
cancer cell lines are predominantly clustered on the left half of the graph, and colon 
cancer cell lines on the right half (Fig. 5.1A). Smaller changes in the miRNA expression 
data can be observed in subsequent axes of the PLS-DA model. Indeed, an unsupervised 
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separation of oxygen tensions within each cell line (apart from SW837) could be 
identified along PLS axis 6 (Fig. 5.1B), demonstrating the existence of altered miRNAs 
between the three different oxygen tensions within each cell line. Finally, the magnitude 
of change for each miRNA contributing to this separation under hypoxic conditions was 
extracted from the PLS-DA analysis (Appendix Fig. 4).  
 
Because the PLS-DA is merely an exploratory tool and cannot uncover significant 
changes in the variables between different samples, an alternative multivariate analysis 
(linear regression) was used to model the relationship between miRNA expression 
profiles between the three different oxygen tensions for each cell line. In this model, 
oxygen tensions were assigned a numerical variable meaning that the oxygen tensions are 
linked (i.e. 20.9% is higher than 1% and 1% is higher than 0.2%). This enabled the 
identification of miRNAs whose expression was significantly different between the three 
oxygen conditions. A single p-value was then determined for each miRNA across all six 
cell lines, and revealed 41 miRNAs with a p-value less than 0.05 (Table 5.1). 
 
Fold change in expression in both hypoxic tensions (1% and 0.2%) were normalised to 
the normoxic (20.9%) counterpart. Log transformed fold changes for the 41 altered 
miRNAs are illustrated in a heatmap and ranked according to their PLS-DA axis 6 
loadings (Fig. 5.1C). Not surprisingly, one of the most significantly altered miRNA 
across the six cell lines was miR-210. Previous literature reports indicate that miR-210 is 
the most consistently up-regulated miRNA following hypoxia (reviewed in [523]). In 
fact, sequencing data analysis from literature reports show that the promoter region of 
miR-210 contains hypoxia-responsive-elements (HREs) [329, 523], which are strongly 
conserved among species. In conclusion, the up-regulation of miR-210 in all six cell lines 
confirms the importance of this miRNA in the cellular response to lack of oxygen in CRC 
in vitro.  
 
miRNAs are often found to be clustered within the genome and can be produced from the 
same primary transcript (Section 1.3.1.1) which generally contain members of the same 
139 
 
 
miRNA family (reviewed in  [431]). In addition, miRNA families are often co-expressed 
(especially those that are clustered together) and have close similarity in their seed 
sequences thereby increasing the synergistic effect they have on a common target. 
Interestingly, more than one member of five different miRNA families were shown to be 
dysregulated under hypoxia (colour coded miRNAs; Table 5.1). For instance, two 
members of the miR-320 family, miR-320b and miR-320c, were shown to be up-
regulated under hypoxic conditions. Also, the PLS-DA loadings of PLS axis 6 (Appendix 
Fig. 4) of miR-320b and miR-320c demonstrated high loading scores, highlighting the 
fact that these miRNAs have a large impact on the separation of the miRNA data between 
the three oxygen conditions. 
 
In conclusion, the microarray and subsequent analysis discovered a number of 
significantly altered miRNAs under hypoxic conditions in CRC in vivo. To confirm these 
changes, validation of the candidate miRNAs using a second experimental method is 
critical. In total, 12 miRNAs (miR-19b, -106b, -141, -147, -1180, -21, -29a*, -210, -30d, -
320a, -320b and -320c) were selected for further validation by qRT-PCR. The selection of 
these miRNAs was non-random and based on previous reports linking these miRNAs to 
hypoxia or therapy resistance and/or based on their significance value (p-value). 
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Figure 5.1. Altered miRNA expression profile under hypoxic conditions. Fold change (log2) in 
expression of significant altered miRNAs between normoxia (20.9%) and both low oxygen conditions (1% 
and 0.2%) in six CRC cell lines. (A) Data was subjected to PLS-DA, which was supervised according to 
cell line and unsupervised to oxygen tension. PLS Axis 1 vs Axis 2 is shown. (B) Subsequent PLS-DA Axis 
5 vs Axis 6 are illustrated. (C) Significantly altered miRNAs under hypoxia were subsequently identified by 
linear regression multivariate analysis. A heatmap of log transformed fold changes between the different 
oxygen tensions normalised to 20.9% is shown. The miRNAs are ranked according to PLS-DA loadings on 
the right-hand side of the heatmap.  
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Table 5.1. Differentially expressed miRNAs under hypoxic conditions. Significant differentially 
expressed miRNAs under hypoxia determined by multivariate analysis, ranked by p-value. A p<0.05 was 
considered significant.  miRNA family and cluster information is noted for each miRNA. Families with 
more than one miRNA altered under hypoxia are indicated with a different colour. Candidate miRNAs 
selected for further validated are in bold and underlined. 
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5.3 MiRNA array validation  
In the hunt for a potential miRNA biomarker for hypoxia in CRC tissue, the validation of 
the miRNA array was focused on up-regulated miRNAs as these would be more easily 
detected than miRNAs that were to be down-regulated. Validation of 12 up-regulated 
candidate miRNAs in hypoxia (miR-19b, -106b, -141, -147, -1180, -21, -29a*, -210, -
30d, -320a, -320b and -320c) was performed via qRT-PCR on an independent set of 
experiments in all six cell lines (n=3). One of the main challenges faced when validating 
miRNAs via a different platform (i.e. qRT-PCR) is the way in which the data is 
normalised. Microarrays are often normalised to the overall plate mean intensity which 
takes into account the intensity of all probes, producing robust and reliable signatures of 
differentially expressed miRNAs. By contrast, qRT-PCR relies on the selection of one or 
more stable miRNAs for normalisation. To identify a stable miRNA for normalisation of 
the qRT-PCR, expression values from the original array were investigated. Two miRNAs 
displayed stable expression across all three oxygen tensions and all six cell lines (miR-16 
and let-7a). In addition, a third small non-coding RNA (RNU19) was also tested. The 
expression of miR-16, let-7a and RNU19 was assayed via qRT-PCR in the six cell lines 
under three oxygen conditions (n=3). One way ANOVA analysis indicated that the 
expression of let-7a was significantly altered between the three different oxygen tensions 
in two of the six cell lines (HCT116, p=0.0053; HT29, p=0.0326; Fig. 5.2A). The 
expression of miR-16 and RNU19 was not significantly altered between the three 
different oxygen tensions in any of the six cell lines. RNU19 expression was slightly up-
regulated in VACO4s but this was not significant (p=0.08; Fig. 5.2A). Closer inspection 
of the variation (standard deviation) between the expression in 20.9% oxygen vs hypoxia 
(both 1% and 0.2%) of miR-16 and RNU19 showed that this was much smaller for 
RNU19 than for miR-16. In particular, when 20.9% was compared to 0.2%, the standard 
deviation was significantly lower (20.9% vs 0.2%, p=0.0135; Fig. 5.2B). In addition, 
RNU19 has been used for normalisation purposes in previously published in vitro 
hypoxic experiments [524, 525]. For these reasons, RNU19 was selected to normalise the 
miRNA expression data. 
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Figure 5.2. RNU19 is an appropriate normaliser for miRNA expression. Three miRNAs (RNU19, miR-
16 and let-7a) were tested for miRNA normalisation. (A) The expression (2
-ΔCT
) for each miRNA was 
determined by qRT-PCR (n=3). (B) The graphs represent the standard deviation (StDev) for each of the 
miRNAs in six cell lines between 20.9% oxygen and 1% or 0.2% oxygen tensions, respectively. Bars 
represent mean values with SEM. 
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Next, normalised qRT-PCR data of the 12 candidate miRNAs was subjected to 
multivariate analysis to uncover the relationship between the expression of each miRNA 
and the three oxygen conditions within each cell line. In collaboration with Dr. Jake 
Bundy (Imperial College, UK), a linear regression model was used to determine a p-value 
for each miRNA. Expression values for the 12 miRNAs are displayed in a heatmap and 
ranked according to their p-value (Fig. 5.3A).  
 
In summary, validation by qRT-PCR confirmed the up-regulation of six (miR-21, -210, -
30d, -320a, -320b and -320c) of the 12 candidate hypoxia-responsive miRNAs. To 
explore the relevance of two of these miRNAs in CRC tissue samples, miR-21 and miR-
210 were selected for further investigation in ex vivo human CRC tumour samples. 
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Figure 5.3. Candidate miRNA validation by qRT-PCR. Twelve candidate miRNAs were selected for 
validation by qRT-PCR in an independent set of experiments (n=3) in three colon (DLD-1, HCT116 and 
HT29) and three rectal (HT55, SW837 and VACO4s) cell lines. A heatmap of fold change (log2) in 
miRNA expression between the three oxygen conditions normalised to 20.9% oxygen (n=3). The heatmap 
is ranked according to the p-values obtained from the multivariate analysis. Asterisks indicate significantly 
altered (p<0.05) miRNAs.  
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5.4 MiR-210 is up-regulated in rectal cancer tissue and positively 
correlates with the expression of hypoxia marker CAIX 
 
In vitro validation by qRT-PCR confirmed the up-regulation of six candidate miRNAs in 
hypoxic conditions (Section 5.3). However, assessing their expression in CRC tissue is 
essential to evaluate their potential as biomarkers for hypoxia ex vivo. Therefore, small 
RNAs (including miRNAs) were extracted from 13 FFPE blocks with CRC tumour tissue 
by a previous PhD student without our lab (Dr. Alexandra Parker). Hematoxylin & eosin 
staining on a serial section was used to outline tumour tissue. A second serial section was 
stained for the hypoxia marker CAIX (Section 2.17) via IHC and percentage CAIX 
expression within the CRC tumour was determined according to protocols used by others 
[430]. I, then determined the expression of miR-210 and miR-21 by qRT-PCR and 
normalised to let-7a and miR-16. The correlation between the expression of both 
miRNAs and CAIX staining within the tumour was determined (Spearman’s Rank 
correlation). Correlation analysis demonstrated that the expression of miR-210 positively 
corresponded to the expression of the hypoxia marker CAIX in the 13 CRC tumours 
analysed (Rho=0.679, p=0.012, Fig. 5.4A). By contrast, miR-21 expression did not show 
a correlation to CAIX expression (Rho=-0.019, p=0.938, Fig. 5.4A). Furthermore, three 
other miRNAs (miR-30d, -141 and -147) were also tested for correlation between CIAX 
and miRNA expression. Neither of these miRNAs demonstrated a correlation to CAIX 
expression in CRC tumour tissue (Appendix Fig. 5). 
 
To further explore the localisation of the miRNAs in CRC tumour tissue, I performed in 
situ hybridisation for miR-210 and miR-21 on eight FFPE blocks containing CRC tumour 
tissue. A serial section was stained for CAIX for comparative analysis. MiR-21 was 
selected despite the lack of correlation with CAIX shown by qRT-PCR. miR-21 is 
increased under hypoxic conditions in vitro and in situ hybridisation will reveal which 
cell types express this miRNA in comparison with CAIX. Images of CAIX, miR-210 and 
miR-21 are shown in Fig 5.4C-E, respectively. In all tumours, both CAIX and miR-210 
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expression was found in the epithelial cells of the gut crypts and their expression 
coincided in the majority of the tumours (Fig. 5.4C-D). Conversely, miR-21 expression 
was predominantly present in stromal cells underneath the epithelial cells, regardless of 
the presence of CAIX in the overlying epithelial cells (Fig. 5.4C, E). These observations 
explain the positive correlation between miR-210 and CAIX as well as the lack of 
correlation between miR-21 and CAIX. The positive expression of miR-21 in the stroma 
surrounding the cancer cells may suggest that miR-21 plays a role in tumour progression 
and invasion via modulation of the tumour microenvironment. 
 
In conclusion, expression analysis of miR-210 demonstrated a positive correlation to the 
tumour hypoxia marker CAIX in CRC tissue, emphasising the importance of miR-210 in 
CRC tumour hypoxia. To further elucidate the potential of miR-210 as a biomarker of 
treatment response, evaluation of miR-210 expression in additional CRC tumour samples 
with treatment response data is required. 
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Figure 5.4. In situ expression of miR-210 positively correlates with the hypoxia marker CAIX in CRC 
tissue. (A-B) Scatter plots of miR-210 and miR-21 expression (1/2
-ΔCT
) assessed by qRT-PCR and 
percentage of CAIX-positive staining within the tumour (n=13). Correlation efficiency calculated with 
Spearman’s Rank. Rho values and p-value are shown above. (C-E) IHC of CAIX and in situ hybridisation 
of miR-210 and miR-21 performed on serial sections of FFPE blocks of CRC tumours (n=8). Black 
rectangles outline the position of the zoomed images shown below. 
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5.5 HCT116 cells are resistant to 5-FU under hypoxia 
The chemotherapeutic agent 5-FU has been the standard first-line treatment for many 
cancers, including CRC, for the past 40 years [95]. In recent years, the availability of 
other compounds used in combination with 5-FU has broadened treatment options. For 
example, adjuvant treatment with 5-FU/Leucovorin in CRC has been shown to increase 
overall survival in a number of studies [96-98]. This combined treatment now forms the 
basis of treatment for patients with CRC stage III, although, the benefit of the use in stage 
II CRC tumours is less obvious [99]. Despite increased response rates with combined 
therapy, tumour resistance is still a major concern in the treatment management of 
advanced CRC [526]. Solid tumours are a very complex and heterogeneous tissue, 
comprising of cancer, stromal and immune cells. Nearly all solid tumours contain regions 
of hypoxia and early evidence indicated that a decrease in oxygen tension could 
contribute to this drug resistance in solid tumours (reviewed in [121-123]). Indeed, 
tumour expression of HIF-1α has been correlated to 5-FU resistance in gastric cancer 
[527], and the colon cancer cell line HCT116 is more resistant to 5-FU under hypoxic 
conditions, which may be reversed by knockdown of HIF-1α [528]. 
 
To verify hypoxia-induced resistance to 5-FU under hypoxia in my CRC cell line model, 
HCT116 cells were treated with various concentrations of 5-FU (1 µM, 5 µM, 10 µM, 
100 µM and 1 mM) or the same concentration of vehicle (Dimethyl sulfoxide, DMSO) 
under three oxygen conditions (20.9%, 1% or 0.2%) for 48 hr. Cells were fixed with 3.7% 
PFA and nuclei were stained with Hoechst 33342. Nuclei were imaged using the IN Cell 
Analyzer microscope 1000 and were then counted. Cell counts for each drug 
concentration was normalised to the vehicle control treated cells. One-way ANOVA 
statistical analysis was performed and demonstrated that HCT116 grown under hypoxic 
conditions are more resistant to 5-FU compared to their normoxic counterpart. This was 
the case for all 5-FU concentrations measured (all 5-FU concentrations p<0.05, Fig. 
5.5A). Post-hoc tests (Tukey’s) were performed to determine which groups differed and 
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demonstrated that HCT116 cells maintained under 0.2% oxygen were significantly 
different compared to 20.9% (Fig. 5.5A). 
 
Having previously validated hypoxia-responsive miRNAs (Section 5.3), including miR-
21, miR-210 and miR-30d, I hypothesised that a) these hypoxic-responsive miRNAs may 
play a role in the resistance to 5-FU in HCT116 cells under hypoxic conditions and b) that 
the inhibition of the expression of these miRNAs under hypoxia could sensitise the cells 
to 5-FU. To test the hypotheses, HCT116 cells were transfected with NTC, pre- or anti-
miR for all three miRNAs (miR-21, -210 and -30d) for 48 hr and then treated with 10 μM 
5-FU or DMSO for a further 48 hr under 20.9% or 0.2% oxygen (Fig. 5.5B). This 
timeline was selected to allow for sufficient functional knockdown of targets by the 
miRNAs. Following treatment with 5-FU, an increase in survival was observed when 
cells were cultured under 0.2% oxygen and transfected with NTC (20.9%, NTC, 
mean=48.6%; 0.2%, NTC, mean=83.2%; p=0.0390, Fig. 5.5C). This resistance was 
similar to that previously obtained with 10 μM 5-FU (20.9%, mean 45.5%; 0.2%, 
mean=80.3%; Fig. 5.5A). Also, when cells were cultured under 20.9% oxygen, the 
combination of miRNAs and 5-FU treatment did not significantly alter the cell survival 
compared to NTC transfected cells, indicating that the transfection of NTC did not the 
response to 5-FU. By contrast, when the expression of miR-21 and miR-30d was 
inhibited with transfection of the anti-miR, cells were slightly more sensitive to the 5-FU 
treatment. (NTC, mean=83.2%; anti-miR-21, mean=69.4%; anti-miR-30d, mean=71.1%; 
Fig. 5.5C). Statistical analysis, however, demonstrated this decrease was not significant 
when compared to NTC transfected cells (anti-miR-21, p=0.2027; anti-miR-30d, 
p=0.1297; Fig. 5.5C).  
 
In addition, further over-expression of miR-210 under 0.2% oxygen reduced cell survival 
compared to NTC transfected cells (pre-miR-210, p=0.0838, Fig. 5.5C). Literature reports 
have shown that miR-210 targets key modulators of cell cycle progression resulting in a 
decrease of cell proliferation (reviewed in [529]). Indeed, cells transfected with pre-miR-
210 (DMSO treated only) demonstrated a decrease in cell survival under both oxygen 
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tensions (Appendix Fig. 6), indicating that in HCT116 cells an overexpression of miR-
210 results in a decrease in cell survival. In summary, this data demonstrated that 
HCT116 cells are more resistant to 5-FU under 0.2% oxygen conditions compared to 
normoxic conditions. The inhibition of hypoxia-responsive miRNAs miR-21 and miR-
30d may be a potential method to increase sensitivity to 5-FU but requires further 
investigation.  
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Figure 5.5. HCT116 cells are resistant to 5-FU under low oxygen conditions. (A) HCT116 cells were 
treated with various concentrations of 5-FU (1 µM, 10 µM, 100 µM or 1 mM) or the appropriate vehicle 
control (DMSO) for 48 hr under three oxygen conditions (20.9%, 1% or 0.2%). The graph represents the 
percentage of cell survival normalised to each vehicle control. Significance was calculated with one-way 
ANOVA tests. Asterisks indicate significant changes between 20.9% and 0.2% identified by post-hoc tests 
(Tukey’s). (B) The experimental time-line of transient transfections of miRNAs in combination with 5-FU 
treatment under two oxygen conditions (20.9% or 0.2%). (C) The graph represents the percentage of cell 
survival normalised to vehicle controls following transfection with NTC and pre- or anti-miR of miR-210, -
21 or 30d. Bars represent mean values with SEM. *p<0.05, **p<0.01 and ***p<0.001.  
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5.6 In vitro cell metabolism is altered under hypoxic conditions 
Cells have evolved mechanisms to adapt to low oxygen conditions which include 
decreasing their mitochondrial respiratory rate by decreasing the cellular ATP levels 
[530-532]. Additionally, HIF-1α may be activated by low cellular ATP levels indirectly; 
ATP deficit increases glycolysis and HIF-1α activity [533]. Also, AMP-activated protein, 
induced following ATP-deprived cellular conditions, activates HIF-1 [534]. These 
observations link the hypoxia induced-HIF-1 signalling pathway to altered metabolic 
activity. Recent research is focussed on exploiting these cellular metabolomic changes 
under hypoxia to identify new strategies for anticancer drug development and/or 
identifying prognostic biomarkers for treatment response.  
 
To identify changes in cellular metabolites under hypoxia, the six CRC cell lines used 
previously (DLD-1, HCT116, HT29, HT55, SW837 and VACO4s) were maintained 
under three differential oxygen conditions (20.9%, 1% or 0.2%) for 48 hr. In 
collaboration with Dr. Adam (Oxford University), the six cell lines were prepared for CE-
TOF/MS (Section 2.20) and shipped to the Institute for Advanced Biosciences at Keio 
University, Japan, where cellular metabolites were assessed. The resulting metabolite 
profile was subsequently modelled using multivariate analysis, in collaboration with Dr. 
J. Bundy (Imperial College, UK) (Section 2.21). Similar to the multivariate analysis 
performed on the miRNA data, metabolite profile in the six cell lines was modelled 
against the three oxygen conditions. This analysis demonstrated a significant (p<0.05) 
relationship between 92 metabolites under hypoxia.  
 
Various computational tools are available to group the metabolites into metabolic 
networks or pathways. Two examples are MetaboAnalyst (www.metaboanalyst.ca) and 
ImPaLa (http://impala.molgen.mpg.de), which offer a range of functions including 
metabolic pathway analysis. Both tools use the KEGG database [535]. An overview of 
the online computational tools is reviewed in [536]. The 92 significantly (p<0.05) altered 
metabolites were subject to an over-representation analysis to identify altered pathways 
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under hypoxia using these two different platforms. An over-representation analysis 
evaluates whether a particular group of metabolites is represented more than expected by 
chance within a metabolite list. In the context of pathway analysis, this illustrates if 
metabolites involved in a particular pathway are enriched. To further enhance the over-
representation analysis, the user may upload a list of all metabolites that were detected by 
the platform to acts as a “background” for the analysis. The analysis in MetaboAnalyst 
was performed both with (Fig. 5.6A) and without (Fig. 5.6B) the background. Ten 
pathways were significantly (p<0.05) enriched in hypoxia of which the top five are shown 
(Fig. 5.6A). However, once background metabolites were taken into account, this was 
reduced to only a single enriched pathway in hypoxia, which was the aminoacyl-tRNA 
biosynthesis (Fig. 5.6B). Next, a second analysis with ImPaLa was performed on the 
same metabolite profile (with background) which identified six metabolite pathways that 
were enriched in hypoxic conditions (Fig. 5.6C). Interestingly, the aminoacyl-tRNA 
biosynthesis pathway was also enriched using this different analysis software (highlighted 
in red; Fig. 5.6A-C). 
 
Among the 92 significantly altered metabolites in hypoxia, 13 are involved in the amino-
acyl-tRNA biosynthesis pathway. To illustrate their expression profile, fold change (log2) 
in concentration (fmol/cell) was calculated for each of the six cell lines and is shown in 
Fig. 5.7. Strikingly, the metabolite profile in hypoxia is very different amongst the six cell 
lines. For instance, in two cell lines (SW837 and HT55) all 13 metabolites were altered 
consistently in both 1% and 0.2% oxygen compared to 20.9%. By contrast, the change in 
metabolite concentration in hypoxia in the other cell lines is mixed, with some of these 
metabolites increased whilst others were decreased (Fig. 5.7).  
 
In conclusion, in silico analysis of altered metabolites under hypoxia in six CRC cell lines 
demonstrated an enrichment of the aminoacyl-tRNA biosynthesis pathway. This 
preliminary data will need to be validated and could form a platform for future 
experiments which will be discussed in the discussion in Section 5.8.4. 
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Figure 5.6. Altered metabolite pathways under hypoxia. (A) The top five metabolite pathways altered in 
hypoxia determined by an over-representation analysis performed with MetaboAnalyst software. 
Metabolites with a p<0.05 were used for the analysis. Total = the total number of metabolites in a given 
pathway, Expected = the number of hits expected by chance, Hits = number of metabolites significantly 
altered in hypoxia, and p-value = Bonferoni correct p-value. (B) The same analysis as in A, but with 
background metabolite profile taken into account. Detected/total = the number of metabolites detected using 
CE-TOF/MS / the total number of metabolites in a given pathway. (C) The six metabolite pathways 
significantly (p<0.05) altered in hypoxia determined by an over-representation analysis performed with 
ImPaLa software. Metabolites with a p<0.05 were used and background metabolite profile has been taken 
into account. The common pathway, aminoacyl-tRNA biosynthesis, is highlighted in red. 
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Figure 5.7. Altered metabolites under hypoxia involved in the aminoacyl-tRNA biosynthesis pathway. 
Fold changes (log2) in metabolite concentration compared to 20.9% oxygen are shown for each of the six 
CRC cell lines.   
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5.8 Discussion and future work 
5.8.1 Altered miRNA profiles under hypoxia in six CRC cell lines 
Using three colon (DLD-1, HCT116 and HT29) and three rectal (HT55, SW837 and 
VACO4s) cancer cell lines as a model, differential expression of miRNAs were 
determined using a miRNA microarray (Section 5.2). MiRNA profiling under hypoxia in 
CRC has been previously studied, however, often the cell lines used, oxygen tension, and 
the time under hypoxia are variable. For example, many publications reports altered 
miRNA profiles in a single cell line such as Caco-2 [537] or HeLa cells [538]. Oxygen 
concentration and the time under hypoxic conditions also vary; Caco-2 cells were 
cultured under 1% oxygen for 48 hr, whilst HeLa cells were maintained at 0.01% oxygen 
for a 24 hr period. The closest comparison to the microarray performed in this thesis is a 
miRNA analysis by Kulshreshtha and colleagues in 2009 [323]. In this study, two colon 
(HT29 and HCT116) and two breast cancer (MCF7 and MDA-MB231) cell lines were 
maintained at 0.02% oxygen for 24 and 48 hr [323]. Statistical analysis of all four cell 
lines combined across both time lines identified a number of miRNAs significantly 
altered, and four were common between their results and mine (miR-181a, -192, -21 and -
210). This suggests that some miRNAs are commonly up-regulated under hypoxia in both 
colon and breast cancer cell lines. 
 
The miRNA analysis performed in this thesis represents the change in expression under 
three different oxygen conditions in six cell lines combined. This was done to uncover 
miRNAs that were hypoxia-responsive despite differences between the cell lines. 
Undeniably, the PLS-DA analysis demonstrated the presence of inherent differences in 
miRNA expression between the six different cell lines (Section 5.2). Further analysis of 
each of the six cell lines independently, or grouped into rectal and colon cancer cell lines, 
might uncover additional hypoxia-responsive miRNAs regulated in an origin-specific 
manner.  
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Data validation by a second method is crucial to confirm the changes observed by 
microarrays are genuine. The expression of 12 candidate miRNAs was determined by 
qRT-PCR in an independent set of experiments for all six cell lines (Section 5.3). In 
contrast to the array, data normalisation of qRT-PCR data relies on one or two genes that 
are stable under the various conditions. The small non-coding RNA RNU19 was shown to 
be most stable under hypoxia of the miRNAs that were tested (miR-16, let-7a and 
RNU19), and has been previously shown in the literature to be a stable housekeeping 
control under hypoxia [524, 525], and was therefore used for normalisation. Of the twelve 
candidate miRNAs tested, six were successfully validated by qRT-PCR (miR-21, -210, -
30d, -320a, -320b and -320c). One of the most significantly up-regulated miRNA in the 
array was miR-210 (p=0.002). In addition, the loadings from the PLS-DA analysis 
showed that miR-210 had the largest loading score (Appendix Fig. 4), indicating that 
miR-210 contributed highly to the separation of the groups along PLS-DA axis 6. These 
results echo literature reports demonstrating that miR-210 is up-regulated under various 
oxygen conditions in a range of cell lines from different tumours (reviewed in [523]). 
 
miRNAs tend to be up-regulated in clusters, many of which contain members of the same 
miRNA family (introduced in Section 1.3.1.1). Interestingly, five miRNA families of 
which more than one family member was altered under hypoxia, were identified. Apart 
from the miR-320 family which was subsequently validated, two members of the miR-
182 family (miR-182, -183 and -96) were significantly up-regulated (miR-182 and miR-
96). Also, miR-183 was up-regulated but just missed the significance cut off of p<0.05 
(p=0.067). The expression of miR-182 has been previously shown to be up-regulated in 
CRC [539-541], and correlated to poor prognosis and overall survival [540, 541]. 
Furthermore, overexpression of miR-182 promoted cell survival and proliferation of 
colon cancer cell lines [542]. The second member of the family altered under hypoxia, 
miR-96, was shown to be induced in CRC tissue and correlated to liver metastasis [283].  
 
 
Further experiments could include: 
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1. The validation of the three members of the miR-182 family (miR-96, -182, and -
183) by qRT-PCR; 
2. If these validate, in situ hybridisation of these miRNAs in CRC tissue could be 
performed to test a) the localisation in CRC tissue and b) whether the expression 
correlates with the hypoxia inducible factor CAIX; 
3. The knockdown of this family via transfection of anti-miRs in CRC cell lines 
could be performed to assess whether they are able to modulate the response to 5-
FU under hypoxia; and 
4. The Target ID Library system could be used to elucidate of genome-wide targets 
of this miRNA family.  
 
5.8.2 miR-210 is up-regulated in rectal cancer tissue and positively correlates to 
hypoxia marker CAIX 
To benchmark the in vitro findings, miRNA expression of miR-21, -210 and -30d was 
determined in rectal cancer ex vivo and correlated to the expression of hypoxia-inducible 
protein CAIX. Correlation efficiency analysis demonstrated a positive correlation 
between miR-210 and CAIX expression in rectal cancer tissue (Section 5.4). A recent 
report by Qu and colleagues indicates that miR-210 expression is up-regulated in human 
CRC tissue compared to normal tissue [543]. This work demonstrated a positive 
correlation between miR-210 and HIF-1α mRNA expression, which supports a common 
conclusion between their data and mine. In this report, miR-21 was shown to be up-
regulated in CRC tissue compared to normal tissue, however, it was not apparent whether 
this correlated with HIF-1α mRNA expression [543]. This might be because Qu and 
colleagues did not observe any correlation but did not report this. This might provide an 
explanation as to why I did not observe a correlation between miR-21 and CAIX.   
 
In situ hybridisation experiments demonstrated co-localisation between miR-210 and 
CAIX expression in the epithelial cells in rectal cancer tissue (Fig 5.4C, D). A study in 
2012 also showed a correlation between miR-210 and CAIX in cancer tissue samples of 
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non-small cell lung carcinoma [544], which lends support to the hypothesis that miR-210 
is up-regulated in hypoxic regions of solid tumours. Furthermore, in situ expression of 
miR-210 expression was co-localised to VEGF expression in idiopathic osteonecrosis, an 
area prone to being hypoxic [545]. VEGF is involved in angiogenesis and its expression 
is driven by HIF-1α, further indicating a link between miR-210 and hypoxic tissues.  
 
In addition to miR-210, miR-21 was also investigated by in situ in rectal cancer tissue 
sections. miR-21 was found to be expressed in the stromal-like cells in rectal cancer 
tissue, but this did not correlate with the expression of CAIX (Fig. 5.3C-E). However, the 
lack of direct correlation between miR-21 and CAIX expression does not mean that miR-
21 is not expressed in hypoxic regions. In other tissue types there might be a link with 
expression of this miRNA and hypoxia. For example, in situ analysis of miR-21 
expression found up-regulation in hypoxic cells in the lungs of mice [546] and human 
hypoxic arteries [547]. Furthermore, the observation that miR-21 is predominantly 
expressed in fibroblast-like cells within tumour has been confirmed by others who have 
used the same probe: miR-21 is up-regulated in stromal-like cells in colon cancer [548, 
549] and breast cancer [550]. By contrast, groups that performed in situ hybridisation 
with other commercial probes for miR-21 observed expression mainly in the tumour cells 
[286, 551]. The differences in probe might explain some of the differences in localisation 
of miR-21 expression.  
 
Assessing miRNA as potential biomarker is a rapidly developing area of research. To 
predict whether a patient’s tumour will respond to CRT by using miRNA expression 
profiles as a guide is the ultimate goal. For instance, the prognostic value of miR-210 
expression in tissue samples has been studied in many cancers (reviewed in [343]). A 
single paper has recently identified that high miR-210 expression in CRC tissue is a 
prognostic factor for overall survival [543]. However, further investigation of the 
prognostic value of miRNAs, including miR-210, is required. For example, to determine 
if miRNAs could be used for predicting response to neo-adjuvant treatment of CRCs, a 
retrospective study should be performed using at least two large independent cohorts of 
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patients; miRNA expression would be determined in a routinely-taken tumour biopsy 
before treatment, scored, and then be used to classify patients and determine if 
differentially expressed miRNA profiles can predict treatment outcome.  
 
Circulating miRNAs could be exploited as biomarkers in clinical use as they have several 
advantages: readily detectable, stable in serum, and profiling is relatively cheap and 
quantitative [552]. Circulating miRNAs, including miR-21 and miR-210, have been 
intensively studied in various cancers [343, 553]. Interestingly, circulating expression 
levels of miR-21 were dysregulated in prostate [554, 555], ovarian [556, 557], pancreatic 
[352, 558], liver [559, 560] and oesophageal cancers [561], but has not yet been 
investigated in CRC. Similarly, miR-210, was dysregulated in blood samples (serum or 
plasma) in pancreatic [352], lung [562], non-small lung [563] and renal cancers [564, 
565], but again has not yet been looked at in CRC. Therefore, there is a real need to 
investigate the potential for circulating miRNAs as a diagnostic/prognostic biomarker for 
CRC and to predict treatment response. Future work to investigate this could include:  
 
1) The collection of blood samples at time of diagnosis or pre-treatment. Circulating 
miRNA profiles should be determined, preferably by array or RNA sequencing. 
This data could then be used to determine if certain miRNA signatures may 
predict treatment outcome;  
2) Candidate miRNAs could then be further investigated ex vivo. For example, in situ 
hybridisation of candidate miRNA could be performed in CRCs that did not 
respond to neo-adjuvant therapy; and 
3) The investigation of candidate miRNAs could be performed in vivo. The response 
to chemotherapeutic drugs, such as 5-FU, following transfection with pre-miR and 
anti-miR of candidate miRNAs in CRC cell lines. These experiments could 
elucidate their role in the sensitivity of chemotherapy drugs in vivo. 
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5.8.3. Hypoxia induces resistance to chemotherapy drug 5-FU in HCT116 cell line. 
The chemotherapeutic agent 5-FU forms the basis of the standard treatment of many 
cancers, although resistance to this drug is a major concern in treatment of CRC patients. 
Interestingly, hypoxia in solid tumours is linked to 5-FU therapy resistance [121-123]. In 
Section 5.5, I demonstrated that HCT116 colon cancer cells maintained under hypoxia 
demonstrated a significant resistance to the chemotherapy drug 5-FU at various dosages, 
which confirms existing literature reports in the same cell line [528]. However, Ravizza 
and colleagues showed that HCT116 maintained under 1% oxygen for 24 hr demonstrated 
an increased resistance to 100 μM and 250 μM 5-FU, but they did not observe increased 
resistance using 10 μM 5-FU. This is in contrast to my observations where HCT116 cells 
maintained under lower oxygen tensions (0.2% oxygen) were significantly more resistant 
to a range of 5-FU dosages, but not significantly different under 1% oxygen (Fig. 5.5A). 
These contradicting results might be due to the differences in treatment time: Ravizza and 
colleagues treated HCT116 cells with 5-FU for 24 hr, whereas I cultured mine for 48 hr.  
Nevertheless, resistance to 5-FU under hypoxic conditions has been demonstrated in other 
cell lines, including gastric cancer cell lines [566], oral squamous cell carcinoma cell 
lines [567] and oesophageal squamous cell cancer cell lines [568], indicating that 
resistance to 5-FU under hypoxic conditions is a feature of cell lines originating from 
multiple tumour types. 
 
I hypothesised that the hypoxia-responsive miRNAs might play a role in the 5-FU 
resistance observed in the HCT116 colon cancer cell line. The suppression of miR-21 or 
miR-30d by transfection with an anti-sense miRNA induced a slight, but not significant, 
sensitivity to 5-FU under 0.2% oxygen (Fig. 5.4C). Interestingly, no change in 5-FU 
sensitivity was observed under normoxic conditions, suggesting that the miRNA 
regulatory effect may be oxygen tension dependent and that some of their targets are only 
present under these hypoxic conditions. Other groups have shown that miRNAs are able 
to modulate the sensitivity to 5-FU under normoxic conditions of a number of CRC cell 
lines. These including miR-31 (HCT116; [569]), miR-129 (HCT116; [570]), miR-192 
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(RKO; LoVo; [571]), miR-21 (HT29; [572]), miR-23a (HCT116; HT29; [573]) and miR-
143 (HCT116; [574]). These literature reports show that the experimental time lines, 
including the duration of 5-FU treatment and the transfection time-frame are crucial. For 
example, Wang and colleagues demonstrated that HCT116 were more sensitive to 5-FU 
following 24 hr of suppression of miR-31 but not after 48, 72 or 96 hr [569]. Further 
experiments to optimise experimental conditions will need to be performed to assess if 
the suppression of miR-21 and miR-30d could modulate 5-FU sensitivity in HCT116 cells 
under hypoxic conditions. For future experiments I would propose to conduct the 
following experiments: 
 
1) The treatment of 10 µM 5-FU in HCT116 cells (and potentially other cell lines) 
for various lengths of time. Firstly, cell survival should be assayed following 5-FU 
treatment under 0.2% oxygen to determine drug resistance across a variety of time 
point;  
2) Next, cell lines could be created with lenti-viral vectors producing anti-sense 
miRNA of the candidate miRNA in order to assure sustained suppression of these 
miRNAs over a longer period of time; and 
3) Cell survival would be assayed following 5-FU treatment under 0.2% oxygen in 
these cells to elucidate the role of miRNAs in 5-FU resistance. 
 
miR-210 is one of the most studied miRNAs under hypoxia and is greatly induced under 
these conditions. It was, therefore, surprising that the suppression of miR-210 with an 
anti-sense miRNAs under hypoxia did not modulate 5-FU sensitivity (Fig. 5.5C), 
particularly as miR-210 is a direct target of HIF-1α which has been previously shown to 
be involved in the resistance to 5-FU under hypoxic conditions in HCT116 cells [528]. It 
may be that the up-regulation of miR-210 under hypoxia is too strong to be counteracted 
with the transient transfection of the anti-sense miRNA strands. As mentioned above, in 
order to assure stable knockdown of miR-210, a stably expressing cell line could be 
produced with the use of lenti-viral vectors producing anti-sense miR-210. Future 
experiments using this cell line could include: 
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1) The maintenance under hypoxic conditions for various lengths of time. To 
confirm the knockdown of miR-210, qRT-PCR should be performed at various 
time points to assure sufficient knockdown to counteract the strong up-regulation 
of miR-210 under hypoxia; 
2) A number of tumourigenicity assays could be performed to elucidate the role of 
miR-210 in tumourigenesis under hypoxia: cell survival/proliferation, cell 
migration and colony formation. These experiments could highlight the 
importance of miR-210 under hypoxic conditions; and 
3) Sensitivity to 5-FU could be assayed in these cells under hypoxic conditions, 
especially under 0.2% oxygen.  
 
5.8.4. Altered metabolite profile in six CRC cell lines under hypoxia 
Metabolomics is a powerful tool developed to systematically analyse the metabolic 
fingerprint of a cell. In Section 5.6, I demonstrated an altered metabolite profile under 
hypoxic conditions (1% and 0.2%) and pathway analysis revealed an enrichment in the 
aminoacyl-tRNA biosynthesis pathway by two independent pathway analysis tools 
(MetaboAnalyst and ImPaLa). However, the metabolic profile of the 13 metabolites 
altered in this pathway for each of the six cell lines is very different. For instance, in two 
cell lines, the majority (DLD-1) or all (HT55) of the 13 metabolites are increased. In three 
cell lines, the majority (HCT116 and VACO4s) or all (SW837) of the 13 metabolites are 
decreased and in one cell line (HT29) approximately half of the 13 metabolites are either 
increased or decreased response under hypoxia (Fig 5.8). Due to the intrinsic differences 
between the cell lines, the mixed changes observed here is perhaps unsurprising. In fact, 
the PLS-DA analysis already demonstrated that these cells are very different based on 
their miRNA expression. (Fig. 5.1A, Section 5.2). 
 
A similar study by Frezza and colleagues was conducted on a single cell line [575]. They 
investigated the metabolite profiles of HCT116 when maintained at 1% oxygen for 36 hr, 
165 
 
 
and detected 241 metabolites, 32 of which were significantly altered under hypoxia. 
Interestingly, of the 32, 18 were amino acids and were increased in concentration (apart 
from L-kynurenine which was decreased). Seven of these amino acids were commonly 
dysregulated under hypoxia in HCT116 cells between the two studies: Threonine, Proline, 
Phenylalanine, Histidine, Methionine, Asparagine and Serine. In contrast to their 
findings, these seven amino acids were down-regulated in HCT116 cells under both 1% 
and 0.2% oxygen in my analysis.  
 
There are several important differences between the study conducted by Frezza and 
colleagues vs the one conducted in this thesis. These are outlines below. 
  
1. Timepoint: 36hr vs 48hr. 
2. Oxygen concentration: 1% oxygen vs 1% and 0.2% oxygen combined. 
3. Mass-spec platform: LC-MS vs CE-TOFMS. 
 
These differences, especially the different mass-spec technique, may have contributed to 
the differences in the concentration of the amino acids. For instance, LC-MS uses high-
powered liquid chromatography (LC) to separate the particles before its mass-to-charge 
ratio is analysed. By contrast, CE-TOFMS is a relatively new technique in which the 
mass-to-charge ratios are determined by the time that it takes for the particles to reach a 
detector (time of flight (TOF)).  
 
Future experiments to further this research could include: 
  
1) The validation of the altered metabolites under hypoxia in vitro. A targeted 
metabolomics experiment could be performed to validate the change in metabolite 
expression of the 92 significantly altered metabolites and/or metabolites; and 
2) To determine whether there is a link between the changes in miRNA expression 
and the altered metabolite profile, the expression of both miRNAs and metabolites 
should be determined for each individual cell line. Target prediction tools could 
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then be used to identify potential mRNA targets that involved in regulating the 
production of the altered metabolites. 
 
One interesting additional finding by Frezza and colleagues was that autophagy increases 
under hypoxia [575]. Autophagy is a catabolic pathway in which proteins and organelles 
are sequestered into autophagosomes and fused with lysomes for digestion. The 
autophagy pathway is part of a normal cell homeostasis process to replace damaged cell 
membranes and organelles, however, autophagy is up-regulated under physiological 
stress conditions, including cell starvation (reviewed in [576]). Recently, reports indicate 
that hypoxia-induced autophagy is HIF-1α dependent [577, 578] and inhibition of 
autophagy under hypoxic conditions reduces tumour cell viability [578].  
 
Furthermore, miRNAs have been implicated to regulate various steps in the autophagy 
pathway (reviewed in [579]). For instance, miR-30d targets multiple genes involved in 
the autophagy pathway including many of the ATG core proteins [580], and miR-30d 
regulates cisplatin-resistance by promoting autophagic survival in thyroid carcinoma cells 
[581]. Additionally, miR-210 enhances autophagy by down-regulating Bcl-2 expression 
in colon cancer cells [582]. Interestingly, the inhibition of hypoxia-induced autophagy 
resulted in an increased sensitivity to the chemotherapy drug 5-FU in DLD-1 cells [583]. 
Therefore, work to further this line of investigation would include: 
 
1) To determine the expression of putative targets in the autophagy pathway for miR-
30d and miR-210 under both normoxia and hypoxia. CRC cell lines would be 
transfected with pre- or anti- miRs and cells cultured under normoxia and 
hypoxia. qRT-PCR and western blotting techniques would be used to confirm the 
regulation of key autophagy players by these miRNAs at the mRNA and protein 
level, respectively; and 
2) To determine the involvement of autophagy in 5-FU resistance under hypoxic 
conditions in HCT116 cells. Similar experiments to those conducted in Section 
5.5 could be performed. In addition to 10 µM 5-FU treatment, cells could be 
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transfected with siRNA against ATG5 (siRNA against this gene is most often used 
to disturb the autophagy pathway) under both 20.9% and 0.2% oxygen. Nuclei 
counts would be calculated using the IN Cell Developer v1.8 to determine cell 
viability. 
 
The pathway analysis that was performed with two independent tools highlighted a 
common pathway dysregulated under hypoxia; the aminoacyl-tRNA biosynthesis. This 
pathway plays an important role in decoding the genetic message by facilitating the 
transfer of the amino acids onto the growing peptide chain to create proteins. The 
enzymes that catalyse the ligation of amino acids to their tRNA are aminoacyl tRNA 
synthesases (AARs). Besides their role in protein synthesis, their non-canonical function 
has been linked to metabolic conditions, neural pathologies and several cancers (reviewed 
in [584]). Very early reports already reported an increase in methionine-acyl tRNA 
synthesase in colon cancer [585], and, more recently, trypophanyl-tRNA synthesase was 
associated with disease recurrence of colon cancer [586]. 
 
During cellular stress, such as hypoxia, tRNAs can be cleaved to produce transfer RNA-
derived fragments (tRFs), which can inhibit protein synthesis [587] and modulate cell 
proliferation [588]. A recent report demonstrated that tRFs contain anti-tumour and anti-
metastatic properties in breast cancer in vitro and in vivo, and that this is mediated 
through Y-box binding protein-1 (YB-1) [589]. Interestingly, YB-1 promotes EMT [590] 
and is linked to the response to therapy in various cancers [591], including rectal cancer 
[592]. To further this line of research I would: 
 
1. Perform a targeted mass-spectrometry of all amino acids to validate the CE-
TOF/MS findings under hypoxic conditions in vitro.  
2. Evaluate the expression of the AARs enzymes under hypoxic conditions in vitro. 
Their expression could be measured at the RNA and protein level by qRT-PCR 
and western blotting, respectively.  
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3. Assess the expression of YB-1 at the RNA and protein level under hypoxic 
conditions in vitro. Further evaluation of YB-1 could be performed in FFPE 
sections in CRC in vivo, and correlated with hypoxia markers miR-210 and CAIX. 
 
5.8.5. Target ID Library preparation (Appendix) 
Target identification of miRNAs is crucial to provide information on which cellular 
processes a given miRNA influences. To date, 3’-UTR luciferase reporter assays are 
considered the gold standard to confirm whether a miRNA targets a particular mRNA 
sequence. However, this is a highly laborious exercise and requires preliminary 
knowledge guided by in silico target prediction identification. In our laboratory, we have 
recently obtained a novel system (Target ID Library, Sigma, UK) which will allow us to 
discover genome-wide direct mRNA targets of any miRNA of choice and provide insight 
into the regulatory function of miRNAs in key cellular pathways. 
 
HeLa cells were chosen as a suitable cell type for creating a cell line stably expressing the 
Target ID Library constructs as expression analysis demonstrated a low endogenous level 
of our three key candidate miRNAs (miR-21, -210 and -30d) relative to the six CRC cell 
lines. Transfected cells were treated with Zeocin (500 μg/ml) to positively select cells that 
had stably integrated cDNA constructs containing a TKzeo fusion gene and PCR analysis 
on DNA from selected cells indicate the presence of the library of constructs (Appendix 
Fig. 9). Although the Target ID Library claims to contain constructs for 16,922 unique 
genes, next generation sequencing (NGS) performed by Gaken and colleagues 
demonstrated the presence of only 5,626 genes in their MCF7 clones [593]. Therefore, the 
next step is to sequence the library cDNA inserts to confirm satisfactory genomic 
coverage within the HeLa cell population.  
 
Once we are satisfied with the genomic coverage of the cDNA inserts, transfection with 
lenti-viral vectors producing our candidate miRNAs (miR-21, -210 or -30d) will be 
performed. Additionally, a fourth miRNA, miR-34a, will be screened for targets, too. 
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NGS analysis to uncover genes that are directly targeted by these miRNAs within their 
3’-UTR region will be performed. More importantly, to benchmark the results, NGS data 
will be compared directly to the publically available combined pulsed SILAC and 
microarray analysis data sets for miR-34a [475, 476]. The data generated will provide a 
comprehensive cross-platform analysis, which will demonstrate the similarities but also, 
importantly, highlight the difference between these different technologies. Next, 
identified targets from the Mission ID/NGS analysis will be analysed with Ingenuity 
Pathways Analysis (IPA) software in collaboration with QMUL Bioinformatic service in 
order to elucidate relevant pathways modified by the candidate miRNAs. Identified 
targets in potentially dysregulated pathways will then be validated at the protein level via 
transfection of the candidate miRNAs in isolated fibroblasts (miR-34a) and CRC cell 
lines (miR-21, -210 and -30d). The validation of important pathways regulated by these 
miRNAs may provide valuable insights into cellular mechanisms that are fundamental to 
the development of fibrosis (miR-34a) and the cellular responses to hypoxia and/or 5-FU 
resistance mechanisms in CRC (miR-21, -210 and -30d). Finally, once validated in vitro, 
key targets will be validated in vivo in CD fibrosis and CRC tissue and their potential as 
biomarker will be investigated. 
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Chapter 6: General conclusions 
6.1 Summary of main findings 
 
 Identification of a subset of miRNAs that play a significant role in the 
development and progression of two intestinal diseases, CD and CRC. 
 Changes in miRNA expression in the epithelial mucosa often reflect changes in 
other parts of the intestine and/or tumour. For example: 
o The expression of miRNAs is different between mucosa overlying 
strictured compared to non-strictured mucosa, 
o The miR-29 family is down-regulated in SCD vs NSCD. 
 Experimental studies using both primary cultures and cell lines can be used to 
model disease processes and identify mechanisms involving miRNAs notably: 
o TGF-β-mediated down-regulation of miR-29b results in the up-regulation 
of ECM molecule production, such as collagen 1 and 3, 
o The anti-apoptotic protein Mcl-1 is indirectly up-regulated by miR-29b via 
IL-6 and IL-8. 
 That hypoxia has a significant impact of miRNA expression, which in turn 
influences cellular metabolism profiles and drug response in CRC cell lines. For 
example: 
o Hypoxia alters the miRNAs signature in CRC cells in vitro; 
o miR-210 is overexpressed in hypoxic regions of CRC and correlated with 
the hypoxia marker CAIX; 
o CRC cell line HCT116 is more resistant to the chemotherapy drug 5-FU 
under 0.2% oxygen compared to 20.9%; 
o The inhibition of miR-21 or miR-30d under 0.2% slightly increases the 
sensitivity of HCT116 cells to 5-FU; and 
o Hypoxia alters cellular metabolism in CRC cell lines in vitro. 
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6.2 The clinical relevance of these findings 
6.2.1 How are miRNAs altered during disease processes and what role does the 
intestinal microenvironment play in this? 
The absence of appropriate animal models that mimic intestinal fibrosis in CD have 
historically hindered the functional analysis and discovery of genes and pathways 
involved in the progression of fibrosis. The majority of mouse models are used primarily 
to study inflammation, and do not reproduce the fibrogenic changes that occur in CD 
patients. Additionally, a fundamental problem with studying the pathogenesis of intestinal 
fibrosis in humans is that by the time fibrosis is detected, early pathogenic events have 
already occurred and the fibrogenic process is fully established. Consequently, the key 
initiating events in the pathogenesis of fibrosis can no longer be investigated. If the early 
events could be modelled in vivo (e.g. mouse models) then this would represent a 
significant step forward and offer the opportunity to test new drugs that target fibrosis 
rather than just interfere with the inflammatory process. However, recently, a number of 
mouse models have been established that mimic in part the initial events of fibrosis [594]. 
The evaluation of miRNA-based therapeutic, such as the miR-29 family, will determine 
their potential in modulating the various stages of intestinal fibrosis.  
 
Molecular changes in the human gut mucosa reflect the changes that happen in the deeper 
layers [201]. Therefore, the down-regulation of the miR-29 family in the mucosa in SCD 
areas may provide information regarding the cellular processes that happen deeper in the 
tissue. Functionally, this family of miRNAs is important in the pathogenesis of fibrosis in 
various organs [372-378]. Therefore, assessing the expression miRNAs, such as miR-29 
family, in biopsies taken routinely during CD disease monitoring could be used to detect 
early changes in the mucosa that may reflect the initial stages of intestinal fibrosis in the 
deeper layers. Evaluating the utility of the miR-29 family as biomarkers would require a 
significant prospective clinical trial focussed on newly diagnosed CD patients and 
following their progress over time by collecting samples during routine surveillance 
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endoscopy. The expression of miRNAs in these samples (biopsies/serum) should be 
correlated to clinical parameters such as disease activity and progression into the various 
disease subtypes (inflammatory, stricturing or penetrating CD). 
 
Environmental factors play a key role in the development of many human diseases, 
including IBD and cancer. An excessive immune-response to antigens and microbiota in 
the gut is one of the contributing factors leading to IBD (both CD and UC). The 
modulatory effects of the gut microbiota on miRNA expression have broadened our view 
of the regulatory functions of miRNAs in disease. Interestingly, two members of the miR-
200 family (miR-200b and miR-200c) were decreased in conventional mice upon 
infection with microbiota [595]. These miRNAs are known to regulate EMT, an 
important process that is often dysregulated in both cancer and inflammation/fibrosis. In 
fact, work in our laboratory has demonstrated that three members of the miR-200 family 
(miR-141, -200a and -200c) are down-regulated in inflamed strictured areas of CD 
patients where there is evidence of EMT (Mehta et al., unpublished data). The impact of 
the microbiota on miRNA profiles and the cellular inflammatory responses in the mucosa 
is an undeveloped area of research. Further work should evaluate whether the use of 
faecal transplants could be a beneficial therapeutic strategy to modulate the 
inflammatory/fibrogenic events through altering the miRNA profiles in the mucosa of 
IBD patients. 
 
6.2.2 Can miRNAs be used as diagnostic or prognostic tools in CD or CRC?   
Clinical features in CD have some prognostic value, although, they are often 
heterogeneous and their use remains problematic. Inflammatory biomarkers, such as C-
reactive protein and fecal calprotectin, may be used to distinguish active from inactive 
IBD, but hold no true predictive value for the development of fibrosis [596]. Bodily fluids 
provide an excellent source of circulating miRNAs and have non-invasive biomarker 
potential as their expression is stable and can be readily detected. Work in our laboratory 
has demonstrated the potential use of serum-based miRNAs as biomarkers to distinguish 
173 
 
 
the stricturing CD phenotype (Lewis et al., 2015, in print). This has opened up 
opportunities to investigate further the expression of circulating miRNAs, such as miR-
29b, as potential prognostic biomarkers for intestinal fibrosis.  
 
Particular miRNAs are able to discriminate tumour subtype, origin and identify important 
cellular mechanisms in tumourigenesis. Also, circulating miRNAs can be used to 
distinguish cancer patients from healthy individuals and diagnose early stage cancer [399, 
597]. Additionally, miRNAs can be used to predict response to treatment, which is of 
significant clinical value and has been investigated intensively over the past decades. For 
example, increased miR-21 expression is an indicator of poor outcome in various cancers 
[286, 415]. However, these studies were performed in tumour tissue, retrospectively. 
Giving the importance of hypoxia-responsive miR-21 in tumourigenesis, and its potential 
role in 5-FU resistance under hypoxic conditions in vitro, the use of miR-21 to predict 
treatment response in CRC needs to be evaluated in prospective cohort studies with 
validation across independent centres.  
 
Recently, the expression of miR-210 in CRC tissue was significantly correlated to large 
tumour size, lymph node metastasis, advanced clinical stage and poor prognosis [543]. To 
confirm these findings the expression of miR-210 should be further investigated 
retrospectively in a large number of CRC tissues and a correlation between miR-210 
expression and clinical parameters including treatment response should be determined. 
Additionally, miR-210 expression should be evaluated in the serum of early diagnosed 
CRC patients. These patients should be followed up and miR-210 expression correlated to 
various clinical parameters to assess the utility of miR-210 as a non-invasive biomarker to 
predict treatment in CRC.  
 
While the use of miRNAs as biomarkers clearly has significant potential advantages when 
compared to protein-based serum biomarkers, systematic high-throughput miRNA 
measurement for clinical samples is still in its infancy. The results obtained from different 
platforms (qPCR or NGS based) from different vendors are likely to contribute to 
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inconsistent measurements. Also, miRNA data normalisation remains a fundamental 
challenge. Currently, there is no standardised method and steps to generalise this method 
are urgently needed to obtain more consistent, comprehensive and accurate miRNA 
signatures that may be adopted for clinical use. 
 
6.2.3 Do miRNAs represent suitable anti-fibrotic or anti-cancer therapeutic targets?   
An ideal drug target should have disease-modifying properties, a proven function in the 
pathophysiology of the disease and predictable potential side effects. miRNAs are an 
attractive therapeutic target as they regulate many cellular processes. The majority of 
current therapeutic agents are aimed towards a single molecular target which induces a 
modest response. Hence, the ability to repress many targets at once across various 
oncogenic pathways provides a strong rationale for developing miRNA-based 
therapeutics, although this does have the potential to increase off-target effects and 
consequent side-effects. A number of miRNAs have already shown potential in pre-
clinical models and a few have entered the initial phases of clinical trials 
(http://mirnarx.com/pipeline/mirna-pipeline.html). Biopharmaceutical company miRNA 
Therapeutics Inc is leading the way by having developed a broad pipeline of miRNA-
based therapeutics. Their main compound, MRX34, is a miR-34a mimic drug which 
entered phase I clinical trials in 2013. MRX34 is piloted as an anti-cancer drug in patients 
with un-resectable liver cancer (www.clinicaltrials.gov) and the phase I results are 
encouraging. In the context of fibrosis, an antagonist for miR-21, RG-012, is a potential 
anti-fibrotic agent in renal fibrosis in mice. Phase I clinical trials for the use of RG-012 in 
Alport syndrome patients (a hereditary nephritis disorder disease characterised by end-
stage kidney disease) are to begin in 2015. Important for future anti-miR drugs, this trial 
will determine the pharmacokinetics, cellular uptake, miRNA inhibition and off-target 
effects of the therapeutic drug. The knowledge this will determine whether anti-miR-21 
may present a suitable anti-fibrotic therapy and in the longer-term could be piloted in 
other fibrotic diseases, including intestinal fibrosis. 
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The role of miR-210 has been investigated intensively over the past decade and miR-210 
is now considered a master sensor of reduced oxygen tension. Its impact on a large 
number of cellular pathways has presented miR-210-based therapeutics with exciting 
prospects. Many studies have demonstrated the anti-tumourigenesis properties of miR-
210 in vitro. However, more importantly, miR-210 is able to repress tumour growth of in 
vivo xenografts of laryngal [598] and liver cancer [599]. Further evaluation of the anti-
tumour properties of miR-210 in additional tumour xenografts models, including CRC, 
will provide additional evidence for miR-210-based therapeutic in cancer.  
 
MiRNAs have emerged recently as key regulators of cellular metabolism, including the 
metabolism of glucose, lipids and amino acids [600]. A shift in glucose metabolism from 
oxidative phosphorylation to aerobic glycolysis is a classic hallmark of tumour cells, 
called the “Warburg effect”. Under hypoxia, this adaptive metabolic shift has been 
proposed to be advantageous to the tumour cell through the promotion of survival, 
proliferation and even resistance to cancer treatment. The altered miRNA and metabolite 
profiles obtained under hypoxia in vitro in this thesis provide valuable insights into the 
way that miRNAs regulate the cellular metabolism under these conditions. The 
development of miRNA-based therapeutic to suppress this metabolic shift could lead to 
novel therapeutic strategies to inhibit tumour growth or drug-resistance in CRC. For 
instance, miR-210 is known to target a variety of key players in important metabolic 
pathways to reduce mitochondrial metabolism and increase glycolysis. Particularly under 
hypoxia, the development of anti-miR-210 therapeutics is one that holds much promise.  
 
While the use for miRNA-based therapeutics is encouraging, some of the limitations for 
miRNAs as therapeutic entities should be considered. For instance, the safe delivery of 
the miRNA mimic or antagonist to the target cell is crucial for the treatment to be 
functionally successful. The complex intestinal human defence includes the innate and 
adaptive immune system and drug degradation by gastric enzymes, which may prevent 
drugs reaching their target site. Also, the variability of these factors between CD patients 
is high, which may further impact the successful delivery of miRNAs in these patients. 
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However, several promising strategies to enhance colon-specific delivery, such as 
microcapsules, might facilitate the transport of therapeutic agent to the site of disease. 
Results from initial clinical trials are awaited and will address some of the challenges that 
miRNA-based therapeutics is faced with. 
 
6.2.4 Limitations of this thesis   
The functional in vitro studies performed in this thesis have highlighted potential 
candidate miRNAs as therapeutic entities in intestinal fibrosis in CD, as well as anti-
cancer agents in CRC. In order to unravel the downstream mechanism of miRNAs, the 
most fundamental step is the identification of mRNA targets. Much of the current 
knowledge on the cellular function of miRNAs and their targets is predominantly built 
around online prediction tools. The incorporation of pathway analysis into these 
prediction models have allowed identification of putative targets for miRNAs and the 
pathways they might impact on. However, despite the significant increased knowledge on 
miRNA biogenesis and function, gaps in the precise mechanism by which they modulate 
protein expression remain. For instance, novel targets that are not identified by the 
prediction algorithms have been elucidated, highlighting the existence of alternative ways 
in which miRNAs modulate their targets. The Target ID Library is a recent development 
which enables high-throughput analysis of genome-wide targets of candidate miRNAs 
(Target ID Library appendix). Follow-up studies using this system will include the 
identification of novel targets of selected candidate miRNAs. Secondly, mRNA targets 
will be validated subsequently at the protein level in vitro and in vivo. The modulation of 
5-FU resistance by inhibition of miR-21 and miR-30d was only observed under hypoxic 
conditions, suggesting that perhaps the targets involved in 5-FU resistance are only 
present under these circumstances. Therefore it will be more importantly to confirm novel 
miRNA targets in the correct cellular and disease contexts.   
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Chapter 8: Appendix Tables and Figures 
Appendix Table 1. MiRNAs outside the microarray detection limit. miRNAs with fluorescent values 
over 60000 in either group were considered outside the detection range Mean fluorescent intensity and 
standard deviation values of miRNAs are shown for each group (n=6). The miRNAs are ranked in 
numerical order. 
 
miRNA NSCD mean  NSCD Stdev SCD mean  SCD Stdev 
hsa-let-7a 65231 90.72854 64719.42 713.5631 
hsa-let-7c 53165.05 10852.14 61298.38 4353.523 
hsa-let-7f 64550.27 1048.211 64728.45 581.9631 
hsa-let-7g 65259.99 42.7569 64516.42 1300.471 
hsa-miR-1246 63777.89 3194.615 61946.67 3149.818 
hsa-miR-125a-5p 62567.12 2103.862 62010.74 3076.071 
hsa-miR-125b 62040.64 2897.026 64645.71 1565.292 
hsa-miR-1274b 62649.88 3852.055 64467.1 1080.001 
hsa-miR-143 64573.46 910.919 64720.56 505.6736 
hsa-miR-145 61774.85 1862.461 59771.46 4054.616 
hsa-miR-146a 58928.45 5332.376 63229.99 2859.887 
hsa-miR-148a 61695.38 3502.753 63722.82 1234.12 
hsa-miR-150 64782.89 491.8828 64545.14 1120.818 
hsa-miR-191 63458 1803.962 64728.41 1009.837 
hsa-miR-192 64700.54 791.1251 52806.59 22664.21 
hsa-miR-194 64970.88 464.6906 54832.75 21872.47 
hsa-miR-200b 64682.57 1003.68 53010.34 21983.21 
hsa-miR-200c 64776.06 912.2013 58880.99 14979.28 
hsa-miR-21 64975.96 582.5917 64614.2 948.4555 
hsa-miR-214 57484.82 6560.773 62260.69 4286.634 
hsa-miR-215 63966.94 1817.542 52483.16 24551.44 
hsa-miR-223 63357.81 2285.193 63123.24 3768.269 
hsa-miR-23a 64298.17 1304.531 64714.14 717.0644 
hsa-miR-23b 64594.38 935.3724 64106.89 788.4298 
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hsa-miR-24 59316.12 3257.537 61121.67 3381.464 
hsa-miR-25 61741.95 4026.395 64263.52 1635.017 
hsa-miR-26a 64929.19 551.2634 64849.67 782.2091 
hsa-miR-26b 64472.19 603.2704 64441.05 1880.022 
hsa-miR-27a 58097.38 5052.814 63581.89 1805.699 
hsa-miR-27b 55278.55 5277.181 60173.87 4441.18 
hsa-miR-29b 62140.1 3882.261 62976.71 3538.593 
hsa-miR-30c 57763.14 5669.622 60297.95 4990.575 
hsa-miR-30d 64204.91 1421.48 63907.17 2073.305 
miR-320a,b,c,d 63925.98 1917.901 63372.55 1820.957 
hsa-miR-375 65051.37 282.7126 55421.88 19594.96 
hsa-miR-544 60152.79 12570.68 54914.52 15177.2 
hsa-miR-720 64319.63 2034.63 64149 1039.136 
hsa-miR-768-3p 63424.84 3896.227 64523.2 1125.593 
hsa-miR-92a 62243.82 2337.274 62269 2723.357 
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Appendix Figure 1.  In situ hybridisation of U6 in intestinal mucosa. FFPE section of intestinal mucosa 
probed with in situ hybridisation probe for small RNA U6. (A) Negative and (B) positive staining for U6 
within the same section.  
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Appendix Figure 2. Collagen transcripts are up-regulated in SCD vs NSCD tissues. Paired NSCD and 
SCD tissue samples (n=5) were assayed for the expression of COL1A2 and COL3A1 via qRT-PCR. Bars 
represent mean values with SEM. *p<0.05. 
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Appendix Figure 3. Mcl-1 antibody validation. Cell lysates from six CRC cell lines were subjected to 
western blotting. Antibodies against Mcl-1 and Beta-actin were used at 1:250 and 1:50,000, respectively. 
Molecular weight for Mcl-1L, Mcl-1S and Mcl-1ES are 40kDa, 31kDa and 24kDa, respectively 
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Appendix Figure 4. PLS-DA axis 6 loadings. Log transformed miRNA data was subjected to 
unsupervised PLS-DA analysis. Loadings from PLS-DA axis 6 for each of the miRNAs are shown. 
Rectangle boxes outline the location of the bar graphs below.  
  
213 
 
 
 
Appendix Figure 5. Expression of miR-30d, -141 and -147 did not correlate to the expression of 
hypoxia marker CAIX. (A-C) Scatter plots of miR-30, -141 and -147 expression (1/2
-ΔCT
) assessed by 
qRT-PCR and percentage of CAIX-positive staining within the tumour (n=13). (D) Correlation efficiency 
are calculated with Spearman’s Rank. Rho values and p-value are shown. 
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Appendix Figure 6. Cell survival following transfection of pre- and anti-miR candidate miRNAs. 
HCT116 cells were transfected with pre- and anti-miRs and treated with DMSO (vehicle control) for a 
further 48hr under two oxygen conditions (20.9% or 0.2%). Graph represents percentage of cell survival 
normalised to untransfected cells. Bars represent mean values with SEM. 
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Target ID Library  
Due to their short seed sequence, miRNAs have the capability to modulate the expression 
a large number of genes. Identifying these targets would provide an important insight in 
the cellular pathways that a miRNA is involved in. Since miRNAs were discovered, many 
prediction tools are now available to identify targets based on the complementarity 
between the miRNA and mRNA sequences. However, these various tools utilise different 
algorithms to predict miRNA targets. Alternative 3’-UTR sequence databases are used 
between the various programmes [601, 602], resulting in major differences between 
prediction results. Additionally, the false positive rate of these identification tools has 
been shown to be up to 70% [603-605], emphasising the importance of experimental 
validation of mRNA targets for each specific miRNA. Luciferase reporter assays 
containing the 3’-UTR sequence of the mRNA, combined with mutagenesis of the 
predicted miRNA binding site, still remain the gold standard practise to validate novel 
targets. This, however, is a highly laborious exercise and a limited number of targets are 
selected based on preliminary knowledge guided by the online prediction tools. Recently, 
a novel system, the MISSION® Target ID Library (Sigma, UK), has been designed which 
essentially removes this target discovery bottleneck and allows novel mRNA targets to be 
identified on a genome-wide scale. The library contains ~17,000 unique human cDNAs 
cloned downstream of the 3’UTR of a thymidine kinase-zeocin fusion protein (Appendix 
Fig. 7). This library is then stably transfected into a cell model of choice. Subsequently, 
cells stably expressing the library are transfected with a miRNA of choice and genome-
wide mRNA targets can then be identified.  
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Appendix Figure 7.  MISSION® Target ID Library. The Target ID Library is a pool of plasmids, each 
with a human cDNA inserted into the 3’-UTR after a thymidine kinase-Zeocin fusion protein (TKzeo). 
Cells are transfected with the Target ID Library and allowed to recover for 3–5 days. Constructs can 
integrate into the genome during this recovery period and express the encoded transcript. After recovery, 
cells are exposed to Zeocin. Cells expressing the TK/Zeo fusion protein from stably integrated Target ID 
constructs survive Zeocin selection, whilst untransfected cells die. Following the transfection of these 
Target ID cells with a miRNA expression construct of interest, cells are selected with gancliclovir. Cells 
producing thymidine kinase (TK) in the presence of ganciclovir (i.e., cells expressing TK/Zeo constructs 
not targeted by the miRNA) will die. On the other hand, cells containing Library constructs with miRNA 
target sites will not produce TK, and therefore, will survive ganciclovir selection. Surviving cells can be 
grown, gDNA isolated, and the cDNA containing miRNA target sites PCR-amplified using the Target ID 
Amplification primers. PCR products will be sequenced by Next Generation Sequencing (NGS) and aligned 
with the human genome to identify miRNA targets.  
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Cells that express a cDNA construct (or constructs) that is targeted by the candidate 
miRNA will survive and the cDNA will be picked up by sequencing as a target. 
Therefore, to keep experimental background to a minimum, a cell line with low 
endogenous expression of the candidate miRNA is required. Based on the work presented 
previously (Section 5.2-Section 5.5), miR-21, -210 and -30d were selected for further 
investigation. Three colon cancer cell lines (DLD-1, HCT116 and HT29), three rectal 
cancer cell lines (HT55, SW837 and VACO4s), a cervical cancer cell line (HeLa) and a 
breast cancer cell line (MCF7) were tested for endogenous expression of miR-21, -210 
and -30d by qRT-PCR. Analysis demonstrated that HeLa cells presented a consistent low 
expression of all three miRNAs (Appendix Fig. 8A-C) and was, therefore, selected as the 
cell line model for the transfection of the Target ID Library. The Library cDNA 
constructs contain a Zeocin resistance element enabling transfected cells to be positively 
selected using this antibiotic. A kill curve for Zeocin was performed on untransfected 
HeLa cells to determine the minimal lethal dose. Cells were treated with a range of 
concentrations of Zeocin (0, 300, 400, 500, 600 or 700 μg/ml) and cell survival measured 
at day 3, 6 and 9. A concentration of 500 μg/ml Zeocin killed 95% of cells after 9 days 
(Appendix Fig. 8D), and this reached 100% by day 14. This same concentration (500 
μg/ml) was used previously by others when the system was optimised [606]. 
Subsequently, HeLa cells were transfected with 2 μg cDNA construct (Target ID Library, 
Sigma, UK) for 5 days before transfected cells were selected with 500 μg/ml. HeLa cells 
were expanded with Zeocin-containing media for two weeks and stocks frozen down for 
future use.  
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Appendix Figure 8. Target ID Library preparation (n=1). (A-C) Endogenous levels of miR-21, miR-
210 and miR-30d in three colon (DLD-1, HCT116 and HT29), three rectal (HT55, SW837 and VACO4s), a 
cervical cell line (HeLa) and a breast cancer cell line (MCF7). The graphs represent the un-normalised Ct 
values determined via qRT-PCR. (D) Untransfected HeLa cells were exposed to a range of concentrations 
of Zeocin to determine the minimum concentration to achieve maximum cell death. Cell survival was 
measured at three time points (3, 6 and 9 days). 500 μg/ml Zeocin was sufficient for maximum death after 9 
days.  
  
219 
 
 
Next, DNA was extracted from three individual flasks of cells stably expressing the 
Target ID Library constructs and one flask of untransfected HeLa cells. PCR 
amplification was performed using the amplification primers which specifically amplified 
the cDNA constructs (provided by Sigma, UK). PCR products were then were run on a 
2% agarose gel for visualisation (Appendix Fig.  9A). The DNA samples from cells 
transfected with the Target ID Library (HeLa + ID Library) demonstrated clear bands, 
while the untransfected cells (HeLa – ID Library) and the water control was negative, 
suggesting that the transfection of the cDNA constructs was successful (Appendix Fig.  
9A). The cDNA constructs vary in length between 0.5kb and 4kb (Target ID Library 
Technical Bulletin, http://www.sigma-aldrich.com), and a smear of DNA was observed 
with a few distinct bands between 700bp and 2000bp. Sigma provided a similar PCR 
from cells (unknown) transfected with the Target ID Library. A similar DNA smear with 
a few distinct bands can be seen (Appendix Fig.  9B).  
 
These results demonstrate that HeLa cells were successfully transfected with the Target 
ID Library constructs. In the future, these cells will be used for the screening of genome 
wide targets of candidate miRNAs.  
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Appendix Figure 9. Target ID Library cDNA contructs in HeLa cells. (A) PCR performed with primers 
that amplify cDNA insert specifically. Four DNA samples were used: HeLa transfected with the Target ID 
Library x3 and one of untransfected HeLa cells. PCR products were run on a 2% gel. (B) PCR image 
supplied by Sigma demonstrating the presence of the target ID library (cell line unknown).  
 
 
